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Abstract
A recent report of a case of variant Creutzfeldt-Jakob disease (vCJD) possibly
transmitted by blood transfusion implies infectivity in the blood of vCJD patients.
There is therefore an increasing need for screening tests able to identify infected
individuals during the incubation phase of disease to ensure the safety of transfused
blood products and reduce the incidence of iatrogenic disease transmission.
Firstly this thesis assesses the potential of the detection ofPrPc as a surrogate marker
for CJD by an analysis of blood from vCJD patients, sCJD patients, non-CJD
neurological controls and healthy adults, PrPc was measured by DELFIA and cell-
associated PrP was measured by flow cytometry. There are differences in free and
cell-associated PrP found in blood ofCJD patients and control groups, some of
which may be useful as surrogate markers of disease. In addition the development of
a DELFIA based test designed for the detection of the disease-associated PrPSc in
human peripheral blood is the other main focus of research studies detailed within
this thesis. The use of atomic dialectric resonance spectroscopy analysis techniques
to explore potential differences in frequency and atomic resonance which may allow
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Chapter 1: Introduction
1.1 TSEs: Overview
The transmissible spongiform encephalopathies (TSEs) are a family of transmissible
neurodegenerative diseases including CJD and Kuru in humans, scrapie in sheep and
goats, chronic wasting disease (CWD) in deer, and bovine spongiform
encephalopathy (BSE) in cattle. They are characterised clinically by dementia,
ataxia, and myoclonus, and histopathologically by astrogliosis, dendritic spongiosis,
and neuronal loss '.
A key event in the pathogenesis ofTSE diseases is the post-translational
conformational conversion of cellular prion protein from its soluble protease
sensitive isoform (PrPc) to the pathological protease resistant scrapie isoform (PrPSc).
Frequently neuroinvasion and accumulation of PrPSc into the central nervous system
is responsible for, and is a feature of the pathology of the condition. Consequently
PrPSc is used as a surrogate marker for and is thought to be synonymous with
infectivity 2"4. TSEs are characterised by long incubation periods that vary from
months in experimental animal models to many years in certain forms of human
CJD.
1.2 Prion Protein and the Prion theory
In humans the normal cellular isoform of prion protein PrPc is a 35-kDa
glycosylphosphatidylinositol (GPI)-anchored membrane glycoprotein expressed
predominantly on neurones but also on many other cell types and tissues including
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all blood cells with the exception of eosinophils 5"8. PrPc can also be detected in a
soluble form in blood and plasma, known to be released from platelets and vascular
endothelial cells, with the largest cellular component expressed on mononuclear cells
and platelets 9'10. Its physiological function however is not clearly understood. PrPc
is known to interact with glial fibrillary acidic protein (GFAP), and
immunoprecipitation and cell culture studies have demonstrated interactions with
calnexin, calreticulin, laminin, heat shock proteins, and heparin sulphates. PrPc may
have roles in synaptic function, copper transport, superoxide dismutase activity,
signalling, and cell survival and differentiation.
The protein has two sites of asparagine linked glycosylation at residues 181 and 197,
and a disulphide bridge between cysteine residues at 178 and 213 11. NMR studies of
recombinant human PrP found that there is a C-terminal core region (124-231)
folded into three a-helices. The disulphide bond bridges cysteine residues on the
second and third helices. There are also two anti-parallel beta sheet strands. The N-
terminus (23-124) is relatively unstructured and is highly flexible 12, (Figures 1, 2).
The disease associated prion protein PrPSe was found to be insoluble in non-ionic and
non-denaturing anionic detergents, had a propensity to form aggregates, and was
partially resistant to proteolysis with proteinase K (PK) . The protease resistant core
denoted PrP27-30 assembles into amyloid polymers 13. No chemical modification
was found to be associated with the formation of PrPSc from PrPc 14, suggesting that
conformational differences may be responsible for different properties of the two
forms ofPrP. Analysis of both PrPc and PrPSc by fourier-transform infrared
spectroscopy and circular dichroism measurements illustrate differences in
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conformation. PrPc was found to have 42% a-helix and very little if any (3-sheet
(3%), whereas PrPSc was found to have high levels of (3-sheet (43%) and less (21%)
a-helix, these differences are illustrated in Figure 3. It would appear therefore that
the conversion of one isoform to another is based upon conformational changes
which appear to be fundamental to prion propagation 15.
Figure 1
Adapted from 12, 3D structure of human prion protein, the helices are shown in red, the (3
strands in cyan, unstructured c terminus in yellow, and the flexible tail in yellow dots.
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Figure 2
P.'asra uemorane Fa&iw 'SevOrar.e
Human Prion Protein from 16. The amino acid sequence is shown with single letter code for
the mature protein after removal of the N-terminus signal peptide and the C-terminus signal
sequence. Main proteinase K cleavage sites are shown with arrows. The single disulphide
bond is shown between C178 and C213. The two potential glycosylation sites at N181 and
N197 are illustrated with branched arrows. GPI indicates the glycosyl phosphatidylinositol
anchorage to the cell membrane attached via S230. The epitopes recognized by some
widely available monoclonal antibodies are identified. FH11 and BG4 Institute for Animal
Health Compton Laboratories; 3F4 ± Senetek Inc: 6H4 Prionics; F89 as MAI-750 Affinity
Bioreagents Inc.
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The exact mechanism of conversion remains controversial. The protein only
hypothesis states that PrPSc is propagated by the conversion of PrPc molecules to an
altered conformation; two models have been proposed. Firstly PrPSc may act as a
template upon which PrPc is refolded into a nascent PrPSc molecules through a
-3 1 n
process facilitated by another protein often referred to as protein X .
The template conversion theory is supported by a large amount of empirical evidence
which include experiments where hyper and drowsy hamster transmissible mink
encephalopathy strains were able to convert PrPc into distinct sets ofprotease
resistant PrPSc-like products in a cell-free system 18. This suggests that three-
dimensional structure could be the molecular basis for disease strains. These
findings were supported by transmission studies using brain extracts from FFI and
familial CJD (E200K) and sCJD to transgenic mice expressing a chimeric human-
mouse PrP gene. Characteristic deglycosylated protease resistant fragments of 19-
Kda for FFI and 21-Kda for familial and sCJD brain material were faithfully
reproduced when mice brain extracts were analysed 200 days post inoculation 19.
Additional transmission studies investigating incubation periods and neuropathology
found that a scrapie strain when transmitted to Syrian hamsters had distinct
properties from the same strain passaged through transgenic mice with chimeric
Syrian hamster / mouse prion protein genes suggesting that strain diversity
enciphered in conformation seems to be restricted by PrPc substrate, while supporting
the propagation of PrPSc by template interaction 20. Conformational analysis of
scrapie strains by equilibrium unfolding found different strains have unique




Diagram illustrating conformational differences between PrF* and PrPSc
Figure 4
a) Template conversion theory
PrF* binds to an unknown chaperone which initiates conformational change in PrF*. PrP^c
then binds to this conformationally altered PrP*. The incoming PrPSc acts as a template
refolding PrP* to PrF^c which results in the formation of a dimer of PrPSc, protein X is
released and is available once again to reinitiate conversion events.
b) Nucleation theory
Both PrPf and PrPSc exist in equilibrium, monomeric PrPSc nucleates into aggregates. PrF^c




The second model states that the conversion process may be facilitated by nucleation
of unfolded PrPc where the hydrophobic 96-112 amino-acid sequence is exposed, see
Figure 4. This region was found to be exposed in PrPc but hidden in PrPSc, and has
been found by peptide deletion and antibody mapping to be essential to
conformational change associated with the formation of PrPSc 22"24. Peptide
aggregation experiments suggest that this sequence may initiate the formation of
stable aggregates from monomelic PrPSc molecules via a nucleation-dependent self-
9 S
assembly mechanism . It is also thought that parts of the aggregates may break
from the larger assembly and may be capable of initiating PrPSc seeding in distinct
areas.
What is certain is that PrPSc facilitates the conversion of normal PrPc and there is
compelling evidence provided by in vitro conversion experiments that describe the
amplification ofPrPres. An excess of PrPc is utilised as a substrate for conversion,
and is converted to PK resistant forms by minute quantities of PrPSc 26,27. Aggregates
formed when PrPc is incubated with PrPSc are disaggregated by sonication thereby
producing smaller aggregates and amplifying sites available to facilitate additional
conversion events. Recent evidence has indicated that host encoded RNA (>300
nucleotides) cofactors are required for the amplification ofPrPres in vitro since the
use ofRNase prevented the production of PrPSc dose dependently28. PrPres was
amplified six fold following incubation of uninfected hamster brain homogenate with
infected hamster brain homogenate. When homogenates were treated with RNase to
deplete all single stranded RNA no amplification occurred; there was 24-fold
amplification with the addition ofRNA.
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1.3 The Viral theories
Although PrPSc is thought to be the infective agent, and infectivity has been found to
co-purify with PrPSc preparations, not all PrPSc is associated with infectivity 29. A
recently described murine model (101L) of TSE disease with leucine mutation at
amino acid 101 exhibits no detectable PrPSc but brain material remains infectious to
homozygous 101L mice with extremely short incubations periods 30. Similar results
have been obtained in the transmission of BSE to mice 31.
The inability to generate infectivity in protease resistant PrPSc converted in-vitro
from PrPc 32 and the fact that classical amyloid diseases, which share protein
misfolding as a feature of pathogenesis, are not easily experimentally transmissible
make many sceptical of the 'protein only' explanation for TSE infectivity.
The exact nature and structure of the infective agent is far from clear and critics of
the prion theory doubt whether structure and conformation alterations are sufficient
to encode the complex biological and biochemical properties of different TSE
strains. PrPSc may propagate through interaction with an as yet unidentified
additional infectious agent. The virino theory supports the existence of a host
independent replicable information molecule which is associated with host prion
protein and encodes TSE strain characteristics 4'33"35. The virus hypothesis suggests
that the infectious agent and genetic information is carried by a conventional virus 36.
In a recent publication 37 an anti-DNA antibody 'OCD4' and a single stranded DNA
binding protein 'g5p' are described which bind to PrPSc and disease associated
protein but not PrPc. Since the antibodies are raised with a nucleic acid immunogen,
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and 'g5p' is a DNA binding protein, their interaction with PrPSc would imply that the
disease-associated protein is associated with DNA or a DNA associated molecule.
This has important implications in understanding the associations and interactions of
PrPSc and may provide the evidence that strain characteristics are in-fact encoded by
a nucleic acid as implied in the virino hypothesis. It will be interesting to discover
whether the protein-nucleic acid species retain infectivity following immunocapture
and isolation from infected brain tissues with 'OCD4' and 'g5p', whether these are
specific interactions between antibody and a nucleic acid component of a prion
protein complex, and whether the anti-DNA antibody recognises PrPSc.
1.4 Species barrier
Experiments in animals illustrate that a species barrier reduces the ease of TSE
transmission between species. This causes an increase in the length of the incubation
period prior to the appearance of clinical symptoms, and causes a reduction in the
number of inoculated animals that succumb to clinical infection. The species barrier
is affected by polymorphisms in the sequence of host PrP which may not be
compatible with the PrP sequence of the donor, prion strain and the route and dose of
infective agent. What is interesting is that on secondary passage through the same
species there is a reduction in the barrier to transmission, a reduction in incubation
period and strain characteristics become more consistent. Transgenic mouse models
have been developed where mice express human or bovine PrP with the host mouse
PrP or in isolation. Since these models express PrPc that is compatible with the
inoculated agent this removes the species barrier causing a reduction in incubation
periods and allows strain typing of human TSEs in mouse models. These models
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suggest that PrPc is the major determinant in species barriers. Transgenic mice such
as these which express human PrPc have been used for strain typing ofBSE and
vCJD. Similar strain typing support the view that vCJD and BSE are caused by
exposure to the same agent strain 38'39. PrPc is not the only determinant of the species
barrier since transgenic mice expressing human PrP do not exhibit a barrier to
infection with sCJD, however a barrier is apparent in transmission of vCJD 40 despite
the fact that donor and recipient PrP have the same codon 129 genotype and identical
primary structure.
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1.5 Animal and experimental TSEs
1.5.1 Natural and experimental scrapie in sheep
Scrapie was first described in 1755 in the British parliament as a fatal disease
affecting sheep. In 1936 transmissibility was demonstrated by the successful
transmission of scrapie to two healthy sheep by intraocular inoculation with a 1-2
year incubation period 41. Scrapie is endemic in all countries that farm sheep, with
the exception ofNew Zealand and Australia. Clinical signs include odd behavioural
patterns: animals lie down and have abnormal gait, bite and rub themselves against
objects causing pruritis. The infection in the latter stages affects the animals' ability
to feed and sheep become emaciated and die.
Scrapie pathology is characterised by vacuolation of the grey matter neurophil;
vacuolar lesions in the neocortex; neuronal degradation; astrocytosis; amyloidosis
and the deposition of PrPSc.
The exact mode of transmission of natural scrapie between sheep and flocks is
unknown. The oral route of transmission is suspected to be the most likely route.
The susceptibility and development of clinical scrapie in sheep is strongly associated
with certain genetic types, initially scrapie was thought to be a genetic disease, it is
clear however that exposure to the infectious agent is essential for the development
of scrapie 42 and that the PrP gene sequence has significant effects upon disease
susceptibility. This is primarily controlled by amino-acid sequence at codons
136,154, and 171. Since sheep carry two chromosomes with the PrP gene allele,
there are many possible different combinations, despite this only 5 alleles are
commonly found in sheep: VRQ, ARQ, ARR, AHQ, ARH of these the VRQ/VRQ
genotype is at most risk of developing scrapie, and ARR/ARR the most resistant
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genotype. Certain genotypes are restricted to certain sheep breeds, however in light
of the strong associations ofparticular genotypes with disease susceptibility the UK
national scrapie plan aims to breed sheep to ensure a higher frequency of sheep with
the less susceptible genotype to reduce the risk of infection.
1.5.2 Bovine spongiform encephalopathy (BSE)
BSE was first recognised in Britain in November 1986 and led to an epidemic which
grew considerably until the early 1990s. The disease affects animals 4-5 years old,
clinical disease lasts several weeks and is fatal. Clinical effects include
abnormalities in posture and gait, with behavioural abnormalities.
BSE was considered an extended common source epidemic and there was no
evidence of between cattle transmission. All cases ofBSE were found in herds
which used a commercially produced compound feed which contained meat and
bonemeal. Material from scrapie infected sheep is the most likely culprit for the
infective agent 43. The epidemic was sustained by the presence of BSE infected
cattle material being recycled in feed and cattle becoming infected by eating the
infected remains of other cattle. The risk of exposure was thirty times greater for
calves than adult cows 43. The sudden emergence of BSE is thought to be caused by a
change in the rendering processes in the late 1970s early 1980s which led to an
increase in the levels of the infective agent during the processing of animal by¬
products into meat and bonemeal as a result of using lower temperatures and
solvents, thereby allowing the agent to infect cattle 44.
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The exact origin of the infective material is unknown; one theory is that the agent
arises from the presence of scrapie infected sheep material in feed. The
neuropathological characteristics ofBSE are very similar to scrapie 43, the incidence
of scrapie increased significantly in the 1980s and therefore suggests that its presence
in feed may have risen accordingly. Britain had the highest ratio of sheep to cattle
during this time, so although other countries were employing similar rendering
processes the level of sheep material in the composite feed was highest in Britain.
Alternative explanations include a sporadic event much like sCJD which occurred by
spontaneous mutation in a cow causing BSE in other cattle when the carcass was
processed and included in feed, however this would not explain why the emergence
ofBSE was restricted to Britain and why there were no cases prior to 1985. The
BSE enquiry favoured the spontaneous mutation hypothesis, and thought this to be a
more likely cause than that of scrapie infected feed. The Horn enquiry did not rule
out scrapie as the culprit, it established that during the 1970s Britain began to
introduce meat and bonemeal into calf feed from 2 weeks old and given that they are
more susceptible to infection from contaminated feed this may have been key to the
BSE epidemic 45. In Australia there was a similar change to feed meat and bonemeal
to calves however BSE did not arise in Australia perhaps because the country is
scrapie free. BSE however is biologically and molecularly distinct from all scrapie
strains, which would appear to disprove the scrapie link 46.
In an attempt to control the BSE outbreak a ban in 1988 was enforced to prevent
cows eating cow derived feeds. This feed ban had a dramatic effect upon the number
ofBSE cases which by 1992 were falling by a rate of 40% per year. The delayed
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effect of the ban was consistent with the long incubation period for BSE, and
confirmed that contaminated feed had indeed been responsible for disease
transmission. Unfortunately BSE cases continued to occur after the ban, possibly a
result of cross contamination of feed intended for pigs that still contained cattle
derived meat and bonemeal 47. Additional preventative measures banning the
presence of any mammalian protein in animal feed were introduced in the UK in
1996. This was largely a response to the identification of vCJD in the same year.
These measures were introduced in the EU in January 2001. To date 69 cases of
BSE in animals born after the ban of 1996 have been detected by passive or active
surveillance 48.
Since BSE has emerged several policies have been introduced in order to ensure the
safe consumption ofBritish beef. In 1989 a ban on specified bovine offal (SBO) was
introduced to prevent tissues from entering the human food chain. Infectivity studies
of scrapie in sheep had identified the presence of the infective agent in the brain,
spinal cord, tonsil, thymus, spleen and intestines 49. This was followed by a policy
that no British cattle over the age of 30 months should be consumed, as advised by
the Spongiform Encephalopathy Advisory Committee in May 1996. This policy is
now under review considering the vast reduction ofBSE in the UK. BSE has
occurred outside the UK due to the export of cattle derived products and meat and
bone meal contaminated cattle feed. Table 1 illustrates the numbers of confirmed
BSE cases worldwide. A recent case ofBSE has occurred in a dairy cow in
Washington State USA. This animal was subsequently confirmed to have been
imported from a Canadian herd in Alberta Canada, in 2003 Canada confirmed its
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BSE in European Union Countries 2004
2004 2003 ■ Totalsince1987
Austria 0 0 1
Belgium 11 15 129
Czech Republic** 7 4 17
Cyprus** 0 0 •
Denmark 1 2 14
Estonia** - - "
Finland 0 0 1
France 54 137 951
Germany 65 54 369
Greece 0 0 1
Hungary** - - -
Ireland 126 182 1488
Italy 7 31 126
Latvia** 0 0 •
Lithuania** 0 0 •
Luxembourg 0 0
Malta** 0 0 °
Netherlands 6 19 77
Poland** 11 5 22
Portugal 92 133 954
Slovak Republic** 7 2 1 19
Slovenia** 2 1 5
Spain 137 167 538
Sweden 0 0
UK (GB & Northern Ireland)* 398 611 182807
Figures as at 31 December 2004.
* UK figures include Great Britain figures for passive and active surveillance, and a Northern
Ireland total of 34.
** Countries that joined the EU on 1 May 2004.
Sources: for UK: Defra, DARD and Braakman.
Data compiled by Food Standards Agency (http://www. food, gov, uk/).
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1.5.3 Chronic wasting disease (CWD)
CWD was first described in 1980 as a spontaneously occurring form of spongiform
encephalopathy affecting mule and black tailed deer in captive populations in
Colorado and Wyoming 50. The disease was subsequently found to affect both
captive and free ranging deer populations and rocky mountain elk. CWD causes
widespread spongiform change in the grey matter, neuronal loss, astrocytic
hypertrophy and hyperplasia and the deposition of amyloid plaques 51. PrPSc is
detectable in the brain and lymphoreticular tissues of infected animals 52. Clinically
the disease is characterised by behavioural problems, chronic weight loss, and death
from two weeks to eight months after infection 50. The disease is infectious and
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contagious, however the specific mode of transmission remains unidentified.
Contaminated foodstuffs are not responsible, lateral transmission is important to the
spread of disease. The disease may be transmitted via the faeces or saliva, the
infectious agent has been detected in lymphoid tissues of the alimentary tract, and
contaminated pasture has been responsible for further outbreaks.
The disease origin is unknown, it is possible that CWD may be an adapted scrapie
strain, although strain typing and biochemical analysis does not suggest scrapie PrPSc
is related to the form found in CWD 53. Other explanations to explain the emergence
of CWD are that it may have been a spontaneous sporadic incident, or a genetic form
arising in deer and subsequently transmitted amongst the deer population and to
other species.
1.5.4 Transmissible mink encephalopathy (TME)
TME was first recognised in the 1940s in Wisconsin and Minnesota USA. The
disease has arisen in farmed mink in other countries including Russia, Canada, and
Germany but disease outbreaks remain rare 54. The cause of TME is uncertain,
initially epidemiological evidence indicated that scrapie contaminated foodstuffs
may be the source of outbreaks, however transmission experiments found that mink
were only susceptible to scrapie by intracranial (IC) inoculation and not by ingestion
55. Mink were found to be highly susceptible to transmission of disease by both the
oral and IC route if the disease was firstly passaged through cattle 56. TME has been
well characterised by transmission to hamsters where it exhibits two different strains:
hyper and drowsy which have different incubation periods and whose PrPSc has
18
different biochemical properties . It may be plausible that in order for the agent to
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become infectious to mink it required prior propagation in distinct animal species.
Clinically the disease is characterised by increased aggression, ataxia, hyperesthesia,
and has an incubation period of 7-12 months 54. Histopathology of the disease
includes widespread vacolation of the neurophil, neuronal cell death and astrocytosis.
Because TME has arisen as a result of oral exposure to infected feed by either a
scrapie or BSE type agent, it is unlikely to pose a future problem due to the exclusion
of sheep and cattle from feedstuffs.
1.6 Human TSEs
In humans CJD can be divided into four groups: sporadic, familial, iatrogenic, and
variant.
CJD may occur sporadically with an incidence of between 0.5-2 cases per million
population a year typically affecting older people between the ages of 55 and 80.
Cases of familial prion diseases are a result of autosomal dominant mutations in the
prion gene PRNP open reading frame; they often clinically resemble sporadic forms
of the disease.
CJD has been transmitted iatrogenically via the use of contaminated neurosurgical
equipment, by dura mater, corneal transplants, and by contaminated cadaveric
gonadotropic growth hormones57.
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The National CJD Surveillance Unit first identified new variant Creutzfeldt-Jakob
so
disease (vCJD) in 1996 as a novel transmissible spongiform encephalopathy (TSE) .
vCJD is characterised by its specific neurological profile, young age at onset,
unusual clinical course as compared with sCJD, the absence ofmutations within the
PRNP gene and no recognised risk factors for iatrogenic CJD. There is compelling
evidence that vCJD results from the consumption ofbeef infected with BSE.
1.6.1 Sporadic CJD
Sporadic CJD is a rapidly progressive multifocal dementia, which may feature
monoclonus, cerebellar ataxia, pyramidal and extrapyramidal signs, and cortical
blindness59. Sporadic CJD accounts for ~ 85% of all detected human prion disease
60'61, it has a uniform world-wide incidence of 1 case per million per year with an
average age at onset of 60 years.
The cause of sporadic CJD is unknown but it is thought that it may arise from
spontaneous PrPSc production, somatic mutation, post-translational modification of
PRNP, or unidentified prion exposure 59. Neuropathologically the condition can
cause spongiform change, neuronal loss, and astrocytosis in the cerebral cortex,
occipital lobe, thalamus and cerebellar cortex. PrPSc deposition is usually detected in
areas of spongiform change. A polymorphism at codon 129 ofprion protein gene
which encodes either methionine or valine amino-acid residues exerts an influence
upon the susceptibility of Caucasians to sporadic CJD. Heterozygotes are
significantly protected against developing sporadic CJD62"64. A great deal of clinical
heterogeneity can be observed in sporadic CJD, and although the causes are not fully
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understood it is likely that a combination of codon 129 genotype and prion strain
contribute towards this.
Strain typing studies using transgenic mice expressing human PrP support the
suggestion that strain characteristics are encoded in the conformation and
glycosylation patterns of PrPSc, which are maintained on passage40. Analysis by
western blot of infected mouse brain tissue treated with PK allows distinction
between strains based on the pattern of fragment migration due to different N-
terminal cleavage sites, and also glycosylation ratios of diglycosylated,
monoglycosylated and unglycosylated PrP banding patterns. These differences are
due to differences in glycosylated PrP species. Such strain typing has allowed the
identification ofPrP isotypes which have different phenotypes of sporadic CJD40'65"68
and are associated with specific clinical and pathological criteria. Parchi 65 identified
two molecular types of PrPSc in sporadic CJD. A type 1 western blot pattern was
found to associate with methionine homozygosity at codon 129 and with typical
sporadic CJD disease phenotype. Type 2A blotting pattern was associated with all
genotypes at codon 129 and with atypical rarer clinical variants of sporadic CJD65,68.
These types along with type 2B, which shares the same fragmentation as type 2A but
has a different glycoform ratio due to its heavy diglycosylation (vCJD), are used to
characterise acquired forms of CJD including vCJD (see Figure 6).
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Figure 6
CJD S S V
Codon 129
Genotype MM W MM
Molecular types 1 2A 2B
Western blot analysis of 2 sCJD types and vCJD (Adapted and reproduced with permission
from Dr Mark Head). The blot illustrates the banding patterns of diglycosylated (top band),
monoglycosylated (middle band), and unglycosylated (bottom band) prion protein after
treatment with PK which are associated with sporadic and variant forms of CJD. Type 1 and
2A patterns are associated with sCJD of different genotypes at codon 129 and there are
differences in the migration of the unglycosylated band. The monoglycosylated band is the
most prominent in type 1 sCJD. vCJD * binding pattern is similar to type 2 sCJD but the
diglycosylated band is much more prominent.
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An alternative nomenclature for the classification ofboth sporadic and acquired
forms of CJD has been proposed where there are 6 types used to categorise both
sporadic and acquired CJD in humans 59. In this classification CJD types share the
same association with codon 129 genotype as those proposed by Parchi et al 40 but
Hill et al59 claim to have identified additional types for iatrogenic and sCJD based
upon differences in molecular mass and fragment sizes when samples are analysed
by western blotting techniques. Subsequent to these findings is a report that a
significant heterogeneity in pH among CJD brain homogenates exists which in turn
influences the size of the PrPSc core generated by protease digestion. By
demonstrating that the heterogeneity ofhuman PrPSc type 1 within specific groups
(MM orMV subjects) strictly depends on pH variations among CJD brain
homogenates, this study provides a reasonable technical explanation for the PrPSc
molecular heterogeneity 69.
1.6.2 Iatrogenic CJD
The first case of iatrogenic CJD was reported in 1974 in the recipient of a corneal
graft from a donor who had died of unknown CJD 70. The major causes of iatrogenic
CJD include contaminated human cadaveric human growth hormone, and dura mater
grafts which were first recognised as risks in the 1980s 71'72. Data included in a
recent review of iatrogenic CJD examined 267 cases in total ofwhich 139 were
infected through human cadaveric growth hormone, 114 by dura mater, of the
remaining cases <5 in each group were due to transmission by corneal transplant,
7T
contaminated EEG or neurosurgical equipment , or through contaminated
gonadotropin57. The majority of cases of iatrogenic CJD caused by contaminated
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growth hormone (>50%) have occurred in France, similarly >50% of the cases of
CJD transmission due to dura mater graft have occurred in Japan.
Iatrogenic CJD due to contaminated human growth hormone has been best
characterised by studies in France 74. Pooled human growth hormone infected by at
least one cadaver with preclinical CJD caused the majority of these cases. Of 1700
patients receiving human growth hormone 74 developed CJD (4.4%), the mean
incubation period was 10 years, the long duration most likely due to the low levels of
infectious dose and route of administration.
The codon 129 M/V polymorphism was found to affect incubation period in certain
forms of iatrogenic CJD, 80% of iatrogenic CJD cases were homozygous,
Methionine homozygotes were found to be the most susceptible group in dura mater
cases. In cases of growth hormone transmission a notable 32% were valine
homozygotes, and their contribution is particularly noticeable among UK patients
(Table 2). In analysis ofUK iatrogenic growth hormone cases 35 of 1880 (1.9%)
developed CJD. Of the 20 cases codon 129 genotyped, 11 were valine homozygotes
(55%) with only 1 methionine homozygote. The appearance of this susceptible
group may be simply that the contaminated donor shared the same codon 129
genotype and therefore those recipients who share the same genotype are most
susceptible, however the low levels of iatrogenic cases suggest that susceptibility
will be due to additional factors.
In the French studies heterozygotes were found to be significantly (p=0.003) less
susceptible and had longer incubation periods than homozygotes, however studies of
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129 genotype in cases in the United States and the UK could find no significant
association between incubation periods and codon 129 genotype 57.
Table 2
Iatrogenic Patients Number tested Met / Met Met / Val Val / Val
UK 20 1 8 11
USA 9 5 2 2
FRANCE 53 33 7 13
Codon 129 genotype ofpatients in different countries who contracted CJD via growth
hormone treatment
Increased knowledge of the transmissibility of CJD, improved surgical instrument
decontamination, plus the availability of recombinant growth hormone and factor
VIII products should eventually eliminate the risk of iatrogenic CJD. Concerns
remain over the potential transmission of vCJD through blood and blood products,
which have been justified considering the recent emergence of a case of vCJD in the
recipient of a blood transfusion from a donor who later died of vCJD 75,76 (see vCJD
section). The episode of vCJD transmission by blood transfusion remains a
possibility and is not a proven causal connection; it is though a recognised risk. If
transfusion was the cause of disease transmission it illustrates that blood can be
infectious when the disease is at an undetected preclinical stage, and that there is an
extremely long incubation period before the emergence of disease in the recipient.
This connection was identified by means of collaboration between the National CJD
Surveillance Unit and the UK national blood authorities known as the 'Transfusion
Medicine Epidemiology Review'. As part of this study patients who receive blood
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products and develop vCJD are investigated and transfused products are traced to
donors.
1.6.3 Familial CJD, GSS, and FFI
Hereditary CJD, Gerstmann-Straussler-Scheinker Disease (GSS) and Fatal Familial
Insomnia (FFI) are associated with mutations in the open reading frame of the prion
protein gene (PRNP) and are inherited in an autosomal-dominant manner. Mutations
can be point mutations where one amino acid is substituted for another. Insertions
can also occur where 2-9 copies of a 24 base pair region encoding the octapeptide
repeat sequence are added between codons 51-91 77'78. There exists a great deal of
heterogeneity in disease phenotype in this group of inherited conditions as result of
direct effects of the mutation coupled with additional effects of the codon 129
genotype. This combination is referred to as the disease associated haplotype of
which more than a dozen have been characterised in hereditary CJD and one in FFI
78'79. All hereditary CJD, FFI, GSS are transmissible. The mutation's effect is to
cause a disruption in the conformational structure of the prion molecule, and it is this
change in conformation which determines the disease phenotype. These changes in
conformation can be visualised by western blot analysis following PK treatment. An
analysis of the Asparagine (N) to Aspartate (D) substitution at codon 178 where the
codon 129 genotype was valine homozygous (D178N-129V) differed in migration
and glycosylation pattern to FFI mutation D178N-129M haplotype 80, these
migration and glycosylation patterns are now referred to as type 1 and type 2 as
mentioned earlier in classification of sporadic CJD. Different mutations and PrPSc
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conformation therefore appear to be critical to disease phenotype, since one causes
familial CJD and the other FFI.
Hereditary CJD accounts for 10 % ofhuman prion disease and is associated with
over 20 different combinations ofmutation and codon 129 genotype. The most
common haplotype in inherited CJD is caused by substitution of Lysine (K) for
Glutamate (E) at codon 200 with Methionine homozygosity at codon 129 (E200K-
129M). Due to the nature of inheritance clusters or kindreds occur, for this particular
mutation large clusters have been discovered amongst Jews of Libyan origin and in
Slovakia and Chile 81~84. The onset of disease associated with this mutation is quite
variable occurring between ages of 40-80 with a mean duration of 6 months. Clinical
features resemble sporadic CJD associated with Methionine homozygosity at codon
129, with type 1 PrPSc. The same codon substitution associated with Valine at
codon 129: E200K-129V is associated with a rapid progressive dementia, ataxia, and
type 2 PrPSc similar to Valine codon 129 sporadic CJD cases.
Other well-characterised haplotypes include D178N-129, which was the first familial
CJD case recorded in 1924, V210I-129M, V180I-129M, and M232R-129M
haplotypes.
In addition a considerable number ofPRNP haplotypes have been found in isolated
cases ofCJD, affecting single subjects which lack family history, therefore linkage
analysis is unavailable and it is difficult to assess whether the mutation is the cause
of the condition. These include I213M, G142S, Q160S, T188R, R208H, T188K,
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T188A, E196K, V203I, E211Q, P238S 78. This group ofmutations exhibit a clinical
disease phenotype identical to that of sporadic CJD MM1.
The remaining mutations involve either insertion or deletions within the octapeptide
repeat region between codons 51-91. The insertion ofbetween 1 and 9 (but not 3)
extra octapeptide repeats is associated with hereditary CJD. More than 20 insertion
mutations which differ in number and arrangement of repeats have been described
no
which affect 20 families with 95 affected individuals . Deletions of 1 octapeptide
repeat sequence is a common mutation which occurs in 1-2.5% of the population and
o c
.
is not associated with the development ofCJD . However the deletion of 2
octapeptide repeat sequences is associated with CJD and has been characterised in 2
individuals 86'87.
FFI is the third most common type ofhereditary CJD linked to D178N-129M
haplotype. This mutation is also responsible for a form of familial CJD (D178N-
129V) methionine homozygote at codon 129. Disease course in FFI is influenced by
codon 129, as expected homozygotes have a shorter disease duration 12+/"4 months
_!_/ oo
compared with heterozygotes 21 "15 months . Clinical signs include sleep,
autonomic and motor function abnormalities. Insomnia, drowsiness, and apathy are
symptoms along with autonomic, endocrine disturbance. The distinct feature of FFI
is severe atrophy of the anterior ventral, mediodorsal and pulvinar thalamic nuclei
accompanied by the loss of the majority of neurons and a significant increase in
levels of astroglial cells 78'89. PrPSc deposition is usually absent in FFI cases except
in cases where there is a long disease duration, and when found is of type 2 90.
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1.6.4 Kuru
Kuru is a neurological condition historically endemic amongst the Fore linguistic
tribes resident in the eastern highlands ofNew Guinea since 1941. Cannibalistic
rituals were established as the cause of the disease transmission 91. These
cannibalistic rituals were abandoned by the late 1950s so halting disease exposure,
however due to the long incubation periods associated with the disease, Kuru
maintained its incidence for a further 40 years. Although Kuru was seen to share
characteristic features with sheep scrapie, it was not until successful experimental
09
transmission to apes that it was established as a form of TSE .
The disease duration ranges from between 4-24 months and is clinically
characterised by uniform pan-cerebellar dysfunction. Homozygosity at codon 129 of
the PRNP gene especially methionine homozygosity is linked to a younger age at
Q-3
onset and a shorter disease duration . Characteristic neuropathological features
include neuronal loss, myelin degeneration, astrocytic gliosis, microglial
proliferation, spongiform change associated with the deposition of PrP, and the
presence of amyloid PrP plaques 94.
The study ofKuru, an oral transmissible disease occurring in humans has important
implications in the study ofvCJD which is linked to consumption ofBSE infected
beef. The two diseases are phenotypically similar, and studies ofKuru can be used
as essential background for the eventual elimination of vCJD.
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1.6.5 Variant CJD
New variant Creutzfeldt-Jakob disease (vCJD) was described in 1996 as a novel
transmissible spongiform encephalopathy (TSE)58. 10 cases were reported all with
neurologically unique profiles, affecting relatively young people with a clinical
course and disease duration atypical of sporadic CJD. Clinical features included
psychiatric and sensory disturbance, dysaethesiae, foot pain, ataxia, and memory
impairment, all patients developed progressive dementia. Myoclonus was also a
feature later in the clinical course. In addition EEG features normally associated
with sporadic CJD were absent. Neuropathologically vCJD cases showed
spongiform change, neuronal loss, and PrP plaque formation. Spongiform change
and astrocytosis were most evident in the thalamus and basal ganglia, but also
present in the cerebrum and cerebellum. The most unusual feature was the presence
ofPrP plaques in cerebrum, cerebellum, thalamus and basal ganglia. The plaques
were unique and resembled the florid-like plaques first found in the transmission of
Icelandic scrapie in mice and recently reported in a subset of Japanese dura mater
iatrogenic cases 95. They have a dense glassy eosinophilic centre and pale periphery
















The cerebral cortex of a patient with vCJD. Arrow locates a plaque surrounded by a ring of
spongiform change.
PrP deposition present in these plaque regions in the cerebral cortex, and cerebellum,
can also be found in the thalamus, basal ganglia, and grey matter. Clinical course,
neuropathology and young age of patients are all very distinct from those you would
associate with sporadic CJD. Genetic analysis found all cases to be MM at codon
129 in the PRNP gene, this group would therefore appear to have increased
susceptibility to infection with the BSE agent which only codes for methionine at the
equivalent site to the 129 polymorphism and is thought to be responsible for vCJD in
the human population. This is not to say that heterozygous or valine homozygote
individuals are resistant to vCJD. It may be that these individuals could be affected
after prolonged incubation periods. Certainly codon 129 genotype influences
incubation periods in recipients of human growth hormone 74 as discussed earlier.
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There is compelling evidence that vCJD results from the consumption ofbeef
products infected with BSE. Transmission studies in mice suggest that the same
strain of prions cause BSE and vCJD, both show similar incubation periods and
neuropathology . Molecular strain typing studies using western blotting techniques
support this hypothesis 96, the vCJD prion is heavily diglycosylated with a fragment
pattern distinct from those associated with other human TSEs. However, this
evidence although compelling only indicates that BSE and vCJD are caused by the
same strain of agent.
vCJD is transmitted by inoculation with, or dietary exposure to infected tissues, and
in contrast to other human TSEs PrPSc can be detected in lymphoreticular tissues of
patients with vCJD 97"99. PrPSc was readily detected in spleen and lymph nodes of
vCJD patients with the highest levels detected in tonsil. Lower levels could also be
detected in the optic nerve, rectum, adrenal gland and in the thymus of 1 patient97'98.
PrPSc deposition could not be found in the same peripheral tissues from other human
prion diseases or controls. Tonsil and spleen samples from patients with vCJD have
also been found to harbour infectivity which can be transmitted when bio-assayed in
The process of neuroinvasion following oral exposure in humans is not clearly
understood. PrPSc is known to accumulate and replicate in peripheral lymphoid
tissues prior to neuroinvasion. Follicular dendritic cells are known to replicate and
accumulate PrPSc in secondary lymphoid follicles in animal models 101. Complement
factors would appear to have an important role in modulation ofprion replication
since mice deficient in these factors were partially or fully protected from infection
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with scrapie 102. The sympathetic nervous system innervates the gastrointestinal
tract, the spleen and lymph nodes and is therefore thought to be most relevant avenue
for neuroinvasion. Experiments in mice comparing wild-type and mice over-
expressing PrPc found that the overexpression ofPrPc by neurons of the peripheral
1 OT
nervous system accelerated neuroinvasion . Studies suggest that these nerves
may not only be involved in prion transport but may also accumulate PrPSc in
lymphoreticular tissues 104.
The role of the sympathetic nervous system as a bridge for CNS invasion is
supported by two recent pieces of research. The first describes the presence of PrPSc
in the celiac and stellate ganglia of the autonomic nervous system in patients with
vCJD, deposition was not found in patients with sCJD 105. The second illustrates
how ablation of chemokine receptor CXCR5 causes the repositioning of follicular
dendritic cells in germinal centres in secondary lymphoid follicles ofmice so they
are closer to sympathetic nerves. This was found to increase the efficacy ofprion
invasion 106. These two studies support the involvement of the sympathetic nervous
system in transmission of PrPSc from the periphery to the central nervous system, and
support an oral route of infection for vCJD. However the exact mechanism of
transport along nerve systems remains unclear, as does the interaction between
immune cells and nerve endings.
The presence of detectable PrPSc in peripheral tissues may provide scope for the
development of a preclinical screening test, and raises the question of the potential
for its transmission by blood transfusion. This raises the possibility of a major
epidemic of vCJD occurring as a result of dietary exposure to BSE prions, and/or
iatrogenic exposure to vCJD prions. Furthermore since little is known regarding
incubation time and blood infectivity prior to the appearance of clinical symptoms, it
is possible that infected blood donors may threaten the safety ofblood transfusion.
Indeed the circumstances surrounding the first possible case of transfusion-
transmitted vCJD reported in December 2003 cause concern 76.
It has been difficult to predict the eventual number of individuals who will go on to
develop vCJD since the variables which would enable a prediction as to the eventual
size of the epidemic such as incubation period, genetic susceptibility and infectivity
levels in food chain are not known. Due to uncertainties about incubation period
mathematical modelling estimates that the vCJD outbreak could affect numbers
ranging from less than a hundred to several hundred thousands 107>108. A more recent
estimation of epidemic sizes based on age-risk assessments gives the total number of
cases to be 205 and the mean duration of incubation period to be 16.7 years assuming
that all infections occurred between 1980 and 1989 and that the risk of developing
the disease in exposed subjects decreases exponentially with age after age 15 109. A
recent decline in the incidence of vCJD has lead to revised predictions for the
eventual numbers of affected individuals. Indeed since a maximum of 28 cases in
2000, the incidence has declined considerably to 20 cases in 2001, 17 cases in 2002,
and 16 cases up to 1st December 2003. A recently published update models
projections of vCJD deaths in the UK by relating estimated exposure to BSE infected
animals to vCJD case data. This estimates the future number of cases to be 40 with
95% prediction accuracy with an upper limit of 500 cases. The mean incubation
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period was calculated at 12.6 years no. Integrating the data generated from the
detection of 1 positive appendix in 8318 tissues tested in a recent study 111 the
estimates increase to 100 cases with an upper limit of 2500. Since all individuals
who have developed vCJD so far are codon 129 methionine homozygotes it may be
that these are the most susceptible group and that the remaining types have been
infected but incubate over a longer period prior to clinical presentation. It is known
from epidemiological studies on Kuru that incubation periods can be as long as 40
years before the appearance of clinical disease signs. It is unlikely that epidemics
will arise in these groups since their non-emergence is either due to a longer
incubation period or reduced susceptibility.
The recent emergence of a possible case of transfusion related transmission 76 is
cause for concern since it is possible that preclinical cases may harbour infectivity
and thus a blood screening strategy is desirable to identify those blood products
which contain vCJD infectivity so they can be removed from the blood supply. In
1996 an individual aged 62 years received a transfusion of 5 units of red blood cells.
Of these products one had been donated by an individual of 24 years who went on to
develop vCJD symptoms 3 years 4 months later and died in 2000 ofpathologically
confirmed vCJD. The recipient began to develop symptoms in late 2002 of
depression and unsteady gait and died 13 months later. Due to the age of the patient
and normal MRI scan the cause of death was recorded as dementia, although the post
mortem reported features indicative ofCJD and subsequent investigations confirmed
the codon 129 genotype to be methionine homozygous and biochemically confirmed
the presence of type 2B prion protein (vCJD) in the brain, and the presence of florid
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plaque deposition. Data indicates that if transfusion was the cause of disease
transmission that the blood of the donor was infectious 3 years before disease
developed, and that there was an incubation period of 6.5 years before disease
development in the recipient. This is cause for concern since it is known that of 135
vCJD cases 15 have donated blood from which 48 products have been transfused to
recipients. Of this number 41 received red blood cell components a third ofwhich
were leucodepleted by filtering to contain <5million leucocytes per unit after the
introduction in 1999 of leucodepletion ofUK blood supply as a precautionary
measure against vCJD transmission. 6 received plasma components, and one
received platelets. Of these recipients none are known to have donated blood, 31




*As at 4th March 2005
Summary of vCJD cases
Deaths
Deaths from definite vCJD (confirmed): 106
Deaths from probable vCJD (without neuropathological 42
confirmation):
1
Deaths from probable vCJD (neuropathological confirmation
pending): 149
Number of deaths from definite or probable vCJD:
Alive
Number of definite/probable vCJD cases still alive: 5
Total number of definite or probable vCJD cases (dead and 154
alive):
There is growing evidence from studies ofmouse scrapie that the initial TSE
infection is carried by cells of the immune system to lymphoreticular tissues prior to
neuroinvasion of the CNS 112"115. sCJD can be transmitted by intracerebral
inoculation of blood and buffy coat from clinically affected patients "6, and recent
reports of the transfusion ofnatural scrapie and experimental BSE by buffy coats
support this theory 117. However despite this, transmission of sCJD by blood
transfusion does not pose a significant clinical problem. Indeed it has been difficult
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for transmission to occur via the intravenous route, much higher doses were required
• 118for successful transmission in studies ofmouse adapted TSE
Numerous animal studies have found low levels of infectivity detectable in
circulating blood from rodents experimentally infected with CJD, BSE, and scrapie
during incubation and clinical phases of disease "9. Recent studies document the
experimental transmission of BSE between sheep by blood transfusion 120, the
detection of infectivity in the plasma ofmice infected with mouse adapted BSE 121,
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and in the buffy coat of a prosimian model experimentally infected with BSE
Infectivity had not been detected in blood from animals with naturally occurring
scrapie until the recent report detailing the transmission ofnatural scrapie by blood
transfusion 123. Twenty-one sheep from a scrapie-free flock were transfused with
blood either whole blood or buffy coat fractions taken from scrapie-infected animals
at different time points. At the time the article was published 4 animals had
developed clinical signs of scrapie receiving blood at 57, 69,77 and 100% of clinical
phase of the disease in donor animals at the time at which blood was taken. Three
received whole blood transfusions, 1 buffy coat transfusion. Recent figures from this
study 117 now indicate 43% (9/21) of sheep transfused with blood from sheep with
natural scrapie have developed the disease, incubation period ranges from 575-1138
days post transfusion. The blood donations were between 53-100% (clinical phase)
of donor survival time. Of the 9 cases of transmission, 4 were whole blood
transfusions developing between 575-1138 days post transfusion, and 5 were buffy
coat transfusions developing 737-1101 days post transfusion.
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Reports illustrating the transmission of CJD by human peripheral blood, for example
transmission by buffy coat from sCJD patients to hamsters 116, must be assessed and
balanced against large numbers of studies which have failed to find infectivity 124.
More importantly until the recent report of the possible transmission of vCJD by
blood transfusion 76 no case ofCJD resulting from the transmission of human blood
• • • • 125 128
or blood products had been identified through epidemiological investigations " ,
and it remains a possibility that the individual may have developed vCJD by oral
exposure to the BSE agent rather than the disease developing as a result of blood
transfusion.
The risk of transmission by blood from patients with vCJD may be increased by the
presence of PrPSc in the reticuloendothelial tissues <)7'100'129. Studies assessing the
infectivity of vCJD blood provide conflicting results. Early studies discovered it was
not possible to transmit vCJD to mice via intracranial inoculation of either buffy coat
or plasma l0°. More recent studies have found the presence of infectivity in vCJD
blood when transmitted to mice 13°.
Considering current precautionary policies of universal leucodepletion and processes
involved in plasma fractionation which attempt to reduce the risks, it is unlikely that
1 T1
transfusion based transmission is occurring at a high level . The recent possible
transmission of vCJD via blood transfusion has prompted the latest ban on donors
who have received blood transfusions since 1st January 1980. The key uncertainty in
attempting to evaluate the risk of vCJD transmission by blood transfusion and
evaluate the efficacy of leucodepletion and plasma fractionation are the numbers of
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blood donors who may currently be incubating the disease and the level and
distribution of infectivity in the peripheral blood in these individuals. In the isolated
case of transfusion related transmission reported in December 2003 the blood was
donated 3 years before disease development in the donor illustrating that the donated
blood if it was the cause of vCJD in the recipient was infectious many years before
disease onset. There is therefore a need for a peripheral blood screening assay
capable of identifying those currently in the preclinical phase of infection to allow
estimation of the public health problem, deferral of high risk blood and organ donors,
and the eventual clinical trials ofpotential prophylactic and/or therapeutic agents
prior to the onset of clinical disease 132.
1.7 Development of assays for the diagnosis of TSEs
The common feature of all TSEs is the accumulation of PrPSc in the CNS and in
some cases in the peripheral tissues. PrPSc is recognised as 'self and so does not
promote immunological responses and there are no detectable nucleic acids
associated with PrPSc. Direct PCR based approaches for detection of a nucleic acid
component are not applicable. PCR amplification of nucleic acid antibody linker
molecules have been used in diagnostic assays but suffer from background problems.
Pre-mortem diagnosis with the exception of a clinical diagnosis is difficult since
PrPSc is concentrated in the CNS with very low concentrations detectable in the
peripheral tissues. As a consequence, the detection of PrPSc as a marker for disease
is best suited to post-mortem neuropathological examination, which at present
represents the gold standard for the diagnosis of TSEs. Post mortem tests include
immunohistochemistry, ELISA, western blotting, and mouse bioassay.
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Immunohistochemical and biochemical approaches exploit the protease sensitivity of
PrPc to identify PrPSc whose conformational^ altered structure is largely resistant to
protease action. An anti-PrP antibody used in either an ELISA or western blotting
assay is able to detect the disease-associated protein. Post-mortem testing using
these methods are employed in cattle slaughterhouse tests to ensure no BSE infected
beef enters the human food chain. There are currently 5 tests available for this
purpose that have undergone evaluation by the European Union. The Enfer TSE kit
2.0 is an ELISA assay, which detects PrPSc in PK digested brain homogenate with a
polyclonal antibody coupled with an enzyme conjugated secondary antibody. The
signal is detected by chemiluminescence. The Prionics-Check LIA uses an identical
approach to the Enfer test except that it uses monoclonal antibodies one ofwhich is
enzyme conjugated for the detection of PrPSc after PK treatment. The signal is
detected by chemiluminescence. Another ELISA based assay system is the Biorad
Platelia which again relies upon PK digestion and is followed by a precipitation and
centrifugation step. PrPSc is detected in a sandwich ELISA using a colour-converting
enzyme conjugated detection antibody. Other assays include the Prionics-Check
Western where the PK digested brain homogenate is separated by SDS-PAGE and
transferred to PVDF membrane. Separated PrPSc is detected using a specific
antibody and an alkaline phosphatase-conjugated secondary antibody. Finally the
InPro Conformation-Dependent Immunoassay relies upon protease digestion of PrPc
but identifies the presence of PrPSc based upon monoclonal antibody binding to an
epitope that is hidden in PrPSc but exposed in PrPc. When denatured more antibody
will bind to a sample containing PrPSc due to the exposure of the hidden epitope.
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Protease treated brain homogenate is treated with phosphotungstate which selectively
precipitates PrPSc. After centrifugation the resuspended sample is divided into two, 1
half is denatured at high temperature the other half (native) sample is left untreated.
Samples are assayed on an ELISA plate precoated with an anti-PrP monoclonal
antibody. A europium conjugated detection antibody is used to bind any PrP present,
and the europium signal is enhanced and read on a time-resolved fluorometer. If
PrPSc is present then the ratio of the signal of the denatured sample divided by the
native sample will be greater than that of a control uninfected sample.
Currently the most widely used tests in Europe are the Prionics-Check western and
the Platelia test. The BioRad test is capable of detecting PrPSc up to 3 months prior
to the emergence of clinical symptoms.
In most TSEs the deposition of PrPSc is confined to the CNS, in scrapie in sheep and
goats and vCJD in humans it can also be readily detected in the peripheral nervous
system and in the lymphoid system in tissues such as the spleen, tonsil and appendix
including numerous other tissues (Table 4).
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Table 4
Peripheral Nervous System vCJD sCJD
Olfactory nerve, cribiform plate NT V
Optic nerve, neural retina V V
Trigeminal nerve V V
Alveolar nerve - -
Sciatic nerve - NT
Celiac and stellate ganglion V -
Lymphoreticular System
Tonsil V -
Gut associated lymphoid tissue V -
Spleen V
Appendix V -
Lymph nodes (mesenteric and cervical) V -
Eye and Oral cavity
Cornea, iris, lens, vitreous body,
choroids, sclera - -
Neural retina and optic nerve V V
Dental pulp, gingival, alveolar nerve,
salivary gland, tongue
Organs / tissues
Heart, liver, lung, kidney - -
Thymus, adrenal gland -
Tissue distribution of PrP30 outside the CNS in patients with vCJD and sCJD, data sourced
from 98'99'105'133'134 presence (V); absence (-), not tested (NT)
This has allowed the tests described above to be used in the preclinical diagnosis of
scrapie. The preclinical detection of vCJD would be possible as illustrated by a
recent retrospective study into tonsils and appendix in the UK where 1 vCJD case
was identified nl. However tests on human peripheral tissues are far too invasive to
be routine, and a more easily accessible fluid such as blood or urine would be the
sample of choice. The level of PrPSc in blood or urine is likely to be extremely low,
ifpresent at all, so preclinical screening tests based upon the detection of PrPSc
would need to be extremely sensitive. Table 5 summarises the sensitivity of several
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promising assay platforms which may have application as screening tests in the
future.
Table 5
Assay technique PrPSc preparation Detection limit Sensitivity (IDsomL"1)
Prionics check western BSE brain homogenate "o1
oo 100 000-1000 000
Enfer TSE kit BSE brain homogenate 10"15 30 000
CD1 DELFIA vCJD brain homogenate 10"5-10"6
Hamster scrapie brain homogenate 103 ID50 mL"1 1 000
Wallac DELFIA BSE brain homogenate 10° 1000 000
CEA ELISA BSE brain homogenate lO"25 3 000
Capillary Electrophoresis Scrapie in sheep buffy coat 3-135pg PrPSc 100-2500
Sensitivity of assays for detection of PrP50 adapted from MacGregor16, and Ironside 135.
Recent developments which may allow the sensitive detection of PrPSc include the
use of reagents which selectively bind and allow precipitation and purification of
PrPSc including NaPTA 21, plasminogen 136, and protocadherin. A reagent that would
transform TSE diagnostics is the availability of a PrPSc specific monoclonal antibody
that would allow the specific detection of the disease-associated protein without the
need for proteases that may also remove some protease sensitive disease associated
proteins. There have been some recent developments including an anti-nucleic acid
antibody which appears to have specificity for PrPSc alone 37, similarly a monoclonal
antibody to a conserved tyrosine-tyrosine-arganine tri-peptide motifwhich is
exposed in PrPSc but not in PrPc was able to precipitate PrP from TSE-infected but
i '>'1
not uninfected brain homogenates . A different approach has been an in-vitro
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amplification technique which allows rapid conversion of an excess ofPrPc to PrPSc
in the presence of a small quantity of PrPSc 21. This may allow the detection of
minute quantities of PrPSc present in tissues and biological fluids. Recent studies
using this technique have found that the transformation in vitro also requires specific
RNA molecules, suggesting that host-encoded catalytic RNA molecules may play a
role in the pathogenesis ofprion disease 28. Another approach is the use of capillary
electrophoresis for the detection of PrPSc 138. A fluorescent-labelled peptide of part
of the amino-acid sequence of PrP is incubated with an antibody specific to this
peptide at a concentration where 50% of the peptide is bound by the antibody. The
mixture is then analysed by capillary electrophoresis and detected using laser-
induced fluorescence intensity to provide information on the ratio of bound to
unbound peptide. The addition of a sample containing PrP (any form of PrP) would
compete with the peptide for antibody binding thereby disturbing the ratio.
Published data claims that this sensitive assay is capable of detecting PrPSc in the
blood of scrapie infected sheep and goats however these results have not been
reproducible for the detection of PrPSc in the blood of chimps experimentally
infected with CJD or CJD in humans 139. There are also some highly technical
spectroscopy approaches for example the use ofFourier transform infrared
spectroscopy (FT-IR) as a test for scrapie and BSE in cattle has been described 140,141
Analysis ofblood serum by FT-IR and by artificial neural networks ormultivariable
pattern recognition analysis allows the sensitive and specific discrimination between
healthy and infected animals. A method of fluorescent correlation spectroscopy has
also been described which has some diagnostic sensitivity for the detection of PrPSc
in the cerebrospinal fluid (CSF) ofpatients with CJD 142.
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Since PrPSc is present at extremely low concentrations outside the CNS and is only
likely to be present in detectable concentrations relatively late on in disease
pathogenesis, alternative disease associated markers have been explored for the
preclinical diagnosis of CJD.
One such marker is Erythroid differentiation-related factor (EDRF) whose expression
was found to be down-regulated in an analysis of 10,000 RNA transcripts from
spleens of scrapie infected mice. Down regulation was also found to occur in scrapie
in sheep and BSE infected cattle when compared to healthy controls 143. The lack of
disease controls in this study is a worry for the disease specificity, but if specific,
EDRF transcripts can be measured in blood by northern blot and would be a suitable
screening strategy for the detection of TSEs to ensure the safety ofhuman blood
products within the transfusion services.
Another such marker is the human leukocyte antigen (HLA) class II DQ7 allele
which was found to have a reduced expression in patients with vCJD but not in
patients with sCJD or in organ donor controls. HLA and DRB tissue typing of 50
patients with vCJD found 6 (12%) expressed DQ7, the same allele was expressed by
12/26 (46.2%) of sCJD patients and by 70/197 (35.5%) of organ donor cadavers.
The reduction of expression in patients with vCJD was found to be highly
statistically significant (p=0.001). These results for Caucasian individuals suggest a
protective effect ofDQ7 and HLA typing may be useful as one of a number of tests
for blood to identify risk groups given the association ofHLA with other infectious
diseases such as Human Immunodeficiency Virus (HIV) and hepatitis B.
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Using a similar approach the presence of cellular nucleic acids circulating in the
plasma of BSE infected cattle have been reported to correlate with disease 144.
Another promising technique uses a sensitive electrocardiogram system used in heart
monitoring to measure a unique heart rate signature present in the early stages of
disease. Tests on 150 cows experimentally infected with BSE found increased levels
of respiratory sinus arrhythmia in 2 animals that died 8 months later, and suggest that
this testing may be able to identify individuals with preclinical vCJD 145.
There are therefore several promising surrogate markers for the detection of TSEs
which may contribute towards the development of a preclinical screening test for
TSEs in humans and in animals. At present the clinical diagnosis of both sCJD and
vCJD are based upon a series of diagnostic techniques with varying sensitivity and
specificity along with clinical observations. It is likely that sensitive and specific
preclinical diagnosis will be based upon several diagnostic criteria.
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1.8 AIMS
This thesis seeks to address the following interrelated topics:
1. Establish and apply analytical techniques of dissociation enhanced lanthanide
fluorescence immunoassay (DELFIA), and flow cytometry to assess the
qualitative and quantitative distribution of prion protein (PrP) in the
peripheral blood ofpatients with vCJD and sCJD. Do there appear to be
differences in the level of expression ofPrP in blood components, and does
flow cytometric analysis highlight differences in the cell surface expression
of PrP?
2. Use available techniques including the use of chaotropic salts and proteinase
K (PK), to assess the possibility of detecting the abnormal prion isoform
PrPSc. Apply to peripheral blood and tissues in cases of vCJD using patients
with sporadic CJD (sCJD) and other neurological conditions along with
anonymous normal volunteers as controls in these studies.
3. Develop a preclinical diagnostic test for vCJD that may also have application
in verifying the safety of donated blood and blood products.
4. Apply ADR spectroscopic techniques for classification of clinical CJD and
control blood samples.
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Chapter 2: Materials & Methods
2.1 Ethics approval and patient consent
Before commencement, the study received approval from the Scottish Multi-Centre
Research Ethics Committee and the Local Research Ethics Committees
2.2 Collection of Blood Samples
Anonymised whole blood samples from 30 healthy adult apheresis platelet donors
were collected by the Scottish National Blood Transfusion Service Edinburgh and
stored for 24 hours at 4° C before separation in order to mimic the conditions of
collection of samples from CJD patients around the country. Blood from CJD
patients and neurological controls was leftover from samples obtained by the
National CJD Surveillance Unit for genetic analysis. Samples were not obtained
solely for this study due to the difficulties of obtaining blood from these patients.
Whole blood samples from 10 vCJD patients, 10 sCJD patients and 8 neurological
controls were used for DELFIA studies. Informed consent was obtained from
patients and donors for experimentation and ethics approval for the study was
obtained as described in section 2.1. All vCJD and sCJD cases had a probable or
definitive diagnosis based upon internationally established criteria 146>147.
Neurological controls were samples referred to the CJD Surveillance Unit from
patients that subsequently did not meet criteria for a diagnosis of definite or probable
CJD. These 8 patients were subsequently diagnosed with neurological disorders
distinct from CJD including Alzheimer's disease (2), paraneoplastic syndrome (2),
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mitochondrial disease (1), Lewy body dementia (1), non-organic depression (1) and
central pontine myelinolysis (1).
2.3 Time-resolved fluoroimmunoassay for Prion Protein
The highly sensitive method of time-resolved dissociation-enhanced
fluoroimmunoassay (DELFIA®) was employed for the detection ofPrP by sandwich
immunoassay. This method was carried out based upon a previously described
protocol 9. The DELFIA employed monoclonal antibody FH11 148 (produced at IAH
Compton against ovine recombinant PrP, originator Dr C.R Birkett) as capture
antibody, and monoclonal antibody 3F4 149 (against hamster PrP and obtained from
TSE Resource centre, IAH, Compton, UK, originator Dr Richard Kascsak)
conjugated to europium3"1" as signal antibody. Eu-labelling reagent and DELFIA
assay buffer, wash concentrate, and enhancement solutions were obtained from
PerkinElmer Life Sciences, Hounslow, UK.
The assay was calibrated using an expired platelet concentrate which had been
calibrated with a recombinant human soluble PrP 150 (Catalogue number 03-041
Prionics, Switzerland). The recombinant human prion protein gene (PRNP) was
amplified from genomic DNA, expressed and purified by Prionics following
previously published methods 151; its sequence constitutes amino-acid residues 23-
230 and has methionine at position 129.
Initially europium labelled 3F4 monoclonal antibody and FH11 coated plates were
obtained from PerkinElmer Life Sciences, UK. Test samples or calibrators diluted in
assay buffer were applied 200 pL / well to 96 well microplates, (Immulon-4 HBX
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Thermolabsystems, Basingstoke, UK) pre-coated with FH11 and incubated for lhour
on a shaker (IKA labortechnik, Germany).
The wells were then washed four times with DELFIA wash buffer using a DELFIA
Platewash (PerkinElmer Life Sciences, UK) and charged with 200 pL / well of the
3F4-europium3+ conjugate at a dilution previously determined by titration against the
platelet standard reagent. After incubation for a further lhour on a shaker the wells
were washed six times with DELFIA wash buffer after which 200 pL of
enhancement solution was added to each well and the plate incubated on a shaker for
5min. This methodology is illustrated in Figure 8.
The acid-detergent-chelate enhancement solution liberates europium3"1" from its
chelation with the 3F4 antibody by low pH and allows the formation of a highly
fluorescent chelate with ligands present in the enhancement solution. The resulting
fluorescent signal was then measured with a Victor2 time-resolved fluorometer
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For the quantification of PrPc data was analysed using WorkOut software version 1.5
provided by PerkinElmer Lifescience. The concentration in Units/mL of five
dilutions of expired platelet concentrate titrated against human recombinant PrPc
were used to calibrate the assay. 1 Unit was found to be equivalent to 26
picograms/mL. The software was programmed to subtract blanks from duplicate
wells and to calculate duplicate means and express these in terms of a concentration
in Units/mL.
2.3.1 Preparation of FH11 coated plates
Immulon-4 HBX 96 well microtitre plates were incubated overnight at room
temperature (RT) with 200 pL/well 5 pG/mL FH11 in bicarbonate-carbonate coating
buffer (Sigma Aldrich, UK) pH 9.6. Plates were washed 4 times with DELFIA wash
buffer and blocked with assay buffer + 1 % bovine serum albumin (BSA) (Sigma
Aldrich, UK) for 1 hour on a shaker at RT, then washed 4 times once again with
DELFIA was buffer prior to loading of samples.
2.3.2 Preparation of Europium3+ conjugated antibody
Monoclonal antibodies used for detection were europium3"1" labelled using Eu-
labelling kit 1244-302 from PerkinElmer Life Sciences, UK.
lmG of antibody whose concentration was determined by measurement of the
absorbance at 280nM divided by the extinction coefficient for IgG (1.36) was added
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to a Microcon-30 concentrator (Millipore (U.K.) Ltd, Watford, UK) and centrifuged
at 10,000g. The eluate was discarded and the retentate washed 4 times with 400 pL
labelling buffer (50mM NaHCCF pH 8.5). The washing step was essential to
removed the phospho-buffered saline (PBS) and replace with carbonate buffer so as
to ensure a suitable pH and to remove any basic charges from the buffer to reduce
competition for the amine groups to which the europium binds.
The absorbance of each eluate obtained following centrifugation was measured using
a spectrophotometer at a wavelength of 280 nM as an indicator for the presence of
protein in order to monitor the retention of antibody in the microcon filter. The
presence of protein in solution can be determined by the presence of aromatic amino-
acid residues tyrosine and tryptophan which exhibit an absorbance maximum at 280
nM.
After the final wash step the retentate was diluted in 450 pL labelling buffer and
added to 0.2mG Eu-labelling reagent n-l(p-isothiocyanatophenyl)-diethylene-
triamine Ni,N2,^-tetraacetate (Figure 9); (DTTA) chelated with europium and
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Chemical structure of the Eu-labelling reagent, N1(p-isothiocyanatobenzyl)-diethylene-
triamine- N 1, N 2, N 3-tetraacetic acid chelated with Eu3+
The labelling reagent DTTA forms a stable complex with Eu3+ and the
isothiocyanate group reacts with the primary aliphatic amino group on the protein at
alkaline pH to form a stable covalent thiourea bond. The high water solubility and
the stability of the chelate, in addition to the mild coupling conditions of the
isothiocyanate reaction enable effective protein labelling.
This volume was then transferred to a Microcon-30 concentrator and centrifuged as
before, the eluate was discarded. The retentate was washed 4 times using elution
buffer (50mM Tris-HCL + 0.9% NaCl, 0.1% NalS^; pH 7.8). The retentate was then
diluted with 200 pL elution buffer and transferred to an antibody storage vial. The
Microcon membrane was washed a further 4 times with 200pL elution buffer and
each wash volume transferred to the antibody vial to give the final concentration of
labelled antibody as 1 mG/mL. The labelled antibody was then filtered through a
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Millex-GV4 (Millipore UK, catalogue number SLGVR04NL) to remove suspended
particles and antibody aggregates, and BSA as a stabiliser added to a final
concentration of 0.1 %.
In order to establish the labelling yield or the number of Eu3+ molecules bound to
each IgG molecule, firstly the Europium content of the labelled antibody was
calculated by comparison with a europium standard supplied with the labelling kit.
The labelled antibody was diluted 1:100 000 in enhancement solution and applied
twice in duplicate to a microtitre plate 200 pL/well. The europium standard was
diluted to a final concentration of 1 nmol/L in enhancement solution and added to the
plate as above. The europium content was calculated using the following equation:
Eu3+ (fjmol/L) = Eu-counts x dilution factor /1000X counts of 1nmol/L Eus+
The protein content of the labelled antibody was then determined by measuring its
absorbance at 280 nM and correcting for the molar absorptivity of reacted labelling
reagent whose absorbance at 280 nM is 8000, 1 pMol gives an absorbance of 0.008.
This value was then divided by the extinction coefficient for IgG 1.36 and multiplied
by 100.
Protein (mG/mL) — [Abs 280nM -0.008 XEu3+ (jumol/L) /1.36] *100
This value was then converted to pMol/L by multiplying by 1000000 and dividing
by 160 000 g/L.
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The yield was then calculated by dividing the europium content by the protein
content as follows:
Yield (Eu3+/IgG) = Eus+ (jumol/L) /Protein (pmol/L)
2.3.3 Titration of expired platelet concentrate against human recombinant
Prpo
Recombinant human PrPc (Prionics, Switzerland) was diluted in doubling dilutions in
a range of 0.78 - 50 nG/mL and applied in duplicate 200 jaL/well to a microtitre
plate precoated with 5 pG/mL monoclonal antibody FH11. The assay was calibrated
using the expired platelet concentrate at 5 fold dilutions from 1:5 -1:3125 assayed in
duplicate 200 pL/well to provide a standard curve.
The calculations for each dilution of recombinant PrPc in units based upon an earlier
calibration where 1 unit = 200 pG/mL was found to be inaccurate and did not reflect
the known concentration of the recombinant material. The concentration of platelet
concentrate was calculated and 1 unit was found to be equivalent to 26 pG/mL.
2.4 Conformation dependent Immunoassay
This approach for the detection of abnormally folded PrP was adapted from methods
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developed by Safar et al . The detection of PrP by MAb 3F4 in native and
denatured portions of the same sample allows detection of abnormally folded PrP
based upon the increased exposure of the 3F4 epitope on denaturation. The 3F4
epitope (aa 109-112 of PrP) is less accessible in abnormally folded PrP, but clearly
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accessible in PrPc. A signal increase in a denatured sample compared with a native
aliquot of the same sample when assayed by DELFIA signifies the presence of an
abnormally folded PrP.
50-100 pL of sample to be analysed was split into 2 aliquots of an equal volume in
0.5mL Eppendorf safe-lock tubes. The aliquots were labelled as either native or
denatured, 8 Molar (M) guanidine hydrochloride (GdnHCL) (Sigma- Aldrich, UK)
was added to the denatured aliquot to double its volume giving a final concentration
of 4M. The sample was then heated to 80°C in a heat block for 6 min. The native
aliquot remained untreated until diluted to 0.65 - 1.0 mL final volume with distilled
water supplemented with protease inhibitors 5 mM PMSF + aprotinin and leupeptin
(Sigma Aldrich, UK) at 4 pg/mL each + 0.308M GdnHCL. GdnHCL was added to
this buffer so that it was present at the same concentration in both native and
denatured samples. Denatured samples were brought to 0.65 -1.0 mL with the same
buffer without the GdnHCL. Samples were then applied in duplicate or triplicate
200 pL per well on a 96 well microtitre plate precoated with 5 pG/mL MAb FH11 or
an alternative capture Ab. The plate was then incubated for 2 hours on a shaker,
washed 4 times with DELFIA wash buffer, before blocking with 200 pL per well
TBS (pH 7.8) containing 0.5 % weight per volume (w/v) BSA and 6 % w/v Sorbitol
(Sigma Aldrich, UK) for 2 hours on a shaker following methods described previously
by Bellon 152. The plate was then washed 4 times and incubated with 200 pL per
well Eu-labelled 3F4 (1/15000 dilution batch 29/10/03) for 2 hours at RT on a
shaker. The plate was then washed and the signal enhanced and read following the
standard DELFIA protocol as described in section 2.3.
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2.4.1 Modified CDI including Sodium Phosphotungstic acid concentration
and PK treatment.
21The CDI protocol can be further adapted following methods of Safar et al to
incorporate the use of sodium phosphotungtic acid (NaPTA) (Sigma-Aldrich, UK) to
enhance the detection sensitivity for PrPSc.
Samples (900 pL) to be analysed by CDI were brought to 1 % sarkosyl (a detergent)
pH 7.4 by the addition of 100 pL of stock solution in a 1.5 mL screw-top tube (10 %
w/v in PBS pH 7.4), vortexed, spun briefly to remove any liquid from the lid, and
incubated at 37°C for 15 minutes.
2 pL of 25 Units/pL benzonase (Sigma Aldrich, UK) final concentration 50 Units
was added to the tube along with 5 pL of 0.2M MgCU (Sigma Aldrich, UK) to a
final concentration of 1 mM. Samples were vortexed and incubated for a further 30
minutes at 37°C in a heat block.
81 pL of a pre-warmed (37°C) stock solution containing 4 % NaPTA and 170 mM
MgCU pH 7.4 was added to 1 mL samples to give a final concentration of 0.32 %
NaPTA and 12.8 mM MgCU. Samples were vortexed and incubated overnight at
37°C in a waterbath.
Samples were then spun at 14,000g for 30 minutes in an Eppendorfbenchtop 5417R
centrifuge and the supernatant removed. Pellets obtained should be grey/brown in
appearance and a white precipitate ofmagnesium salts should not be present. Pellets
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were resuspended by pipette action in 50 pL distilled H2O supplemented with 5 mM
PMSF and aprotinin and leupeptin at 4 pg/mL each, this aliquot was split and sample
processing continued following the standard CDI protocol described in section 2.4.
In order to increase sensitivity, prior to or following the addition ofNaPTA, 12.58
pL 20 mG/mL PK (VWR, Poole, UK), final concentration 250 pG/mL was added
and samples incubated for 1 hour at 37°C after which 10.2 pL lOOmM pefabloc
(Merck UK) was added to give a final concentration of 1 mM.
2.4.2 Modified CDI to incorporate NaCI precipitation.
Methods are exactly as those described in 2.4.1 apart from the following deviations:
Following incubation of samples with benzonase and MgCU, 500 pL 30 % NaCL in
PBS pH 7.4 (w/v) was added to each sample and samples were incubated on ice for
10 minutes with occasional vortexing. Samples were then centrifuged as described
in 2.4.1, however, rather than resuspending the pellet immediately it was washed
with 25 mM Tris-HCL pH 8.8 plus 0.05 % sarkosyl and spun as in 2.4.1. The pellet
was then resuspended and assayed by CDI following methods described in section
2.4.1.
2.5 Flow cytometry
Flow cytometry analysis was performed by Dr Robin Barclay who kindly allowed
his data to be presented in this thesis.
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2.5.1 Blood Samples
Samples were processed by flow cytometry immediately on arrival at the National
CJD Surveillance Unit, and subsequently assigned to clinical groups when diagnoses
were made. An aliquot (0.4 mL) ofwhole blood from each sample was made
available for flow cytometry studies. Any samples that did not fall into the
diagnostic categories were not included in the analysis of results. Blood samples
were also obtained from healthy adults and, because clinical samples were at least 24
hours old before arriving in the laboratory, these healthy adult control samples were
processed by flow cytometry on the day following sampling.
2.5.2 Pretreatment with proteinase K
0.2 mL of the sample was set aside for staining (untreated). The remaining 0.2 mL
was washed once in 2.5 mL of cold Cell Wash (Becton Dickinson), spun down and
resuspended in 0.5 mL of proteinase K (PK) (Sigma Aldrich UK) at 1 mG/mL in
Hank's balanced salt solution with calcium and magnesium (Sigma Aldrich UK) and
left at room temperature for 30 minutes (the PK concentration for complete removal
of cellular prion protein from healthy human blood cells under these conditions was
determined by preliminary titration). The PK treated sample was washed four times
in 2.5 mL of cold Cell Wash and the resultant cell pellet was divided equally
between two 12 x 75 mm Falcon tubes (Becton Dickinson) for flow cytometry
staining.
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2.5.3 Flow cytometry staining and analysis
This was carried out essentially as previously described 6'10 except that a combination
ofMAbs 3F4 and 4F2 was used on the hypothesis that while MAb 4F2 clearly
identifies PrP on human red cells, MAb 3F4 does not bind 29. Therefore the 4F2
epitope on any PrPSc may be more susceptible to PK cleavage than the 3F4 epitope.
These MAbs (5 pL each at 0.5 mG/mL) were added simultaneously to 100 pL of
whole blood or PK treated washed blood with 100 pL ofCell Wash. Second samples
ofwhole blood and PK treated blood received 100 pL of Cell Wash without anti-
prion MAbs as unstained (negative) control. Following incubation and washing,
anti-mouse Ig (human absorbed FITC-conjugated goat anti-mouse Ig F(ab')2,
BioSource) at 1/500 in Cell Wash (100 pL) was added to all tubes. Following
incubation and washing a sample (10 pL) was removed from each tube for red cell
studies, and 5 pL ofPerCP-conjugated anti-CD45 MAb and 5 pL ofPE-conjugated
anti-CD41 MAb (Becton Dickinson) was added to each whole blood tube. To each
red cell study sample was added 5 pL ofPE-conjugated anti-glycophorin A MAb
(Serotec, Oxford, UK). Samples were incubated a further 30 minutes in the dark at
room temperature. The red cell samples were washed twice with 2.5 mL of Cell
Wash and resuspended in 0.5 mL of Cell Fix (Becton Dickinson). The whole blood
samples were resuspended in 2.5 mL of lysing solution (Becton Dickinson) to
remove red cells followed by 2 washes in 2.5 mL of Cell Wash and resuspended in
0.6 mL ofCell Fix. Fixed stained samples were kept overnight at 4°C in the dark
before analysing by 3-colour flow cytometry as previously described 10. Samples
from lysed preparations were collected on linear forward/side scatter axes for
leucocyte studies, and a second set were collected on logarithmic forward/side scatter
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axes for platelet studies. Red cells were collected on linear forward/side scatter axes.
A total of 20,000 events in appropriate forward/side scatter gates were collected to
listmode files for each analysis. Analysis was conducted using FCS Express
(DeNovoSoftware) on a PC. Samples were gated by appropriate forward/side scatter
patterns and additionally by CD45 expression (different leucocyte populations);
CD41 expression (platelets); or glycophorin A expression (red cells). Other markers
of leucocyte populations (e.g. CD14) were susceptible to PK digestion and were not
used. Histograms were made of channel-1 (FITC) expression for negative controls
(no anti-PrP MAbs) and overlaid with histograms for channel-1 for anti-PrP (primary
anti-PrP MAbs) for each cell class: single peaks were seen in each case and their
median fluorescence intensities determined by setting appropriate markers on the
histograms. Net median fluorescence intensity for anti-PrP staining was obtained by
subtracting the negative control (no anti-PrP MAbs) value 10.
2.6 Total Protein measurements
Levels ofPrP were expressed in Units per mL total protein for whole blood and all
separated components to normalise data by compensating for the effects of
separation protocol upon cellular particulate recovery in components and to ensure
that range differences in cell number did not contribute to differences in PrPc levels
between groups. Although studies on full blood counts of clinical patient samples
and controls did not show any abnormalities, full blood count data could not be
generated from frozen stored clinical and control samples used in this study,
therefore normalisation by total protein was essential for all components with the
exception ofwhole blood.
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Measurements of total protein levels were carried out using a Biorad Bradford
protein assay (500-0002 Biorad Hemel Hempstead, Hertfordshire UK). The
microtitre plate format was performed following the manufacturers instructions.
Briefly test and / or standard samples were added to 96 well microtitre plates in
duplicate 5 pL/well. 25 pL/well of reagent A was then added to all wells followed
by 200 pL/well of reagent B. The assay plate was incubated for 15 minutes on a
shaker and read at a wavelength of 655 nM in a spectrophotometer (Biorad
Benchmark, UK). The standard linear curve equation of the standard reagent allows
calculation of the total protein levels in samples assayed.
2.7 Blood component separation protocol
Citrate anticoagulant blood samples taken from referred cases of suspected CJD or
from controls were stored at + 4°C until separated into the component parts for
storage at -80°C. All tubes were labelled with white laminating labels containing the
Unit Associated Number and the suffix for the blood fraction (B=Whole Blood,
BC=Buffy Coat, P=Platelet Poor Plasma, PT=Platelets, R=Red Blood Cells).
Figure 10 provides a chart illustration of the separation process.
This method describes the separation of blood from one 9mL collection tube.
1.5 mL ofwhole blood was transferred to a sterile 2 mL tube (labelled 'B'). Then the
remaining blood (~7.5 mL) from the vacutainer was transferred to labelled, sterile 15
mL Falcon for centrifugation in the sealed buckets of the Sigma 4-15C centrifuge
(Sigma Aldrich, UK) and spun at 450g/ 1455 rpm for 10 minutes.
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The top two-thirds (~2 mL) ofplatelet-rich plasma were transferred into labelled 1.5
mL conical tubes. The Buffy Coat including ~1 mL of the red cell layer (~2 mL in
total with contaminating plasma, platelets, and red blood cells) was transferred to a
labelled 15 mL Falcon. All but the bottom 0.5 mL of red cells were transferred into a
labelled 15 mL Falcon. The Buffy Coat and Red Cell tubes were filled up to the 10
mL mark with PBS and spun at 180g/ 920 rpm for 10 minutes. During this spin step
the tubes containing platelet rich plasma were spun in the Heraeus Biofuge at
16,060g for 10 minutes to pellet the platelets. After this spin the supernatant was
transferred to 2 mL storage tubes and labelled as Platelet Poor Plasma (P), and the
tubes containing the platelet pellets were discarded. The supernatant and the top 0.5
mL of the interface from the RBC tube was discarded into NaOH with a pastette and
PBS was added up to the 14 mL mark. The tube was spun at 180g / 920 rpm for 10
minutes and the supernatant discarded. The RBC pellet was resuspended in PBS to
double the volume giving a 50 % solution of cells, which was transferred to 2 mL
storage tubes (labelled 'R').
The supernatant from the Buffy Coat tube was aliquoted into conical 1.5mL tubes
and spun at 13,000 rpm for 5 minutes to pellet the platelets. After this the
supernatants were discarded and the pellets resuspended in 1 mL of PBS into one of
the tubes. This tube was spun again at 16,060g for 5 minutes and the supernatant
discarded. The final pellet was resuspended in 1 mL of PBS and transferred to a 2
mL storage tube, labelled as Platelets (PT). The Buffy Coat pellet was resuspended
in 14 mL PBS and inverted to mix. Then spun at 180g / 920 rpm for 10 minutes. The
supernatant was discarded into NaOH and 13 mL of distilled water added. The tube
was then inverted for 3 minutes to shock-lyse the RBC, and then 1 mL of 10 times
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PBS was added. The tube was then spun at 180g / 920 rpm for 10 minutes. The
supernatant was discarded and the tube refilled to the 14 mL mark with PBS and
spun at lOOg / 686 rpm for 10 minutes. The supernatant was discarded and the pellet
resuspended in 1 mL of PBS labelled as Buffy Coat (BC). The resulting tubes were
then stored at -80°C.
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Figure 10
Flow diagram to illustrate blood component separation protocol
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2.8 Preparation of brain / tissue homogenates
2.8.1 Homogenisation Buffer
10 mM Tris, 150 mM NaCl, 1 % (Octylphenoxy) polyethoxyethanol (IGEPAL), 0.5
% deoxycholic acid, 0.1 % SDS, 5mM EDTA, pH 8 plus aprotinin and leupeptin at a
final concentration of 4 pG/mL.
2.8.2 Sample preparation
Preparation ofhuman brain and tissue homogenates was conducted in a class 1 bio-
safety hood in a category 3 laboratory.
The required weight of tissue (usually 60-100 mG) was sampled and transferred to a
pre-weighed 2 mL Eppendorf safe-lock tube, using a disposable scalpel and forceps,
samples were kept chilled in a pre-chilled freezer block. All contaminated materials
were disposed of into 2M NaOEl.
Tissue samples were then homogenised in 4°C homogenisation buffer to a 10 % w/v
homogenate using an Eppendorfmicro-pestle. Insoluble crude tissue fragments were
removed by spinning at 2000 rpm for 5 minutes at 4°C in an Eppendorf 5417R
centrifuge. The supernatant was removed and stored at -20°C for further analysis.
2.8.3 Proteinase K treatment of blood / tissue homogenates
Proteinase K stock 20 mG/mL (Merck, Drayton UK) was diluted to 2 mG/mL and
stored at 4°C. PK was added to blood or tissue samples to the final concentration
required and samples were incubated at 37°C for lhour in a heat block. Proteolysis
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was halted by the addition of either Pefabloc SC (Roche, Basel, Switzerland) to a
final concentration of 1 mM, or by the addition ofPMSF (Sigma Aldrich, UK) to 1
mM.
2.8.4 Blood cell lysis buffer (BCL) recipe
0.32 M Sucrose, 10 mM Tris-HCL, 5 mM MgCl2, 1 % Triton X100, pH 7.5. All
reagents obtained from Sigma-Aldrich, UK.
2.9 Western Blotting
2.9.1 SDS-PAGE
Protein separation by sodium dodecyl sulphate polyacrylamide gel electrophoresis
(SDS-PAGE) was carried out using NuPAGE Novex 10 % Bis-Tris gels (catalogue
number NUP0302), Novex gel tank apparatus, MOPS SDS NuPAGE running buffer
(catalogue number NUP0001-02) and sample buffers (catalogue number NP0007) all
from Invitrogen Ltd, Paisley, UK.
Samples for analysis were transferred to screw-top tubes and an equal volume of 2
times sample buffer added. The samples were then heated to 100°C for 10 minutes
in a heat block. The pre-cast gel was rinsed with distilled H20, the white strip and
comb removed and the wells washed twice with running buffer. The gel was then
loaded in the tank and the tank was filled with running buffer. The samples and
molecular weight markers (Catalogue number LC5600, LC5602 Invitrogen Ltd,
Paisley, UK) were loaded and run at 200 Volts constant for 50 minutes.
87
2.9.2 Western Transfer and ECL detection
SDS-PAGE separated proteins were transferred to polyvinylidene fluoride (PVDF)
using NuPAGE transfer apparatus and buffers (catalogue number NUP0006-1,
Invitrogen Ltd, UK). 100 mL ofMeOH was diluted 1/5 in NuPAGE transfer buffer
(Invitrogen Ltd, UK) and 2 pieces of 3 mm blotting paper per gel and transfer pads
were equilibrated in transfer buffer for 20 minutes. One piece ofPVDF membrane
(Hybond-P, Amersham Pharmacia Biotechnology, Chalfont St.Giles, UK) was
wetted in MeOH and washed for 10 minutes in distilled H20 prior to equilibration in
transfer buffer. The SDS gel cassette was opened, and a piece ofblotting paper
placed on the gel. The PVDF membrane was placed on the other side and the gel
placed into the transfer apparatus between several transfer pads. The transfer block
was then filled with transfer buffer and the outer tank with distilled H20 to act as a
coolant. The transfer was then processed at 30V constant for lhour.
The membrane was then washed twice for 3 minutes in 40 mL Tris-buffered saline
with 0.1 % Tween 20 (Sigma- Aldrich, UK) (TBST) and blocked for 45 minutes in
50 mL 5 % milk powder in TBST. The membrane was washed 3 times as before in
TBST followed by incubation with MAb 3F4 (Dako, Cambridgeshire, UK) at 1:1000
in 40 mL TBST for 45 minutes. The membrane was then washed a further 3 times
prior to incubation with HRP anti-mouse IgG (Diagnostics Scotland, Edinburgh, UK)
at 1:1000 in 40 mL TBST. The membrane was washed a further 4 times in TBST
and the fluorescent signal developed by incubating the membrane with ECL PLUS
(Amersham Pharmacia Biotechnology, Chalfont St.Giles, UK) for 5 minutes.
Fluorescence imaging was visualised using the Storm 860 phosphoimager
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(Molecular Dynamics, Amersham Pharmacia Biotechnology, UK) or exposed (e.g.
30 seconds, 3 minutes, 30 minutes) to Hyperfilm ECL (Amersham Pharmacia
Biotechnology, RPN3103K) and developed using a Hyperprocessor (Amersham
Pharmacia Biotechnology, UK).
2.10 Antibodies
A variety of different anti-prion protein monoclonal antibodies (MAb) have been
employed in DELFIA, CDI, and western blotting studies described here. The table
below summarises the name, reactivity, epitope specificity, and immunogen.
Table 6





















2.11 General Health and Safety
Procedures were carried out in accordance with guidelines for work with the agents
of transmissible spongiform encephalopathies (TSEs) published by the Department
of Health Advisory Committee on Dangerous Pathogens (ACDP) Spongiform
Encephalopathy Advisory Committee (SEAC) joint working group
(www.doh.gov.uk/cjd/tseguidance).
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All procedures using infectious tissues and fluids were conducted in Class 1 bio-
safety hoods in a Category 3 laboratory wearing gown/apron, protective footwear,
protective eyewear and double gloves. Aerosol-resistant pipette tips and safe-lock
eppendorf tubes were used. Centrifuge rotors were loaded and unloaded in a class 1
hood, not in the centrifuge. All contaminated plastic wear was immersed in 2N
NaOH overnight. All contaminated liquids were brought to 2N NaOH and left
overnight. Sawdust was added to NaOH decontaminated liquids, the container
sealed and placed in yellow bags for incineration. Any accidental spills were treated
by absorption on paper towel and NaOH decontamination.
2.12 Statistical Analysis
All statistical analysis including t-tests was carried out using NCSS 2001 program
and Microsoft Excel. Box plots were produced by the NCSS 2001 software
according to a common procedure in which boxes represent the interquartile range
(IQR), the top and bottom of the box are the 25th and 75th percentiles, and the
horizontal line through the box represents the median. The line and bar (whiskers)
above and below the box represent the upper and lower adjacent values. The upper
adjacent value is the largest observation that is </= to the 75th percentile plus 1.5
times the IQR. The lower adjacent value is the smallest observation that is >/= to the
25th percentile minus 1.5 times the IQR. Outliers, shown as small circles, are those
values which lie outside the upper and lower adjacent values 153.
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Chapter 3: Study of variation of prion protein in the peripheral blood of
patients with variant and sporadic Creutzfeldt-Jakob disease detected
by dissociation enhanced lanthanide fluoroimmunoassay and flow
cytometry.
3.1 Plan
The first objective was to set up a DELFIA assay suitable for the screening ofwhole
blood and separated blood components from clinical patients and healthy adult blood
donor and neurological controls for the detection ofPrPc.
3.1.1 DELFIA assay calibration and standardisation
3.1.1.1 Comparison and calibration ofplatelet standard reagents
The DELFIA assay design for screening ofwhole blood and separated blood
components was based upon methods developed previously by MacGregor et al 9. In
order to facilitate its successful transfer to the National CJD Surveillance Unit
recalibration and standardisation of coating and detection antibodies and assay set-up
was essential to ensure assay reproducibility. In addition an assessment of suitable
conditions for the screening ofwhole blood and separated blood components was
needed to ensure accurate quantitation of PrPc.
As a source ofPrPc as a standard for assays, a lyophilised platelet standard reagent
supplied by Perkin Elmer Life sciences was titrated against lyophilised platelet
standards (NSL standards) used routinely by MacGregor et al 9 for assay calibration.
Five assays were performed using plates precoated with monoclonal antibody FH11
supplied by Perkin Elmer Life sciences, UK (P820205), and using europium labelled
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3F4 detection antibody at a 1/500 dilution (Lot 070201) also supplied by Perkin
Elmer Life sciences. Assays were performed following the standard operating
procedure described in the methods section 2.3 to provide an accurate evaluation of
the concentration of PrPc in the Perkin Elmer standard reagent. Both standards were
diluted in DELFIA assay buffer at five fold dilutions: 1:5, 1:25, 1:125, 1:625, and
1:3125 and were assayed in duplicate. The NSL standard reagent had been
previously titrated against human recombinant PrP with a ratio of 1 Unit (U) to 200
pG 150 and was assigned an equivalent concentration of 2188 U/mL. Dilutions of this
standard were used to provide a standard curve against which the Perkin Elmer
standard was calibrated. The plate layout for the assays is illustrated in Table 7;
samples were assayed at several dilutions to ensure parallelism and accurate
determination of concentration of PrPc. The results are illustrated in Table 8.
Table 7
1 2 3 4 5 6 7 8 9 10 11 12
A 3125 3125 625 625 125 125 25 25 5 5
B 3125 3125 625 625 125 125 25 25 5 5
C 3125 3125 625 625 125 125 25 25 5 5











Plate map of 96 well microtitre plate showing layout of dilutions of NSL standard (rows A,C)
and Perkin Elmer standard (B,D) for titre experiments. The smaller table below provides
values for the calibration curve.
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WorkOut software version 1.5 provided by PerkinElmer Lifescience was
programmed to calibrate each assay. The means of sample duplicates were
calculated, and blank means were subtracted before calculation of PrPc
concentration. The coefficient of variation (CV) was calculated to ensure good
reproducibility between duplicate wells.
Table 8
Group Wells Raw data Mean Blank Corrected Concentration %CV
Standard 1 A3, A4 797 380 0.7 2.48
Standard 2 A5, A6 1899 1482 3.5 0.15
Standard 3 A7, A8 8137.5 7720.5 17.5 1.59
Standard 4 A9, A10 45441 45024 87.5 2.62
Standard 5 A11, A12 243400 242990 437.5 2.87
Blank A1, A2 417 0 0 0
PE Blank B1, B2 436 10 0.03 4.22
PE 3125 B3, B4 1175.5 758.5 1.64 38.79
PE 625 B5, B6 2471 2054 4.94 4.69
PE 125 B7, B8 10817 10400 22.94 1.02
PE 25 B9, B10 58643 58226 110.78 2.85
PE 5 B11, B12 326390 325973 579.59 2.56
NSL Blank C1, C2 443 26 0.06 0
NSL 3125 C3, C4 939.5 522.5 1.03 17.84
NSL 625 C5, C6 3496.5 3079.5 7.4 9.32
NSL 125 C7, C8 7443.5 7026.5 16.06 1.72
NSL 25 C9, C10 41565 41148 80.01 1.55
NSL 5 C11, C12 206140 205723 373.24 0.77
PE Blank D1, D2 684 264 0.46 0
PE 3125 D3, D4 900 483 0.93 4.56
PE 625 D5, D6 2469.5 2052.5 4.94 1.69
PE 125 D7, D8 11610 11193 24.51 8.92
PE 25 D9, D10 59507 59090 112.34 1.7
PE 5 D11, D12 322630 322213 573.25 1.57
Blank E1-H12
Data for calibration assay 1, values in cpm are shown for raw duplicate mean and blank
corrected values for each sample assayed. The calibrated concentration is expressed in
U/mL and the coefficient of variation (CV) as a percentage. PE: standard supplied by Perkin




PE 3125 1.64 5125
PE 625 4.94 3087.5
PE 125 22.94 2867.5
PE 25 110.78 2769.5
PE 5 579.59 2897.95
Mean 3349.49
Run2
PE 3125 0.93 2906.25
PE 625 4.94 3087.5
PE 125 24.51 3063.75
PE 25 112.34 2808.5
PE 5 573.25 2866.25
Mean 2946.45
Table showing the concentrations of PrF* as calculated by the calibrated DELFIA assay (A),
and these values corrected by the dilution factor (B) and the overall mean for each of two
runs of standard dilutions.
The concentration of each standard was calculated by correcting the calibrated value
by the dilution factor, then calculating the mean of the dilution series as shown in
table 9. Calibration of the Perkin Elmer standard reagent produced values of 3349.49
U/mL, and 2946.45 U/mL for each respective run. This gave an average calibration
value of 3147.97 U/mL. Recalibration of the NSL standard gave a value of 2743.54
U/mL. The concentration of PrPc present in the Perkin Elmer standard is therefore
not dissimilar to the concentration of the NSL standard. Some variation in
concentration exists between dilutions, but this is to be expected when dilution
factors are high and concentration values are relatively low.
The Perkin Elmer standard was re-titrated against the NSL standard reagent a further
three times giving the following values: 2570 U/mL; 2943 U/mL; 2090U/mL. The
mean value generated from these 5 separate experiments was 2800U/mL, a value
used as this standard reagent was used for assay calibration. New standards were
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calibrated against this before use but calibration for assays and data described here
were performed using the PerkinElmer standard reagent.
3.1.1.2 Calibration ofplatelet standard reagent against human
recombinant PrP°
In addition to the introduction ofnew standard reagents, the standard was calibrated
against human recombinant PrPc. Prionics recombinant PrPc was assayed in
duplicate in a dilution series from 5000-0.78 nG/mL, the assay was calibrated using a
lyophilised platelet standard supplied by Diagnostics Scotland, UK which had been
previously calibrated against NSL and Perkin Elmer standard reagents and assigned a
value of 2530 U/mL. Concentrations of dilutions of recombinant PrPc within the
range of the calibration curve were converted to nG/mL, these values did not reflect
the concentrations of recombinant PrPc known to be present in each dilution (Table
10). The calibration was adjusted using the equation below to ensure that the
concentration ofPrPc calculated reflects the concentration recombinant PrPc assayed.











Determination of the concentration of PrF* in nG/mL present in 1 U, calibrated using Prionics
recombinant PrPp
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(485.18 *X)/ 1000= 12.5 nG;
X = (12.5 * 1000)/485.18
X = 25.76 pG
3.1.1.3 Titration of coating antibody
Coating plates with FH11 as an alternative to purchasing precoated microtitre plates
from PerkinElmer Life sciences was explored in an attempt to reduce expenditure.
MacGregor et al9 previously recommended coating of 96 well microtitre plate with 5
pg/mL ofmonoclonal antibody. To ensure maximal binding and the sensitive
detection ofPrPc rows of a microtitre plate were coated with a range of dilutions of
FH11 in doubling dilutions between 0.195 - 25 pg/mL. Following overnight coating
the plate was washed and incubated with a 1/5 dilution ofplatelet standard in
DELFIA assay buffer, except the first two columns which were incubated with assay
buffer alone to assess background binding. Five duplicates of a 1/5 dilution of
platelet standard assessed the level ofbinding for each concentration of coating
antibody. The assay was performed following the standard DELFIA protocol for
detection ofPrPc using europium labelled 3F4 batch 29/10/2003 at a 1/15,000
dilution. The mean europium counts per minute for samples assayed at each
concentration of coating antibody along with the two times standard deviation, to
equal 95% confidence interval, were calculated and the data plotted (Figure 11). The
concentration of FH11 at which the curve flattens off is the point at which further
increases of coating antibody cease to increase the binding and the point at which
coating has reached saturation. The previous assessment of 5 pG/mL by MacGregor
et al9 proved to be correct by this titration, the curve flattened off at 3.125 pG/mL,
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and a coating concentration of 5 pG/mL slightly in excess of this would ensure
maximal binding affinity.
Figure 11
Assessment of coating conditions for monoclonal antibody FH11. Concentration of FH11
(/iG/mL) on the x-axis and detection of 1/5 dilution of platelet standard in counts per minute
shown on the y-axis, the error bars show mean + 2 sd of the 5 duplicate measurements.
3.1.1.4 Comparison of Dynatech lmmunlon-4 HBX and Greiner
microlon microtitre plates
In a continuation of experiments to standardise conditions for PrPc analysis by
DELFIA a comparison was made between two different plate types to assess
whethermedium or high binding plates were best suited for this type of analysis.
Dynatech Immulon-4 high binding flat bottomed plates (those used routinely by
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MacGregor et al 9) and Greiner Bio-One Microlon medium binding plates (product
No. 655080 Greiner Bio-ONE, UK) were coated overnight with 5 uG/mL FH11 and
the standard DELFIA protocol for the detection of PrPc described in section 2.3 was
followed. Microtitre plates were incubated with dilutions of platelet standard, a
plasma quality control sample assayed at 1/5, 1/10, and 1/50 dilutions, blank wells
for an assessment ofbackground binding, and 1/10, 1/20, and 1/40 dilutions of either
untreated whole blood or the same whole blood treated with two episodes of snap
ffeeze-thawing in dry ice and ethanol. The mean europium counts per minute and
standard deviations for blank wells were calculated to give an indication of
background binding. The concentration of the platelet standard was calculated to
assess accuracy ofmeasurement. The flagging of sample duplicates with a CV




Dynatech Immulon-4 plates sd
Blank Mean (n=10) cpm 557 +/- 28.94
Mean concentration




Untreated whole blood U/mL 429 +/- 90.98
Mean concentration
Freeze-thawed whole blood U/mL 590 +/- 67.54
Greiner Microlon plates
Blank Mean (n=6) cpm 2228 +/- 248.86
Mean concentration




Untreated whole blood U/mL 298 +/-71.80
Mean concentration
Freeze-thawed whole blood U/mL 443 +/- 89.96
Assessment of the suitability of two different microtitre plates for DELFIA, Blank means are
shown in cpm and concentrations for platelet standard reagent and untreated and freeze-
thawed whole blood expressed as a concentration in U/mL, standard deviations are also
shown for each calculation.
The results summarised in table 11 show that the Dynatech Immulon-4 HBX plates
are more suitable for DELFIA screening purposes. The background binding to these
plates is a quarter that obtained using the Greiner plates, and is similar to background
levels obtained using the FH11 plates precoated by PerkinElmer. The standard
deviation measurement indicates that the blank wells show less variability than is
seen with the Greiner plates. Calibration of the platelet standard was closer at
2616U/mL in Immulon-4 plates to the previously calibrated value of 2800U/mL in
Perkin Elmer pre-coated plates than that of 2309U/mL obtained using the Greiner
plates. The numbers of duplicates flagged due to a CV in excess of 10 % were three
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times higher using the Greiner plates than using the Dynatech plates. Finally higher
levels of PrPc detected in untreated and freeze-thawed whole blood samples were
obtained using the Dynatech plates than with the Greiner plates. It was decided
therefore to use the Dynatech microtitre plates for future DELFIA assays.
3.1.1.5 Titration and evaluation of europium labelled 3F4
DELFIA assays used europium labelled 3F4 monoclonal antibody supplied by
PerkinElmer life sciences as detection antibody. This was supplied and labelled by
PerkinElmer life sciences with a yield of 12 molecules of europium per IgG
molecule, and recommended for use at a 1/500 dilution with filtration through a 0.22
pM filter. Given that this reagent was in short supply and expensive we explored the
possibility of labelling and using our own antibody to reduce costs. 1 mG of 3F4
antibody obtained from the TSE Resource Centre Compton, UK was labelled (batch
11/7/02) following methods described in the materials and methods section 2.3.2
giving a yield of 24 molecules of europium per IgG molecule. The high labelling
yield was probably a consequence of losses of IgG on the Microcon filter membranes
given that the final protein content of labelled antibody was 0.47 mG/mL from 1 mG
added at the beginning.
The labelled antibody was evaluated firstly by testing at 1/5000, 1/10,000, and
1/20,000 dilutions in parallel with current PerkinElmer labelled antibody for the
detection ofPrPc in dilutions of the standard reagent. The detection in cpm of
binding of each dilution of newly labelled 3F4 was plotted alongside the currently
used PerkinElmer labelled 3F4 to determine which dilution performed similarly to
the PerkinElmer supplied reagent. (Figure 12).
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Figure 12
Graph representing the detection in cpm (y axis) of PrF* present in dilutions 1/5-1/3125 (x-
axis) ofplatelet standard reagent using both the PerkinElmer labelled 3F4 (PE 3F4) and
newly labelled 3F4 batch 11/7/02 at 3 different dilutions. All sample dilutions assayed in
duplicate.
Given that the 1/5000 dilution ofnewly labelled 3F4 produced a calibration curve
with higher europium counts at each dilution of standard reagent with similar
background measurements to values obtained with the 3F4 labelled by Perkin Elmer
this newly labelled 3F4 was used under these conditions. In general when newly
labelled detection antibodies were characterised the conditions that produced counts
>250000 for the 1/5 dilution of platelet standard coupled with a low background
binding and good parallelism between dilutions were adopted as standard.
The second stage of evaluation of the labelled antibody was to assess its suitability
for the detection of PrPc in whole blood and blood components.
Whole blood and separated components including plasma, huffy coat, platelets, and
50 % Red Blood Cells from a healthy adult donor obtained from the Scottish
National Blood Transfusion Service were assayed for PrPc each at doubling dilutions
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between 1/5-1/80. The assay was calibrated using lyophilised platelet standard
obtained from Diagnostics Scotland and a plasma quality control sample was
included for PrPc assessment. The calibrated concentration in U/mL for each
component was corrected for the dilution factor and the means and standard
deviation were calculated. The CV for sample duplicates was also monitored to
ensure it did not exceed 10 %. The chart below illustrates the mean concentrations










Whole Blood Plasma 50% RBCs Platelet Buffy Coat
Bar chart illustrating the mean PrF* concentration in U/mL (y-axis) in whole blood and
separated blood components from a healthy adult donor. The + 2 sd for the calculation of
PrF* by 5 dilutions is shown as error bars.
The assay demonstrated good parallelism between dilutions with low standard
deviations, and sample duplicates did not have CV that exceeded 10 %.
These conditions for use of labelled 3F4 were adopted for future assays for the
detection of PrPc.
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3.2 Experiments to establish conditions for screening whole blood
and separated components, effects of anti-coagulants, and the
suitability of the blood separation protocol
Healthy adult controls in addition to all recieved clinical CJD samples to the CJD
Surveillance Unit were separated using the blood separation protocol described in the
material and methods section 2.7. The following experimental studies were
conducted in order to determine the effects of freeze-thawing upon the detection of
PrPc, and the range ofdilutions most suitable for each component to ensure
parallelism between dilutions and the accurate quantitation of PrPc. Experiments
standardising conditions for DELFIA screening for PrPc have included an analysis of
untreated and freeze-thaw treated blood components, and data suggests that freeze-
thaw treatment causes an increase in the levels of PrPc detectable in peripheral blood.
In addition to these studies full blood count and flow cytometry studies were carried
out on several healthy adults to determine the effects of blood anticoagulants upon
PrPc detection and the purity of separated blood components.
3.2.1 Comparison of refrigerated and freeze-thawed separated blood
components
A 10 mL citrate anti-coagulated whole blood sample from a healthy adult donor was
separated and buffy coat, 50 % red blood cells, platelet, and plasma components
were split into 2 aliquots one ofwhich was stored frozen at -80° C and the other
refrigerated at + 4° C for 24 hours. Each component aliquot was diluted to 1:5, 1:10,
1:20 in DELFIA assay buffer and assayed in duplicate for PrPc by DELFIA. The
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assayed concentrations were corrected by the dilution factor and the means and
standard deviations were calculated for each component, the results are listed in table
12. The highest concentrations of PrPc were detected in freeze-thawed aliquots
compared with refrigerated aliquots. This result was largely expected since PrPc is
expressed on cell membranes as well as in the cell cytoplasm. The action of freeze-
thaw lysis will permit the detection of internal cell PrPc and will disrupt the
association of PrPc with cell membranes, therefore making more available for
detection. These findings though may also be a consequence ofPrPc degradation in
refrigerated samples. The levels ofPrPc detected in different blood fractions are
largely as expected with highest levels detectable in the plasma and buffy coat
components, with lower levels in the Red Blood Cell fraction. What was not
expected was the low concentration ofPrPc detectable in the platelet component
however this may be a consequence of the separation protocol. Where PrPc levels
are high for example in plasma and frozen buffy coat components there is good
parallelism between dilutions, however where levels are low for example in Red
Blood Cell components it would be advisable to assay these components undiluted or
at lesser dilutions.
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parallelism between dilutions, however where levels are low for example in Red









Frozen Buffy Coat 1/5 8.23 41.15 - -
Frozen Buffy Coat 1/10 3.21 32.10 - -
Frozen Buffy Coat 1/20 1.25 25.00 32.75 8.09
Ref Buffy Coat 1/5 0.43 2.15 - -
Ref Buffy Coat 1/10 0.77 7.70 - -
Ref Buffy Coat 1/20 0.20 4.00 4.62 2.83
Frozen RBC 1/5 3.98 19.90 - -
Frozen RBC 1/10 *4.00 40.00 - -
Frozen RBC 1/20 0.46 9.20 14.55 7.57
Ref RBC 1/5 0.34 1.70
Ref RBC 1/10 0.21 2.10
Ref RBC 1/20 0.20 4.00 2.60 1.23
Frozen Plasma 1/5 56.80 284.00 - -
Frozen Plasma 1/10 27.60 276.00 - -
Frozen Plasma 1/20 13.70 274.00 278.00 5.29
Ref Plasma 1/5 49.53 247.65 - -
Ref Plasma 1/10 22.14 221.40 - -
Ref Plasma 1/20 10.85 217.00 228.68 16.57
Frozen Platelets 1/5 0.07 0.35 - -
Frozen Platelets 1/10 0.03 0.30 - -
Frozen Platelets 1/20 0.00 0.00 0.22 0.19
Ref Platelets 1/5 0.02 0.10 - -
Ref Platelets 1/10 0.00 0.00 - -
Ref Platelets 1/20 0.04 0.80 0.30 0.44
Table showing results of DELFIA assay for detection of PrF* in frozen and refrigerated (Ref)
aliquots of buffy coat, RBC, plasma, and platelet components assayed at 3 dilutions.
* Signifies samples where the duplicate coefficient of variation was >10, these Figures were
excluded from mean calculations.
3.2.2 Variability of PrP° detection amongst healthy adult controls
In order to study the degree of variability in PrPc expression in healthy adult controls
citrate anti-coagulated whole blood samples were separated and assayed for PrPc by




Component Mean PrPc U/mL N Range U/mL Deviation
Buffy Coat 68 8 16-156 46.5
Plasma 460 10 357-540 43.2
50% RBC 13 8 6-19 4.6
Platelet 147 8 4-163 67.8
Whole Blood 484 6 289-680 171.2
Blood components from healthy adults (n) assayed by DELFIA for PrF* (U/mL). All samples
assayed in duplicate at 1:5, 1:10, 1:20.
The results compare well with the findings ofMacGregor et al9 with the exception
of levels ofplatelet PrPc which were lower, this is a probable consequence of
differences in the preparation ofblood components. Fresh citrate phosphate dextrose
anti-coagulated whole blood components were prepared by a buoyant-density
centrifugation method over polymorphprep by MacGregor et al 9 in contrast to the
separation method used and described here. These differences may explain why
MacGregor et al found the highest levels ofPrPc in the platelet component. The
separation method used here was not ideal for isolation of the platelet and huffy coat
components; cells often clumped together and proved difficult to resuspend, this may
explain the large ranges in the platelet and buffy coat data. This protocol was
designed to produce these components without the need to use Ficoll. Ficoll, like
dextran sulphate, is a polyanion, and it was thought that it may interfere with the
processing and replication of the infectious agent as has been reported for dextran
sulphate 154. It was necessary to employ a separation protocol that avoided Ficoll
because blood from clinical CJD patients was archived not only for this study but
also for future infectivity studies, and the use of Ficoll may have reduced infectivity
levels in these samples.
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It is possible that the reduced PrPc level detected in platelet fractions was due to the
effects on platelets of using citrate as an anticoagulant or cellular contamination of
non-platelet components with platelets.
In order to evaluate these possibilities 30 mL ofwhole blood from a healthy adult
donor was split into three vacutainers containing citrate, EDTA, and heparin anti¬
coagulants. These samples were then separated following the standard separation
protocol, and whole blood, plasma, RBC, and platelet components were assayed for
PrPc by DELFIA. Full blood counts were performed on the same samples to provide
cell counts and give an indication of cellular contamination of separated components.
Table 14 outlines the findings which show that the use of different anti-coagulants
has a significant effect upon whole blood platelet counts. Counts were at least two
times higher using EDTA than citrated blood. The platelet count using heparin was
particularly low which was expected considering heparin is known to cause platelet
aggregation. Others (G.R.Barclay personal communication) have shown that the
leucocyte-platelet adherence is much less in EDTA than in citrate or heparin, where
platelets may adhere to leucocytes in buffy coat components. The justification for
using citrate as an anticoagulant for clinical and control samples was based upon
claims by Wadsworth et al 155 that copper chelation activity ofEDTA led to changes
in the structure ofPrP. This was found as different cleavage patterns which gave rise
to fragments of different molecular mass in western blotting studies. More recent
studies by Notari et al 156 show however that it is the elevation in pH caused by the
addition ofEDTA and not the chelation activity that causes changes to cleavage
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patterns. In hindsight EDTA may have been the more appropriate anti-coagulant
given the effects of citrate on cell counts.
Table 14
Whole Blood Platelet count RBC count White cell count
Anticoagulant 109/L 1012/L 109/L
Citrate 104 3.98 3.83
Heparin 53 4.37 5.49
EDTA 219 4.28 4.34
Full blood counts of whole blood samples in 3 different anti-coagulants
The effect of different anti-coagulants is evident when whole blood is separated into
constituent components and assayed for PrPe by DELFIA. The concentrations of
PrPc detectable in whole blood, plasma, and platelet components for each
anticoagulant were calculated by assaying each component at three dilutions in
duplicate, any duplicate with a CV greater than 10% was excluded. Red Blood Cell
and buffy coat components were included in this analysis, PrPc levels were at the
limit of detection of the assay and thus could not be determined with accuracy and
were excluded from final results analysis (Table 15). The use of citrate as an anti¬
coagulant causes a decrease in the concentration of PrPe detectable by DELFIA in all
components assayed compared with heparin and EDTA. The use ofEDTA resulted







U/mL Stdev Platelet count 109/L PrPc U/109/L
Whole blood
Citrate 388 35.23 - -
Heparin 714 132.23 - -
EDTA 436 6.81 - -
Plasma - -
Citrate 496 102.53 - -
Heparin 555 30.51 - -
EDTA 733 101.3 - -
Platelets - -
Citrate 139 19.09 64 2.17
Heparin 1353 67.36 151 8.96
EDTA 1804 77.07 306 5.90
Concentrations of PrPp detectable by DELFIA in whole blood, plasma, and platelet
components using different anti-coagulants. The mean concentration (U/mL) and sd are
shown as well as platelet counts for the platelet components.
It is clear therefore that citrate is having an effect upon platelets causing a reduction
in platelet numbers in the platelet component when whole blood samples are
separated. This is unusual since platelet aggregation is usually associated with the
use ofheparin as seen in table 14, which causes inaccurate platelet cell counts when
full blood counts are performed. EDTA is used routinely by haematology
laboratories to investigate platelet cell counts in peripheral blood, because its use is
not associated with aggregation. It is possible that the calcium binding activity of
citrate is in some way responsible for decreases in the detection of PrPc but the exact
mechanism is unknown. What is clear though is that the effects of the separation
protocol coupled with the use of citrate causes major decreases both in platelet
numbers detected by full blood count analysis and in the concentration of PrPc
detectable in platelet components due to this reduction in cell numbers.
Despite these findings the use of citrate was still favoured as the anti-coagulant of
choice; this ensured that results from analysis of all samples were directly
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comparable, however the detrimental effects of citrate on platelet counts is evident in
future results.
Full blood counting of separated components allowed an assessment of the purity of
separated blood components and the suitability of the blood separation protocol.
Citrate anti-coagulated whole blood from two healthy adults was separated into
constituent components on which full blood counts were performed. Cell counts on
separated components found there to be no cellular contamination of the plasma
component, and no cells other than platelets were detected in the separated platelet
component. The Red Blood Cell component was also relatively pure despite a small
amount of leucocyte contamination 0 - 1.57 X 109/L which is relatively small
considering there were > 10 X 109/L leucocytes present in unseparated whole blood
samples. The separation protocol therefore produced components with good purity
and little cellular contamination. However these studies demonstrated the very low
levels of platelets and leucocytes present in respective platelet and buffy coat
components once separated. Platelet counts were 2 X 109/L and 27 X 109/L in the
platelet components compared with 56 X 109/L and 64 X 109/L in untreated citrate
anti-coagulated whole blood samples. Leucocyte cell numbers in separated buffy
coat components were undetectable in one control and 0.81 X 109/L in the second
compared with 10.51 X 109/L and 10.19 X 109/L in untreated citrate anti-coagulated
whole blood samples. Problems associated with the resuspension of cell pellets and
problems with cell clumping associated with the use of citrate are likely to explain
these low cell counts, and these problems are evident in assessment ofPrPc levels in
platelet and buffy coat components from clinical CJD and control groups.
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As a result of the finding of low concentrations of PrPc detectable in Red Blood Cell,
platelet and buffy coat components they were assayed in future at five doubling
dilutions between 1/5 - 1/80. Where levels were particularly low samples were
rescreened as undiluted samples. PrPc was detectable at higher concentrations in
whole blood and plasma components and so they were assayed at doubling dilutions
in the range 1/10-1/160 in order to compensate for quenching evident at lower
dilutions and to ensure good parallelism between each dilution series. Data was
expressed in Units per mG total protein for separated cellular components to
normalise data by compensating for the effects of the separation protocol upon
cellular particulate recovery in components and to ensure that range differences in
cell number did not contribute to differences in PrPc levels between groups.
Although studies on full blood counts of clinical patient samples and controls did not
show abnormalities, full blood count data could not be generated from frozen stored
clinical and control samples used in this study, therefore normalisation by total
protein was essential for all components with the exception ofwhole blood.
The preliminary experiments presented so far represent studies designed to
standardise DELFIA assay procedure and the titration of reagents used therein.
These studies ensure that the assay is sufficiently developed and sustainable to
ensure accurate and comparable measurement of PrPc in whole blood and separated
blood components from both clinical CJD patient and control groups to allow the
investigation of potential differences.
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3.3 Study of variation in concentration of prion protein in the
peripheral blood of patients with variant and sporadic Creutzfeldt-Jakob
disease detected by dissociation enhanced lanthanide
fluoroimmunoassay and flow cytometry
3.3.1 DELFIA analysis
DELFIA technology was employed to study potential variation in the expression of
PrPc in vCJD and sCJD patients, healthy adult controls and neurological controls.
Whole blood separation and the DELFIA PrPc assay were carried out following
methods detailed above (2.3, 2.7). The means, median and standard deviation were
calculated and the Mann-Whitney U test was used to determine the significance of
differences in medians between groups. Data was expressed in Units per mL total
protein, for whole blood and all separated components, to normalise data by
compensating for the effects of the separation protocol upon cellular particulate
recovery in components, and to ensure that range differences in cell number did not
contribute to differences in PrPc levels between groups. Although full blood count
data from clinical patient samples and controls did not show gross abnormalities, full
blood count data could not be generated from frozen stored clinical and control
samples used in this study, therefore normalisation by total protein was essential for
all components with the exception ofwhole blood.
Measurements of total protein levels were carried out using a Bio-Rad protein assay
as described in section 2.6.
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3.3.1.1 Detection of whole blood PrPp by DELFIA
Whole blood samples from 10 patients with vCJD, 10 patients with sCJD, 8
neurological controls, and 29 healthy adults (1 excluded due to lack of correlation
between dilutions) were analysed in duplicate at 5 dilutions by DELFIA. For each
group the median, and interquartile range was calculated and data expressed in U/mL
(Figure 15A, Table 16). There is a significant decrease in the concentration of PrPc
in vCJD (p=0.005) and neurological control patients (p=0.0001) compared with
healthy adults, but not between vCJD and sCJD, nor between neurological controls
and sCJD patients. Despite the significance there was considerable overlap between
the vCJD and healthy adult control groups which indicates that this observation
would have little use as a discriminatory test for diagnosis or screening. These
differences between groups remain in the same relative order and significance when
PrPc concentration is normalized for total protein and expressed as U/mG; there
remains a significant decrease in the concentration ofPrPc in vCJD (p=0.012) and
neurological control patients (p=0.0004) when compared with healthy adults (Figure
14A).
3.3.1.2 Detection ofplatelet poor plasma PrF* by DELFIA
Platelet poor plasma samples from 10 patients with vCJD, 10 patients with sCJD, 29
healthy adults (1 excluded due to lack ofparallelism between dilutions), and 6
samples (2 samples unavailable) from neurological controls were analysed by
DELFIA for PrPc (Figure 14B, Table 16). We found significant elevation in the
plasma PrPc concentration in sCJD patients when compared with both healthy adult
(p=0.022) and neurological control groups (p=0.050), but not when compared to
levels found in vCJD patients. No significant differences were found in comparisons
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between controls and vCJD groups. Statistically significant differences between
groups were not evident when data was expressed in U/mL PrPc (Figure 15B)
3.3.1.3 Detection ofRed Blood Cell PrP° by DELFIA
50% Red Blood Cell samples from 10 vCJD patients, 9 sCJD patients, 26 healthy
adults, and 7 neurological controls were analysed by DELFIA to determine PrPc
concentration (Figure 14C, Table 16). The neurological control group showed a
significant reduction in PrPc concentration when compared with vCJD patients
(p=0.029), sCJD patients (p=0.024), and healthy adults (p=0.001). vCJD, sCJD
patients and healthy adults all exhibited similar median values for PrPc concentration
and therefore did not exhibit significant differences when compared with each other.
3.3.1.4 Detection of Platelet PrP° by DELFIA
Platelet samples from 24 healthy adults, 9 patients with vCJD, 9 patients with sCJD,
and 7 neurological controls were analysed for PrPe concentration (Figure 14D, Table
16). Samples excluded from each group constitute those where PrPc concentration
could not be measured reproducibly across a range of dilutions. The level ofplatelet
PrPc in neurological controls was significantly reduced compared to levels in healthy
adults (p=0.001), vCJD patients (p=0.039), and sCJD patient samples (p=0.017). In
addition the concentration ofplatelet PrPc in the sCJD samples was significantly
reduced compared with levels in healthy adults (p=0.021) but not against vCJD.
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3.3.1.5 Detection of Buffy Coat PrP° by DELFIA
Buffy coat PrPc expression levels were not detected at significantly high
concentrations, particularly in clinical groups, to permit accurate measurement.
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The concentration of PrP^ assayed by DELFIA in separated blood components of clinical and
control samples. The concentration of whole blood (A), platelet poor plasma (B), 50% red
blood cell (C), and platelet (D) PrPp (Units per mG) assayed by DELFIA in vCJD, sCJD, and
















vCJD sCJD Donor controls Neurological
controls
The concentration ofPrF* assayed by DELFIA in separated blood components of clinical and
control samples. The concentration of whole blood (A), platelet poor plasma (B), PrPp (Units
per mL) assayed by DELFIA in vCJD, sCJD, and donor and neurological control groups.
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Table 16
Sample Ulood component N Median U/mG Range 95% CL U/mG
vCJD Whole Blood 10 3.438 1.912-3.593
sCJD Whole Blood 10 3.227 2.073 - 5.754
Donor Controls Whole Blood 29 4.16 3.376 - 6.635
Neurological Controls Whole Blood 8 2.35 0.823-3.375
vCJD Plasma 10 8.375 5.225- 14.912
sCJD Plasma 10 13.446 8.078 - 17.314
Donor Controls Plasma 29 9.316 8.038- 10.624
Neurological Controls Plasma 6 8.405 5.31 - 10.8
vCJD Red Blood Cells 10 0.411 0.19-1.045
sCJD Red Blood Cells 9 0.434 0.162-0.648
Donor Controls Red Blood Cells 26 0.499 0.29 - 0.579
Neurological Controls Red Blood Cells 7 0.16 0.16-0.27
vCJD Platelets 9 293.93 174.42 - 1150.442
sCJD Platelets 9 316.56 213.69-400.75
Donor Controls Platelets 24 581.11 389.29 - 855.15
Neurological Controls Platelets 7 83.37 35.48 - 429.6
Table to illustrate the medians and range (95% confidence limits) in U/mL of separated
components from different clinical and control groups as measured by DELFIA
3.3.2 Flow cytometry analysis
The cell associated PrP (net median fluorescence intensity above background) ranges
for lymphocytes platelets and red cells are shown as interquartile box plots (Figure
16) for healthy adult controls, neurological controls, sCJD cases and vCJD cases.
The only significant difference found between groups was between red cell PrP in
healthy adults and in non-CJD neurological controls (p = 0.008). Although platelet
PrP was raised in both sCJD and vCJD cases compared to healthy adults or
neurological controls, this did not reach significance.
Clinical vCJD and sCJD cases were found to be as sensitive as healthy adults and
non-CJD neurological patients to removal of cell-associated PrP by PK (Figure 17).
The distribution of FITC fluorescence following PK treatment was homogeneous,
showing a single low peak in the FITC channel without any discernible higher peak
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which might indicate the retention ofPK resistant PrP, putative PrPSc, on any
subpopulation of cells.
Results are not reported for neutrophils or monocytes since in these studies we
considered the results unreliable. There appeared to be considerable non-specific
binding of fluorescence by both leucocyte classes especially evident in both healthy

















































































Box plots showing the ranges of expression of cellular PrP shown by flow cytometry on
different clinical and control groups. Expressed as median fluorescence intensity net of
background, on lymphocytes, red cells and platelets.
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3.3.3 Stability of whole blood PrP°
Some samples from clinical groups took longer than 24 hours to arrive in the
laboratory. To consider any effects of prolonged transit time at ambient temperature,
whole blood samples from 3 healthy adult controls were left at 22° C for 72 hours
and samples were removed from each control at 24-hour intervals. Samples were
analysed at each time point by flow cytometry, and lmL samples for DELFIA
analysis were stored at -80° C until analysis for the detection ofwhole blood PrPc.
The expression ofPrP on platelets measured by flow cytometry at 24-hour intervals
showed sequentially decreasing levels ofPrP with time for each individual (Figure
18). This contrasted to identification of increased expression ofPrP on platelets
found in a preliminary analysis of data for sCJD patients compared with healthy
adult controls, and implied sample storage was not responsible for this increase in the
patient group. Levels of PrPc detected by DELFIA remained stable across 72 hours
(Figure 19). Prolonged transit time and ambient storage temperatures had negligible
effects upon PrPc concentration, and are therefore unlikely to contribute to
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Stability ofPrP* in whole blood samples. Samples from 3 healthy blood donors (a, b, c) were
used to investigate the effects of temperature and storage time on the detection of PrF*.
Samples were left at 22° Celsius for 72 hours. Samples were taken every 24 hours and
stored at -80° Celsius until DELFIA analysis. The data points show mean percentage
changes in PrF* concentration, the error bars show + 2 sd. Samples were assayed 3 times
in duplicate.
3.3.4 Relationship between age and PrF* levels
Differences between control and clinical sample groups may be affected by the age
of individuals, considering vCJD usually affects young people and sCJD older
people. The concentration of PrPc (U/mG) in whole blood samples detected by
DELFIA in CJD and control groups was plotted against age and showed that PrPc
expression is unrelated to this parameter (Figure 20). Linear regression analysis was















Scatter graph to illustrate the lack of correlation between PrF* concentration (Units per mL)
and age (years) in vCJD (A) R2: 0.02, sCJD (•) R2: 0.06, and apheresis donor control
sample groups ( ) R2: 0.05.
3.3.5 Haematology of clinical and control samples
To ensure that haematological abnormalities in blood samples from clinical patients
and controls did not contribute to differences in PrP concentration and expression
between groups, full blood count data for clinical and neurological patients was
reviewed. No gross abnormalities were detected. It was not possible to obtain
haematology on the exact same sample taken for genetic analysis and subsequently
separated and analysed for PrPc by DELFIA; this data was obtained from patient
hospital records closest to the time possible and is shown in Table 17.
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Table 17
sCJD Date 1 Date 2 Hb g/dL WBC x109/l_ Pltsxl 09/L RBCX10,2/L MCV f
1452 19/09/2001 03/12/2001 15 6.2 223 5.15 87.4
1467 14/01/2002 21/01/2002 14.9 10.8 311 - -
1472 07/01/2002 17/01/2002 15.4 8.3 243 4.95 92.2
1480 03/01/2002 04/02/2002 14.5 7.4 257 4.74 91
1489 10/01/2002 07/03/2002 13.4 4.5 228 4.77 85
1499 11/03/2002 15/03/2002 13.5 10.3 308 - -
1508 04/03/2002 08/04/2002 15.5 12.7* 237 - -
1517 08/04/2002 02/05/2002 11.9 7.7 190 - -
1514 30/04/2002 13/05/2002 14.4 9.4 219 86
1529 01/05/2002 - 15.2 8.4 256 4.92 91.7
vCJD
1421 18/09/2001 09/10/2001 16.6 5.6 239 5.4 -
1424 26/09/2001 15/10/2001 14.9 5 329 5.02 -
1416 - 25/10/2001 - - - - -
1458 - 29/11/2001 - - - - -
1475 01/01/2002 24/01/2002 14.4 6 264 4.86 -
1476 17/01/2002 05/02/2002 15.8 5.94 364 6.05 -
1509 20/03/2002 26/04/2002 14.3 8.5 260 4.56 -
1518 18/02/2002 07/05/2002 15.2 9.5 208 - -
1526 10/05/2002 29/05/2002 15./ 10.22 319 5.4 83.4
1532 01/06/2002 17/06/2002 15.1 11.6* 404 - -
1630 - 24/01/2003 - - - - -
on-CJD
06/06/2002 03/07/2002 13.1 7 422* 4.41 86
25/07/2002 27/08/2002 10.6* 12.59* 449* 4.14 80
- 28/11/2002 - - - - -
09/04/2003 » - - * -
- 04/07/2003 - - - - -
- 13/11/2001 - - - - -
- 12/12/2002 - - - - -
10/07/2003 17/07/2003 12.6 6.4 679* -
Table detailing haematological data for samples included in PrF* analysis from sCJD, vCJD,
and neurological control groups. Table shows date sample taken for haematology analysis
(Date 1), the date sample was taken for PrFf analysis (Date 2). Data for haemoglobin (Hb),
white blood cell counts (WBC), platelet count (Pits), red blood cell counts (RBC), and mean
cell volume (MCV) are shown. Any abnormalities outside normal ranges are denoted by * -
where no data available.
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Our findings indicate that a reduction in concentration ofwhole blood PrPcmay be
common in vCJD and other neurological diseases but not sCJD. An elevated level of
plasma PrPc may be common in sCJD. These differences between groups appear
genuine, presumably reflecting differences in the disease process in the patients or
their typical situation in these particular groups and not an artefact of age, specimen
collection, storage or analysis. More samples are required for analysis to ensure that
differences remain significant. Despite the significance of differences between
groups the variation in values are large and there is considerable overlap between
CJD groups and control groups, which rules out the exploitation of these differences
in whole blood and plasma in screening strategies. These studies expose the
limitations in the use ofblood PrPc levels as a diagnostic tool. However they
illustrate important observations on the distribution ofPrPc in the peripheral blood of
CJD patients and the potential ofDELFIA-based PrP assays in clinical practice. The
analytical sensitivity ofDELFIA-based assays used here represent a significant step
towards the development ofDELFIA for the detection of PrPSc, which is a much
more reliable indicator of infection, and the current study emphasizes the need to
develop assays for its detection in blood 21'152.
127
Chapter 4: Use of PK and GdnHCL to discriminate between PrPc and
PrPSc
4.1 Introduction
In order to adapt the DELFIA PrPc sandwich assay system used and standardised in
the previous chapter for the detection of the disease associated isoform PrPSc it is
necessary to introduce sample processing capable of either distinguishing PrPSc from
PrPc or removing PrPc. As discussed earlier PrPSc has the same amino-acid sequence
as PrPc, and the two isoforms differ only in terms of conformation, their solubility in
non-ionic detergents, chaotropic salts, and their resistance to proteolysis by PK.
Therefore any anti-PrP antibody used as capture antibody will bind to both PrPc and
PrPSc and there will therefore be competition between the two conformers for
binding. In the absence of a conformational specific antibody for either isoform or
ligands which interact uniquely with one of the isoforms allowing their separation, it
is necessary to develop methods for distinguishing the two isoforms based on
exploitation of physical and chemical properties. One defining property of PrPSc is
its partial resistance to proteolysis by PK as defined by Prusiner et al2. This property
has been exploited in western blot and immunohistochemical methods for the
detection of PrPSc in the CNS and peripheral lympohoreticular tissues, and a common
term for PrPSc has been PrPres referring to the PK resistant portion of the protein.
Although the use ofPK at a concentration of 50 pG/mL is suitable for the removal of
all PrPc for tissue analysis it is likely that conditions used to eradicate PrP° in
peripheral blood would be different. This illustrates the inherent problem of using
PK as a means of distinguishing between isoforms. The amount ofPK required to
remove PrPc from any given tissue or fluid is dependent upon the relative amounts of
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PrPc present. Although PrPSc is partially resistant to protease action it can be
degraded completely in high concentrations ofPK, and several groups allude to the
existence ofPK sensitive disease associated PrP isoforms which would be degraded
with the use ofPK 157. Despite these drawbacks PK remains one of the few means of
distinguishing isoforms from one another to allow the detection of PrPSc.
For these reasons, in a series of three experiments healthy adult whole blood was
treated with range ofPK concentrations. PrPc concentrations were measured by
DELFIA to assess the level ofproteolysis and the suitability of using PK to eradicate
PrPc in whole blood samples.
4.2 Removal of whole blood PrP0 by PK
Citrate anti-coagulated whole blood was obtained from a healthy adult blood donor,
and 100 pL aliquots were treated with 50 pL of a range ofPK concentrations
between 0 and 500 pG/mL in DH2O for one hour in a heat block preheated to 37° C.
Replicate aliquots without PK were also heated in the same manner to ensure results
were comparable. Following incubation 20 pL of 100 mM Pefablock SC (Roche,
Switzerland), a protease inhibitor, was added to all samples. Samples were then
diluted to 1 mL final volume in DELFIA assay buffer (a 1/10 dilution ofwhole
blood, pefabloc present at 2 mM final concentration) and assayed twice in duplicate
by DELFIA for PrPc. The mean PrPc concentrations in U/mL were calculated and
the standard deviation and concentrations of PrPc in U/mL were tabulated along with
a percentage measurement ofPrPc present after PK action as a factor of that present
in the absence ofPK. Results from the first assay show that a 0-50 pG/mL range
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Mean [PrPc] U/mLpG/ML Titre 1 Titre 2 2 SD % of untreated PrP'
0 1291 1326 1308.5 49.50 100.00
2 943 944 943.5 1.42 72.11
4 801 798 799.5 4.24 61.10
10 589 614 601.5 35.36 45.97
20 516 549 532.5 46.66 40.70
25 354 382 368.0 39.60 28.12
40 379 398 388.5 26.88 29.69
50 359 362 360.5 4.24 27.55
Results table showing the level of PrPp detectable after treatment with a range of
concentrations of PK (pG/mL). The mean concentration ofPrf* of two titres is shown in
U/mL along with + 2 sd, and % value for reduction of PrP^ from that present in absence of
PK
The experiment was repeated with the range ofPK concentrations extended to 100
pG/mL. The increased PK concentration was sufficient to reduce starting
concentrations further as illustrated in Figure 21 but did not reduce levels completely
to background but to 17.95 % of levels present in the absence ofPK which represents




Graph shows titration curve of the effects of PK treatment [pG/mL] upon the detection of
PrPe [U/mL] in whole blood by DELFIA in two experiments where ranges of 0-50, and 0-100
pG/mL PK were used.
In a third experiment PK concentrations were increased to a range from 0-500
pG/mL. There was concern that the high concentrations ofPK required to reduce
PrPc levels in whole blood may interfere with the assay. Evidence of signal
disruption by PK and Pefabloc had been inferred (personal communications I.
MacGregor). Controls were included in the assay to monitor the effects of Pefabloc.
To 100 pL whole blood aliquots 50 pL ofDH2O was added to replace PK in addition
to either 20 pL lOOmM Pefabloc or DH20. Given that PK reduces the detection of
PrPc and is thought to interfere with the assay this is a relatively difficult parameter
to measure since its proteolytic action is reducing PrPc levels whilst its inclusion in
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the assay may also be causing a reduction in signal. Provided the same
concentrations are added to all samples any effects will be shared. Treatment with
500 pG/mL PK was sufficient to reduce PrPc detection by 99.86 % to 1 U/mL. This
equates to a final PK concentration of 25 pG/mL or 5 pG in each microtitre well. No
major difference in signal was found between non-PK treated samples treated with
and without Pefabloc; the mean calculated concentrations for PrPc in these samples
were 722 U/mL and 707 U/mL respectively.
4.3 Investigation into inhibitory effects of PK and Pefabloc
In order to consider potential assay disruption by PK or Pefabloc an experiment was
designed in which rows of an FH11 precoated plate were incubated for one hour with
DELFIA assay buffer alone or supplemented with one or both ofPK and Pefabloc at
final concentrations of 25 pG/mL or 2mM respectively. After washing, each row
was incubated with blanks and dilutions of standard calibrator and the DELFIA
protocol for the detection of PrPc was followed. The means europium counts per
minute (cpm) and two times standard deviation for each dilution of the standard
calibrator were calculated for each row and plotted to study effects of the different
pre-incubations on the detection of PrPc. As illustrated in Figure 22 below, pre¬
incubation with assay buffer alone or with 2mM Pefabloc give almost identical
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The graph plots the europium counts in counts per minute (cpm) for the detection of PrF* in
each dilution of platelet standard calibrator. The legend denotes the data series produced
from those rows preincubated with assay buffer (AB), PK (PK), pefabloc (PB) or
combinations thereof. + 2 sd is shown as error bars.
Supplementing the assay buffer with PK either in the presence or absence of2mM
Pefabloc had a significant effect upon the detection ofPrPc in each dilution of the
standard. The detected PrPc expressed in cpm of the 1/5 dilution of standard reagent
was reduced by 89.54 % when assay buffer was supplemented with 25mM PK, and
reduced by 91.08 % when both PK and Pefabloc were added to the assay buffer. It is
clear that exposure ofFH11 coated plate to PK is having an inhibitory effect upon
antibody-antigen interactions limiting the capture of PrPc by FH11. It seems likely
that the proteolytic activity ofPK would cause limited proteolysis of FH11 so
reducing the efficacy of antigen capture, or that despite washing some residual
proteolytic activity is retained in plate wells causing the proteolysis of PrPc in
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dilutions of the standard reagent during the sample incubation. The addition of
Pefabloc at concentrations used in western blotting for halting proteolytic action does
not restore the detection ofPrPc to levels obtained when pre-incubating the plate with
assay buffer alone, despite it being present at levels in excess of that required to halt
proteolysis. Supplementing assay buffer with Pefabloc for pre-incubation shows that
its inclusion has negligible effects upon the detection ofPrPc giving a very similar
data series to that obtained with assay buffer alone. Therefore the inclusion of
Pefabloc in the pre-incubatory buffer alone does not have any inhibitory effects upon
antibody-antigen interaction and also its protease inhibitory activity does not appear
to reduce the effects ofPK. This would indicate that there is proteolytic activity
which is not completely inhibited by Pefabloc and is sufficient to reduce the
detection ofPrPc in standard reagent either by reducing the affinity of antibody-
antigen interactions or by proteolysis ofPrPc by PK remaining in wells after
washing. These results highlight one of the major difficulties in using PK in
DELFIA and other prospective PrPSc assays as a means of removing PrPc; it has a
broad specificity and its activity does not appear to be completely eradicated by
protease inhibitors. Given that levels ofPrPc are likely to fluctuate between different
samples, optimising the use ofPK would be difficult with PK concentrations
requiring constant readjustment to ensure that conditions for proteolysis were
sufficient to remove all PrPc but did not interfere with the affinity of antigen capture.
These finding support those ofMacGregor and Barnard (personal communications)
who have found similar degradative effects ofPK.
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4.4 Assessment of assay inhibition by blood cell lysis buffer
It is likely that the high concentration ofPK required to completely degrade PrPc to
background can be reduced by disrupting cell membranes either by ffeeze-thawing or
using a cell lysis buffer prior to treatment. As seen in the previous chapter the effects
of freeze thawing led to an increase in detectable PrPc as a result of cell lysis, the
disruption of plasma cell membranes and their association with PrPc. Such effects
will make PrPc more accessible not only to maximise its detection, but its exposure
may reduce concentrations ofPK required to eradicate PrPc so reducing inhibitory
effects ofPK upon assay performance.
A blood cell lysis buffer (BCL) recipe was designed (see materials and methods
section 2.8.4) and a series of experiments were carried out firstly to ensure that this
reagent did not interfere with the antibody interactions critical to the DELFIA assay.
An FH11 coated microtitre plate was washed and rows A to D loaded with 200 pL of
assay buffer and rows E to H with a 1/5 dilution ofBCL in assay buffer. Plates were
incubated for 1 hour at RT, and washed. The plate was effectively split into 2 to
assess the effects ofpre-incubation with BCL on the detection ofPrPc in freeze
thawed and BCL treated or untreated whole blood samples. BCL treatment consisted
of supplementing whole blood with an equal volume ofBCL buffer incubating for
ten minutes before centrifugation and dilution of supernatant in assay buffer. The
fact that BCL treated whole blood samples had already been diluted 1/2 was taken
into account when making up final dilutions to allow valid comparisons between the
different treatments. Untreated or two times freeze thaw treated whole blood
samples were diluted 1/5, 1/10, 1/20 in DELFIA assay buffer. All samples were
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assayed 200 pL per well in duplicate on both the assay buffer and BCL preincubated
sides of the microtitre plate alongside platelet standard calibrator and QC plasma
sample dilutions. The mean concentration ofPrPc in U/mL was calculated, as was
the standard deviation between three dilutions. The result for each treated whole
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Chart to illustrate the detection of PrF^ (U/mL) by DELFIA in a quality control (QC) plasma
sample and whole blood samples from a healthy adult pre-treated by freeze thawing (FT),
blood cell lysis buffer (BCL) or a combination of both treatments. Samples assayed on an
FH11 coated plate preincubated with assay buffer are shown in grey, and those assayed on
the same plate preincubated with BCL buffer at a 1/5 dilution in assay buffer are shown in
purple. Error bars show + 2 sd ofmeasurements at 1/5, 1/10, and 1/20.
The raw data and calculated concentrations do not indicate that the pre-incubation
with BCL buffer have any real effect upon the detection of PrPc compared with pre¬
incubation with assay buffer alone. However the standard deviations reflect the large
differences evident in levels of PrPc detected in whole blood samples assayed at
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different dilutions. The detection ofPrPc increases with dilution probably as a result
ofmatrix quenching effect, this is where there is excess antigen bound to the capture
antibody and steric effects prevent interaction of detection antibody paratopes with
their epitopes. It appears that whole blood samples require further dilution to ensure
better correlation between dilutions. These initial results indicate that BCL buffer
treatment ensures the highest detection of PrPc compared with freeze thawing and
combined freeze thaw and BCL treatments, and that its use does not unduly affect
assay performance.
This experiment was repeated with whole blood samples assayed at 1/20, 1/40, and
1/80 in order to achieve better correlation, reduce the standard deviation between
dilution series, and to reassess the effects of the BCL buffer upon assay performance.
The increased dilutions had the desired effect of reducing standard deviations
between the dilutions. Comparison between samples assayed on microtitre plates
preincubated with BCL buffer and those assayed on the part of the same plate
preincubated with assay buffer alone showed a consistent small elevation in
concentration of PrPe detected in all samples assayed on the BCL preincubated area.
These findings are illustrated in Figure 24. The effect of increasing the dilution
factor therefore reduced variation between concentration measurements at different
dilutions. Of all the sample pre-treatments, freeze thawing ensures the highest
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Chart to illustrate the detection of PrP^ (U/mL) by DELFIA in a quality control (QC) plasma
sample and whole blood samples from a healthy adult pre-treated by freeze thawing (FT),
blood cell lysis buffer (BCL) or a combination of both treatments. Samples assayed on an
FH11 coated plate preincubated with assay buffer are shown in grey, and those assayed on
the same plate preincubated with BCL buffer at a 1/5 dilution in assay buffer are shown in
purple. Error bars show + 2sd between measurements at 1/20, 1/40, and 1/80.
This experiment was repeated once again to reconsider the effects ofBCL in assay
performance and in an attempt to further reduce the standard deviation between
dilution series. The assay was carried out exactly as above except that treated whole
blood samples were assayed at 1/80, 1/160, and 1/320 dilutions in DELFIA assay
buffer. The results shown in Figure 25 below are represented in the same manner as
above. The results reconfirm that pre-incubation ofpart of an FH11 coated plate
with BCL buffer at 1/5 dilution in assay buffer causes a small increase in PrPc
concentrations compared with samples assayed on the same plate preincubated with
assay buffer alone. This finding is probably a consequence of detergents present in
the BCL buffer removing weakly bound FH11 from the microtitre plate. This
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ensures that the remaining capture antibody is tightly bound to the microtitre plate
and achieves a better affinity with the antigen. Sample preparation by two times
snap freeze thawing ensures the highest detection ofwhole blood PrPc compared













Chart to illustrate the detection of PrPp (U/mL) by DELFIA in a quality control (QC) plasma
sample and whole blood samples from a healthy adult pre-treated by freeze thawing (FT),
blood cell lysis buffer (BCL) or a combination of both treatments. Samples assayed on an
FH11 coated plate preincubated with assay buffer are shown in grey, and those assayed on
the same plate preincubated with BCL buffer at a 1/5 dilution in assay buffer are shown in
purple. Error bars show + 2 sd between measurements at 1/80, 1/160, and 1/320.
As a result of these findings the use of freeze thawing was adopted as the standard
sample preparation procedure prior to assaying separated blood components for PrPc.
Considering samples were routinely stored at -80° Celsius after blood separation this
sample treatment was also the most convenient for analysis.
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4.5 Titre of PK concentration for the removal of PrP° from freeze-thaw
treated whole blood samples
Continuing studies into exploiting the protease resistance of PrPSc as a strategy for its
detection in peripheral blood, the concentration ofPK required to remove PrPc from
freeze-thawed whole blood was assessed. Experiments were set up similarly to those
conducted in section 4.2. 50 pL of differing concentrations ofPK in DH2O were
added to 100 pL of freeze-thawed whole blood. After incubation for one hour at
37°C, 20 pL of 100 mM Pefabloc was added and 830 pL of assay buffer was added
to make a final sample volume of 1 mL. Pefabloc concentrations were always
present in an excess to halt proteolysis. Samples were assayed twice in duplicate at
1/100, 1/200, and 1/400 dilutions and the mean concentration of PrPc and two times
the standard deviation were calculated.
Firstly the proteolytic effects of a range ofPK concentrations from 0-30 pG/mL
(Figure 26) were assessed. PrPc fell in a dose dependent fashion as concentrations of
PK increased, treatment with 30 pG/mL levels decreased PrPe to 29.26 % of levels
detectable in the absence ofPK but were not sufficient to reduce levels to
background. Treatment of 100 pL ofwhole blood with 50 pF of 30 pG/mL PK
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Graph shows titration curve of the effects of increasing concentrations of PK [pG/mL] on the
detection of PrPp [U/mL] in freeze-thawed whole blood by DELFIA. Error bars + 2 sd.
Consequently PK concentrations were increased three fold to a range between 0-150
pG/mL which represents a final PK concentration within a range of 0-50 pG/mL.
Samples were assayed as above at 1/100, 1/200, and 1/400 dilution. Increasing the
concentration ofPK led to problems in the detection of PrPc. As cpm for the higher
sample dilutions decreased (as a result of decreased PrPc detection due to proteolysis)
they dropped beneath the level of europium counts obtained for the 3125 dilution of
the standard calibrator, their concentration could not therefore be calibrated by the
assay since it fell outside the range of the calibrator. This was the case when treating
with final concentrations of 40 and 50 pG/mL. The graph in Figure 27 below shows




Graph shows titration curve of the effects of PK treatment [pG/mL] upon the detection of
PrF* [U/mL] in freeze-thawed whole blood by DELFIA. Error bars represent ±2 sd
It was therefore difficult to estimate the levels of PrPc present as a mean value from
three dilutions. PrPc values in U/mL at PK concentrations of 120 and 150 pG/mL
were calculated at 1/100 sample dilution only because PrPc levels in U/mL at 1/200
and 1/400 dilutions could not be measured since europium counts dropped to less
than 0.82 U/mL which is the limit of detection of the assay.
In a final experiment 100 pL thawed whole blood aliquots were treated with PK at
the following concentrations in 50 pL ofDH20: 0, 31.25, 62.5, 125, 250, and 500
pG/mL these correspond to the presence ofPK at final concentrations in a range
from 0 - 166.7 pG/mL. In order to ensure low levels ofPrPc expected after
treatment with high concentration ofPK were detectable, samples were assayed at a
1/10 dilution. The assay was performed as described above. The results for this
assay are summarized in Table 19 below and show the amount of PrPc detected
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following treatment with PK at final concentrations between 0 - 166.7 |iG/mL. The
use ofPK at a final concentration of 42 pG/mL is sufficient to reduce levels of PrPc
to less than 1 % of level of detectable PrPc in whole blood in the absence ofPK.
Treatment with PK concentrations of 83.3 and 166.7 pG/mL reduced detectable PrPc
to less than 0.82 U/mL. Therefore a final PK concentration between 42 - 83.3
nG/mL would be sufficient to reduce levels of PrPc to undetectable levels, see table
below.
Table 19







Table of concentration ofPrF* (U/mL) following treatment with increasing concentrations of
PK
This series of assays were beset by problems with PK reducing levels beneath the
limit of detection of the assay. Also it was often difficult to ensure accurate PrPc
measurement supported by parallelism between samples dilutions since the dilution
factor would reduce the concentration ofPrPc present. There were also many
instances where the % CV of sample assayed in duplicate were greater than ten,
implying that the presence ofPK in assayed samples might be disrupting the capture
ofPrPc by monoclonal antibody FH11 as was the case in previous experiments in this
chapter which studied the potential inhibitory effects ofPK.
There are clear difficulties in using PK as a means of removing PrPc for the detection
of PrPSe in DELFIA assays. It is difficult to standardise conditions to ensure the
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removal of all PrPc given that levels are likely to be different in different samples and
different individuals. IfPK concentrations are too high theymay remove PrPSc as
well as PrPc, and ifPK concentrations are too low theywill not remove all PrPc. The
use ofPKwill therefore always be technically difficult and limited in sensitivity.
Most significant though is that PK would appear to have some degradative effects
upon antigen antibody interactions in the DELFIA assay.
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4.6 Guanidine hydrochloride differential extraction of freeze-thaw treated
healthy adult whole blood samples.
A method has been described by Barnard et al 158 which exploits the solubility of
PrPc in low molar concentrations of chaotropic salt guanidine hydrochloride
(GdnHCL) so allowing its separation from disease associated aggregated isoform
PrPSc which remains insoluble at these low molar concentrations but becomes soluble
at higher molar concentrations. This method has been used successfully to
discriminate between PrPc and PrPSc in BSE infected bovine brain tissue. Following
differential solubilisation PrPc and PrPSc were detected by DELFIA. Under non-
denaturing conditions the epitope for the 3F4 antibody is hidden in PrPSc, but
treatment with 6 M GdnHCL denatures the protein increasing its solubility and
exposing the epitope ensuring its detection in the DELFIA assay. Here methods
were adapted to determine whether this extraction method would be suited to the
separation ofPrPc and PrPSc in whole blood and could be used in the future as a basis
for a detection system for PrPSc in whole blood samples from patients with vCJD.
4.6.1 Isolation of PrP° in whole blood samples using guanidine
hydrochloride
Whole blood samples from healthy adult donors were used to assess PrPc levels
using low molar concentrations ofGdnHCL to solubilise the PrPc present in a
sample. To 100 pL whole blood, snap freeze-thawed four times, was added 100 pL
2 Molar GdnHCL in a 1.5 mL eppendorf tube, after a 10 minute incubation 800 pL
DELFIA assay buffer was added and the sample was vortexed and spun at 10,000g in
an eppendorf centrifuge for 10 minutes at RT. The supernatant was removed for
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assay (Snl) and any pellet or cellular debris was resuspended in 200 pL of 6 Molar
GdnHCL and incubated for 10 minutes before the addition of 800 pL ofDELFIA
assay buffer, vortexing, and centrifugation as above. This supernatant was removed
and was assayed (Sn2) (using the standard DELFIA protocol for the detection of
PrPc) along with the Snl twice in duplicate at 1/10, 1/100, 1/200, and 1/400 dilutions
in assay buffer. Untreated ffeeze-thaw whole blood supernatants were also assayed
twice in duplicate at the same dilutions alongside the platelet standard calibrator











Figure shows the mean concentration of PrF* U/mL detectable in freeze-thawed whole blood
samples (wb1, wb2) and levels detectable in 2 assays of extracted supernatants Sn1 and
Sn2. The error bars represent ± 2 sd. Levels of PrF* detectable in Sn2 supernatants are
<0.82 U/mL at the limit of detection of the assay.
] ! ! , !
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Table 20
Sample ID Mean [PrPc] U/mL 2 x SD
WB1 1244.67 233.73
Sn1 1 814.58 141.94
Sn2 1 <0.82 -
WB2 984.9 156.35
Sn1 2 776.8 128.3
Sn2 2 <0.82 -
Table shows mean values and two times standard deviation (SD) for the detection of PrF*
(U/mL) in untreated freeze-thawed whole blood (WB1, WB2) and in Sn1 and Sn2
supernatants generated by the extraction protocol for each sample. Mean values and + 2sd
are calculated from assaying samples at four dilutions as described in the text.
The mean values for detection of PrPc in untreated ffeeze-thawed whole blood
samples and in extracted supernatants tabulated in Table 20 above show that
GdnHCL has been used with some success for the removal of PrPc from whole blood
samples. In the first of two extracted samples the extraction using 1 Molar GdnHCL
was able to solubilise 814.58 U/mL PrPc representing 73.07 % ofmean measurement
of PrPc in two untreated whole blood samples (1114.79 U/mL). In the second sample
in the Snl supernatant 776.8 U/mL PrPc was detected which represents 69.68 % of
mean levels present in untreated whole blood samples. The concentration level of
PrP in Sn2 supematants extracted using 6 Molar GdnHCL is less than the 1/3125
dilution of the assay calibrator at the limit of detection of the assay 0.82 U/mL, so
concentrations could not be determined accurately. The low levels ofPrP in Sn2
supernatants were expected because the majority of PrPc would be solubilised in the
first extraction with 1 Molar GdnHCL and you would not expect to find disease
associated PrPSc in whole blood samples from healthy adult donors. Differential
extraction using GdnHCL can isolate PrPc from healthy adult whole blood samples.
The extraction is not complete; the concentrations of PrPc present in 1 Molar
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supernatants represent approximately 70% of levels in untreated whole blood
samples. It is likely that some residual PrPc remains in the pellets. The performance
of the assay appeared unaffected by the presence ofGdnHCL, the Coefficient of
variation (CV) for sample duplicates remains less than 10 %.
This assay was repeated to ensure results could be replicated and also to investigate
the presence of PrPc in pellets. The assay was set up exactly as before except that the
pellets remaining after the extraction with 6 M GdnHCL were resuspended in
DELFIA assay buffer and assayed at 1/10, 1/100, 1/200 and 1/400 dilutions. Table
21 shows the mean concentrations of PrPc detected for untreated whole blood and the
Snl and Sn2 supernatants and the 1/10 dilution of the resuspended pellet. The two
times standard deviation measurements are high, this is a consequence of including
data for PrPc measurement from samples assayed at 1/10 dilution, under these
conditions values did not show good parallelism as was the case with concentrations
obtained when samples were assayed at higher dilutions, this is due to matrix
quenching. The presence of detectable PrPc in 6 Molar extracted supernatants was
very low and levels could not be calibrated since europium counts were below the
limit of detection of the assay. There were small amounts of PrPc detectable in the
pellets values shown are those calculated from 1/10 dilution, these values could not
be verified with values obtained when samples were assayed more dilute since
europium counts dropped below the limit of detection of the assay.
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Table 21
Sample ID Mean [PrPc] U/mL 2 x SD
WB1 747.5 375.61
Sn1 1 734.73 484.53
Sn2 1 <0.82 -
Pellet 1 20.3 -
WB2 678.23 365.34
Sn1 2 720.75 444.68
Sn2 2 < 0.82 -
Pellet 2 16.5 -
Table shows mean values and two times standard deviation (SD) for the detection of PrF*
(U/mL) in untreated freeze-thawed whole blood (WB1, WB2) and in Sn1 and Sn2
supernatants generated by the extraction protocol for each sample. Mean values and + 2sd
are calculated from assaying samples at four dilutions as described in the text.
The results from this experiment support the findings of the previous experiment; the
majority of PrPc present in control whole blood samples can be solubilised and
extracted using 1 Molar GdnHCL (Snl). PrPc is present at undetectable levels in 6
M supernatants (Sn2) and any loss during extraction can be explained by small
amounts present in the pellets. The results again verify the suitability of using
guanidine hydrochloride as a method for the isolation of PrPc from whole blood
samples. This methodology provides an alternative to PK treatment as a means of
removing PrPc.
4.7 Guanidine Hydrochloride differential extraction of 263K-scrapie
infected and uninfected control hamster brain homogenates
The experiments above illustrate the suitability of using GdnHCL to solubilise PrPc
from human whole blood samples. In order to verify the findings ofBarnard et al 158
that this method is suitable for the isolation ofboth PrPc and PrPSc from TSE infected
brain material the following experiments were performed.
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Brain material from Syrian hamsters infected with 263K-scrapie strain and
uninfected control healthy animals obtained from the Institute ofAnimal Health
Edinburgh, UK were homogenised to 10 % (w/v) following methods described in the
materials and methods section 2.8. Extraction of PrPc and PrPSc was carried out
following methods described by Barnard et al 158. To 50 pL 10 % brain homogenate
was added the same volume of 2 Molar GdnHCL in a 1.5 mL eppendorf tube to give
a final concentration of 1 Molar GdnHCL. After vortexing and a 10 minute
incubation, 900 pL ofDELFIA assay buffer was added and the mixture was spun at
10,000g in an eppendorf centrifuge for 10 minutes at RT. The supernatant was
removed (Snl) and the pellet resuspended in 100 pL of 6 Molar GdnHCL this
mixture was vortexed, incubated and spun as before and the supernatant removed
(Sn2) for analysis. Untreated scrapie infected and control brain homogenates were
assayed alongside the extracted supernatants by DELFIA for PrP, each sample was
assayed in doubling dilutions from 1/200 to 1/1600. In order to verify that the
extraction method separated PrPc from PrPSc, supematants extracted from control and
scrapie infected brain homogenate were treated with 50 pG/mL PK prior to analysis.
Samples were assayed following the standard DELFIA protocol for PrPc. The mean
concentrations ofPrP and two times the standard deviation were measured and















Concentrations of PrP detected by DELFIA in control healthy hamster brain homogenate and
in 263k-scrapie infected hamster brain homogenate. PrP concentrations in untreated
samples and in 1 and 6 Molar guanidine hydrochloride extracted supernatants and in PK
treated 6 Molar supernatant from 263k scrapie sample are plotted, + 2 sd is shown as error
bars. PrP was undetected after PK treatment in both supernatants from control brain
material and in 1 Molar supernatant from 263k infected brain material (data not shown).
The results verify that this method can be used successfully to distinguish scrapie
infected hamster brain from uninfected control hamster brain given the presence of
detectable PrP in 6 Molar GdnHCL extracted supernatant. The aggregated nature
and the conformational differences characteristic of PrPSc make it less soluble in low
molarity chaotropic salt than non-aggregated normal PrPc, so allowing separation. In
an analysis of healthy hamster brain homogenate 97.97 % ofPrPc detected in
untreated brain homogenate was successfully extracted and detected in the 1 Molar
GdnHCL supernatant, there was no detectable PrP in the 6 Molar GdnHCL extracted
supernatant. PrP was absent in PK treated supernatants extracted from healthy
hamster brain homogenate. In assays of scrapie infected hamster brain homogenates
79.14 % of PrPc detected in DELFIA analysis of untreated homogenate was
untreated
Ctrl
Ctrl 1M Ctrl 6M untreated
263k
263k 1M 263K 6M 263K 6M
+ pK
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successfully extracted and detected in the 1 Molar GdnHCL supernatant. Analysis of
the 6 Molar GdnHCL extracted supernatant found extremely high levels ofPrP
(15,580.5 U/mL). Such high levels of PrP are not detectable when the scrapie brain
homogenate is assayed untreated because the epitope for the detection antibody 3F4
is occluded in the altered conformation of aggregated PrPSc. It is only after treatment
with 6 Molar GdnHCL that the PrPSc is unfolded and solubilised, and the 3F4 epitope
is no longer hidden and is exposed for binding. This finding and the absence of
detectable PrP in the 6 Molar GdnHCL supernatants from uninfected healthy hamster
brain argues that the PrP in the 6 Molar GdnHCL supernatant is the disease
associated isoform PrPSc. Indeed PrP remains detectable only in the 6 Molar
GdnHCL supernatant from scrapie infected brain homogenate after treatment with
PK. This is to be expected since by definition PrPSc is partially resistant to
proteolysis with PK. Levels ofPrP are reduced significantly by PK treatment,
probably a consequence of treating PrPSc with PK in the presence ofGdnHCL.
When denatured and solubilised PrPSc is removed from its aggregated state and so
adopts conformations which like PrPc are more susceptible to proteolysis with PK.
In addition the FH11 capture antibody has two N-terminus epitopes one ofwhich is
N-terminal to sites ofPK cleavage, the loss ofwhich would contribute to the reduced
detection of PK treated PrP.
The differential extraction of 263K-scrapie infected hamster brain homogenate and
with brain homogenate from a healthy uninfected hamster was repeated to ensure
reproducibility of the technique. Extracted supernatants were assayed twice in
duplicate at a 1/20 dilution of the original brain homogenate, untreated samples were
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assayed at 1/100, 1/200, and 1/400. This produced similar results and they are
illustrated in Figure 30 below. Again there is very little PrP detectable in the 6 M
GdnHCL supernatant of control healthy hamster brain, but very high levels ofPrP











Concentrations of PrP detected by DELFIA in control healthy hamster brain homogenate and
in 263k-scrapie infected hamster brain homogenate. PrP concentrations in untreated
samples and in 1 and 6 Molar guanidine hydrochloride extracted supernatants are plotted,
error bars show ± 2 sd.
The main difference from the previous experiment is that the concentrations ofPrP
detected in untreated brain homogenates are much higher than levels of PrP present
in the 1 M GdnHCL supernatants whereas in the previous experiment they were very
close as would expected. This finding is a direct result of assaying extracted
supernatants at neat rather than at a range ofdoubling dilutions between 1/100 -
1/1600 as in the previous experiment. Assaying of samples where PrP is present at
153
high concentrations gives a poor quantification of actual levels present due to matrix
quenching effect.
4.7.1 Sensitivity of differential extraction technique for detection of PrPSc
To assess the sensitivity of using GdnHCL for the detection of disease associated
PrP, 263K scrapie infected hamster 10% brain homogenate was spiked into
uninfected healthy control hamster 10 % brain homogenate in serial log dilutions
from 1/10 to 1/10,000,000 (10"1 - 10"7). 50 p.L of each dilution and unspiked healthy
control hamster brain homogenate was differentially extracted following methods
described above and extracted supernatants were assayed twice in duplicate. Mean
concentrations ofPrP in U/mL were calculated and corrected for the dilution factor.
The concentration ofPrP detectable in the 1 Molar supernatant is expected to remain
relatively constant and the presence of disease associated PrP in the 6 Molar
supernatant is expected to decrease with each serial dilution until it approaches
background levels. The assaying of healthy uninfected hamster brain homogenate
will provide a background threshold or cut-off value for the 6 Molar supernatant,
activity in excess of this threshold value would indicate the presence of disease
associated PrPSc. The results for this spiking study are shown in Figure 31 below.
Disease associated PrPSc is readily detectable in 6 Molar supernatants of 10"1, and 10"
2
log spiked samples in excess of the mean cut-off level of 66 U/mL. In spiked
T 7
sample dilutions between 10" and 10" detectable levels ofPrP in 6 Molar
supernatants are similar to levels detected in healthy control hamster brain
homogenate supernatants and cease to decrease with further dilution. At present this
technique has a detection sensitivity of two log dilutions of a 10 % 263K-scrapie
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brain homogenate. Infectivity studies of 263K-scrapie infected hamster brain
homogenate by bioassay titrate its infectivity to approximately 1010 LD50/G 159 since
brain homogenates are at 10 % the starting material is at 109 LD50/G. This being the
case the detection sensitivity found here of at best 10" log dilutions expressed in














Concentrations of PrP (U/mL) detected in 1 (light blue) and 6 Molar (dark blue) guanidine
hydrochloride extracted supernatants from healthy control hamster brain homogenates
spiked in increasing log dilutions (10-1 -10-7) with 263K-scrapie infected hamster brain
homogenate and unspiked controls 1M (green) 6M (yellow). Error bars show ± 2 sd.
i
A
10-1 10-' 10-2 10-2 1a3 10-3 10-4 10-4 105 10-5 106 1C6 10-7 10-7 Ctrl Ctrl
1M 6M 1M 6M 1M 6M 1M 6M 1M 6M 1M 6M 1M 6M 1M 6M
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This spiking experiment was repeated as described above to verify these results, the
• 2
findings are illustrated in Figure 32. The reliable limit of detection is 10" log
dilution as in the previous assay. Levels ofPrP detected in the 6 Molar supernatants
from dilutions 10"3 to 10"7 are often in excess of the cut-off level of 134 U/mL, but
they do not decrease with further dilution and this would indicate that levels have
reached the background and it is difficult to determine with any certainty that these
levels represent disease associated PrP or background binding. If units ofPrP are
represented as a concentration the limit of detection for disease associated PrP in
263K-scrapie infected hamster brain homogenate from these two assays is between













10-1 10-1 102 102 103 103 104 104 10s 105 10e 106 107 107 Ctrl Ctrl
1M 6M 1M 6M 1M 6M 1M 6M 1M 6M 1M 6M 1M 6M 1M 6M
Concentrations of PrP (U/mL) detected in 1 and 6 Molar guanidine hydrochloride extracted
supernatants from healthy control hamster brain homogenates spiked in increasing log
dilutions (10-1 -10-7) with 263K-scrapie infected hamster brain homogenate. Error bars
show + 2 sd.
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4.7.2 Increases in sensitivity by removal of competing PrP° in healthy
hamster brain homogenate.
Despite separation with GdnHCL, the large quantities ofPrPc present in healthy
hamster brain homogenate may be contributing to the presence of total PrP in the 6
Molar supernatants of healthy hamster brain homogenates. It is conceivable that
there will be a limit on the quantity of PrPc able to be solubilised in the 1 Molar
GdnHCL, any PrPc which is not solubilised will be present in the 6 Molar
supernatant and will compete with disease associated PrPSc for binding to capture
monoclonal antibody FH11. To assess whether reducing the amount of PrPc in the
diluent buffer would increase the sensitivity of the assay, scrapie infected hamster
brain homogenate was spiked into homogenisation buffer instead of into a diluent of
healthy hamster brain homogenate. As in the spiking assays described above, buffer
spiked in a range dilutions between 10"1 and 1CT7 logs was differentially extracted
along with both homogenisation buffer and scrapie infected brain homogenate.
Extracted supernatants were assayed twice in duplicate by DELFIA.
Results are illustrated in Figure 33. Disease associated PrPSc in 263K-scrapie
infected hamster brain homogenate can be detected to 10"3 above a cut-off provided
by assaying the presence of signal in the 6 Molar supernatant ofhomogenisation
buffer. It is in fact easier therefore to detect disease associated PrP in the absence of




♦ 1M ■ 6M cut-off
Log dilution
B)
1M • 6M cut-off
Log dilution
The presence of PrP in 1 & 6 Molar GdnHCL supernatants in homogenisation buffer spiked
in log dilutions with 263K-scrapie infected hamster brain homogenate are shown in red and
black. Error bars represent ± 2 sd. The dotted line represents the cut-off of the level of
detectable PrP + 2 sd in the 6 Molar supernatant of homogenisation buffer a signal above
which indicates the presence of disease associated PrP. Graph A) shows a normal scale
and graph B) a logarithmic scale on the y-axis.
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4.8 Differential extraction of human plasma samples spiked with vCJD
brain homogenate.
Guanidine hydrochloride has been used successfully to compartmentalise PrPc from
whole blood samples from healthy human adult blood donors, and to isolate disease
associated PrPSc from 263k-scrapie infected hamster brain homogenate
distinguishing it from healthy control hamster brain. To ensure that this approach
would be a suitable for the isolation and detection of disease associated PrP in
humans with vCJD, brain homogenate from a patient with neuropathologically
confirmed vCJD was spiked into platelet poor plasma prepared from whole blood
samples from healthy adult blood donors and assayed as above. Ideally tests
designed for the detection of disease associated PrPSc in human peripheral blood
from vCJD patients would be developed using blood samples from these patients.
However vCJD clinical blood samples exist in extremely small numbers and in small
volumes. Since PrPSc is likely to be present in very low concentrations in peripheral
blood it is only likely to be detected by the most sensitive assays. It is sensible
therefore to retain these samples for assay validation and develop the sensitivity of
prospective assays using vCJD brain material and peripheral tissues as a source of
PrPSc. Spiking of these into control peripheral blood is an attempt to mimic the
presence of PrPSc in peripheral blood as it supposedly exists in individuals infected
with vCJD.
Platelet poor plasma was prepared by spinning healthy adult whole blood at 3000g
for 30 minutes and removing the supernatant. 10 % vCJD brain homogenate and 10
% brain homogenate from a patient who died of Alzheimer's disease as non-CJD
control were prepared from brains supplied by the National CJD Surveillance Unit,
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Edinburgh, UK to the National Institute ofBiological Standards and Controls for use
as reference standards. vCJD brain homogenate was spiked into platelet poor plasma
in log dilutions in a range between 10"1 and 10"5. 100 pL of spiked plasma, unspiked
plasma, or 10 % brain control or vCJD brain homogenate was differentially extracted
as before. The mean concentrations ofPrP detected in extracted supernatants and
two times the standard deviation were calculated and data was plotted for each
spiked sample and control to establish the sensitivity of this technique for the
detection of disease associated PrP in vCJD brain homogenate spiked into human




• 1M 6M cut-off
Log dilution
B)
-♦ 1M Ctrl ■ 6M Ctrl Cut-off
Log dilution
The presence of PrP in 1 & 6 Molar GdnHCL supernatants in platelet poor plasma spiked in
log dilutions with vCJD (A) and control Alzheimer's (B) 10% brain homogenate are shown.
Error bars represent two times the standard deviation. The dotted line represents the cut-off
or threshold level of PrP detected in the 6 Molar supernatant of control platelet poor plasma
+ 2 sd.
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Using the mean concentration plus two times the standard deviation of the
concentration of PrP in the 6 Molar supernatant extracted from platelet poor plasma
from a healthy adult donor as a cut-off, vCJD spiked material can be detected to 10"2
dilution, a 1/100 dilution of 10 % vCJD brain homogenate. As the presence of the
spike becomes more dilute the level in the 6 Molar supernatant drops beneath the
cut-off. Levels of PrP detected in the 1 Molar supernatant drop as the contribution of
PrPc from the spike becomes less and the detected level reaches that of unspiked
platelet poor plasma. This sensitivity for the detection of disease associated PrP in
spiked plasma samples is the same as that seen in spiking experiments with 263K-
scrapie infected brain homogenate. This experiment verifies the suitability of the use
of GdnHCL and DELFIA assay approach for the detection of disease associated PrP
in samples from patients with vCJD spiked into platelet poor plasma. PrP in the 6
Molar extracted supernatant from plasma samples spiked with control Alzheimer's
brain homogenate is not detectable above cut-off. The disease associated PrP in
vCJD brain homogenate may not be physiologically similar to that which you might
expect to find in the peripheral blood of patients with vCJD, however in the absence
of clear evidence that a disease associated form of PrP in peripheral blood is different
from PrPSc detected in the central nervous tissue, and in the absence of a positive
blood control this is the best and only alternative for the development of these types
of assays.
This assay was repeated to verify the above result using 10 % vCJD brain
homogenate supernatant as a spike rather than whole brain homogenate. As the
Figure 35 illustrates this change to the spike affects the concentrations of PrP
detected in 6 Molar supernatants but not the limit of detection which remains
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2 3unaffected at 10" log dilutions or 10" ofwet vCJD brain homogenate spiked into
platelet poor plasma, see Figure 35 below.
Figure 35
1M ■ 6M cut-off
Log dilution
The presence of PrP in 1 & 6 Molar GdnHCL supernatants in platelet poor plasma spiked in
log dilutions with vCJD 10% brain homogenate supernatants are shown in red and black.
Error bars represent two times the standard deviation. The dotted line represents the cut-off
or threshold level of PrP detected in the 6 Molar supernatant of control platelet poor plasma
+ 2 sd.
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4.9 Use ofguanidine hydrochloride in a conformation dependent
immunoassay (CDI) for the detection of PrF^0 in vCJD brain spiked plasma
samples.
The materials and methods section 2.4 describes an experimental approach for the
detection of abnormally folded disease associated PrPSc isoform, based upon
exposure of the 3F4 monoclonal antibody epitope by the presence of the chaotropic
salt GdnHCL. CDI techniques developed by Safar et al21 were used here to assess
the suitability of this approach for the detection of PrPSc in vCJD brain homogenates
spiked into platelet poor plasma. Platelet poor plasma prepared from a healthy adult
donor was spiked with 10 % brain homogenate in a range of log dilutions between
10"1 to 10"5 in 0.5 log increments. Native and denatured samples from the dilution
series along with native and denatured samples from six platelet poor plasma
controls were assayed twice in duplicate by DELFIA for PrP following the methods
described in the materials and methods section 2.4. The layout of samples assayed is
shown in Figure 36 below. Here we are attempting to detect small quantities of PrPSc
in the presence of substantial amounts ofPrPc. Because the capture antibody binds
both PrPc and PrPSc any detectable signal increase due to PrPSc above the substantial
level of PrPc is likely to be small.
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Figure 36
1 2 3 4 5 6 7 8 9 10 11 12
A BLANK BLANK 10-10 Native 10"10 Denat 10"1-5 Native 10"15 Denat 10"20 Native
B 10"20 Denat 10"2'5 Native 10-25 Denat 10-30 Native 1Q-3.0 Denat 10-35 Native
C 10-3 5 Denat 10"4 0 Native 10'4 0 Denat 10"45 Native 10"45 Denat 10-5.° Native
D 10"50 Denat BLANK BLANK ur10 Native 10"10 Denat 10-15 Native 10"15 Denat
E 10"20 Native 10"20 Denat 10"25 Native 10"25 Denat 10-3° Native 10-3° Denat
F 1Q-35 Native 10-35 Denat 10"4 0 Native 10"4'° Denat 1CT4'5 Native 10~4 5 Denat
G 10-50 Native 1Q-5.0 Denat pppi Native PPP1 Denat PPP2 Native PPP2 Denat
H PPP3 Native PPP3 Denat PPP4 Native PPP4 Denat PPP5 Native PPP5 Denat
Native and denatured portions of each spiked sample are assayed twice in duplicate
alongside five platelet poor plasma samples (PPP) that are assayed to provide the cut-off
value above which the presence of abnormal PrPSc is detectable.
The mean europium counts for each sample duplicate were calculated and the means
of the denatured sample were divided by the means of the native sample to provide a
ratio for each spiked dilution and control. The mean ratio plus two standard
deviation of the six platelet poor plasma samples was calculated and used as a cut-off
for the presence of disease associated PrP, given that you would not expect to find
this in plasma samples selected at random from healthy adult blood donor controls.
The ratios for each of the two dilutions series are plotted in Figure 37 below.
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Figure 37
-♦ ratio 1 ■ ratio 2 cut-off
Log dilution
The mean ratios of denatured / native cpm for two log dilution series (ratio 1, 2) of platelet
poor plasma samples spiked with 10 % vCJD brain homogenate. The cut-off level is the
mean ±3 sd for five platelet poor plasma samples from healthy adults.
The results from this conformation dependent immunoassay (CDI) are not what were
expected. Given that there is no abnormally folded aggregated PrPSc present in
control plasma samples you would expect similar levels of detection in both native
and denatured samples producing a ratio of one or slightly above one considering
that denaturation and unfolding ofPrPc to a monomer may afford a slightly better
interaction with the 3F4 monoclonal antibody than native PrPc. However in this
assay counts decrease in denatured GdnHCL treated samples compared to the
untreated native samples so producing ratios less than one. Analysis of data
produced from the two runs of the spiked plasma samples also show less binding in
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the denatured sample than with the native sample, apart from the 10"'5 log dilution.
This is not what was expected since the vCJD spiked samples contain PrPSc and
denaturation with GdnHCL should expose the 3F4 epitope which remains hidden in
the native sample thereby giving a ratio in excess of one. One possibility is that the
presence ofGdnHCL which is at a final concentration on the microtitre plate of 0.4
Molar may be interfering with the capture of antigen by MAb FH11, however since
GdnHCL is added to native samples at the same final concentration the same degree
of inhibition would also be evident in native samples. More plausible explanations
are that denaturation and unfolding ofPrP reduces the affinity of the interaction
between FH11 and PrP so producing a lower detection in denatured samples than in
native samples, the antibody pairing ofMAbs 3F4 and FH11 is effective for the
detection of denatured PrP, or that denaturation accelerates the breakdown ofPrP.
Despite these unexpected findings, the presence of abnormal disease associated PrPSc
can be detected to 1CT1'5 log dilutions of 10% vCJD brain homogenate when spiked
into plasma above a control cut-off using FH11 and 3F4 monoclonal antibodies. The
use of different anti-PrP monoclonal antibodies as capture may prove more suitable
for a more consistent capture of native and denatured PrP so producing higher ratios
which may increase assay sensitivity.
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Chapter 5 Use of CDI for detection of PrPSc: a comparison of different
monoclonal antibody pairs and their effects upon assay sensitivity.
5.1 Introduction
The conformation dependent immunoassay described in section 4.9 requires
considerable improvements in sensitivity for the detection of PrPSc in brain tissue
from patients with vCJD before it can be considered as a possible means for the
sensitive detection of PrPSc in the peripheral blood ofpatients with vCJD. Capture
and detection antibodies that have a high affinity for PrP under both denaturing and
non-denaturing conditions are one possible route to achieving this. The binding of
the capture antibody to PrP may be affected by it being bound to a solid-phase which
may adversely affect the affinity of the antibody for the antigen due to orientation or
steric hindrance effects. It is essential that both capture and detection antibodies
used in this kind of two-site assay are able to bind simultaneously to the antigen.
Optimum binding is dependent upon the antibody epitopes and the relative affinity of
the antibody antigen interactions. To assess the effects of different antibodies on
assay sensitivity three different monoclonal antibodies were used as capture
antibodies with europium labelled 3F4 as detection antibody in CDI assays for the
detection of 10 % vCJD brain homogenate spiked into platelet poor plasma. The
different capture antibodies used were FH11, D18, and 1120-64-9. Details of epitope
specificity, host and immunogen can be found in Table 6. 10% vCJD brain
homogenate supplied by NIBSC was spiked into platelet poor plasma in log dilutions
between 10"°'5 - 10"5 0 in 0.5 log increments ensuring that there was at least 2 mL of
each dilution. Each dilution was then aliquoted in 125 pL volumes and stored at -
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80° C. Samples from this same dilution series were used in all assays so that
sensitivity measurements between assays using different antibodies were directly
comparable.
5.2.1 MAbs FH11 & 3F4
Coating conditions for monoclonal antibody FH11 were assessed as described in an
earlier titration in section 3.1.1.3 and a concentration of 5 LiG/mL was sufficient to
saturate microtitre wells with antibody ensuring maximal binding. The vCJD spiked
plasma dilution series were assayed twice in duplicate with five plasma samples from
healthy adult donors as controls in each assay. Two separate assays were carried out
on different days following the protocols for CDI described in the materials and
methods section 2.4. The mean cpm for duplicates of native and denatured samples
for each spiked dilution were calculated and the ratio of denatured divided by the
native counts for each sample were then calculated. The mean ratios and two times
the standard deviation were calculated for the two runs of the dilution series and for
the five control plasma samples in each assay, the latter providing the cut-off value
for the presence of disease associated PrPSc. A line graph illustrating the data from
the first assay is shown in Figure 38.
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Figure 38
cut-off ■ Mean Ratio
Log dilution
Detection of 10 % vCJD brain homogenate spiked into platelet poor plasma assayed by CDI.
Error bars represent + 2 sd. The cut-off is the mean ratio + 3 sd calculated from five plasma
samples from healthy adults.
PrPSc in spiked plasma samples can be detected to two log dilutions of a 10 % brain
homogenate spiked into platelet poor plasma using CDI employing FH11 as capture
antibody and europium labelled 3F4 as detection antibody. The limit of detection
has improved by 0.5 logs from the first CDI assay the results ofwhich were shown at
he end of the previous chapter in section 4.9, this is most likely due to improved
technical operator skills and the use of a fresh aliquot ofNIBSC vCJD brain
homogenate. As in the previous CDI assay using the same antibodies the ratio of
cpm for denatured samples divided by the cpm for native samples are less than one
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for the majority of spiked samples and for the unspiked plasma control samples. The
level of detection ofPrP in denatured samples is therefore less than that detected in
the same samples under native conditions. This is most likely due to a reduced
affinity ofMAb FH11 for denatured PrP. The use ofMAb 3F4 in PrP western blot
analysis and differential extraction assays demonstrate that this antibody has a high
affinity for denatured PrP and so it is unlikely to be the cause. If antibodies detected
both native and denatured PrP with the same affinity then you would expect ratios in
unspiked plasma samples to be close to one. The same findings are also
characteristic of the second CDI assay using this antibody pairing. The results are




Detection of 10 % vCJD brain homogenate spiked into platelet poor plasma assayed by CDI.
Error bars represent + 2 sd. The cut-off is the mean ratio + 3 sd calculated from five plasma
samples from healthy adults.
A limit of detection of 2 log dilutions of 10 % vCJD brain homogenate is the same as
in the previous assay and has the same sensitivity as the differential extraction
method for the detection of PrPSc in spiked plasma samples described in section 4.7
which uses the same pair ofmonoclonal antibodies for capture and detection.
Denaturation of the antibody reactant can affect the affinity of interaction with




Monoclonal antibody D18 was kindly supplied by Dr Anthony Williamson at the
Scripps Institute, La Jolla, California, USA and has been described and characterised
previously24.
5.2.1.1 Titration of coating antibody
D18 antibody has not been used before in two-site DELFIA assays as a capture
antibody and therefore required titration to establish coating conditions where the
antibody is present at saturating concentrations and antigen capture is maximal. D18
was titrated in exactly the same way as MAb FH11 as described in section 3.1.1.3 in
a range between 0.195 and 25 pG/mL. The mean europium counts per minute for
samples assayed at each concentration of coating antibody along with the two times
standard deviation, to equal 95% confidence interval, were calculated and the data
plotted. Counts ofbackground binding to coated wells incubated with assay buffer
alone were also plotted to give an indication of how background measurements




—•—mean cpm • blank mean Linear (blank mean)
Assessment of coating conditions for monoclonal antibody D18. Detection of a 1/5 dilution of
platelet standard in counts per minute is shown on the y-axis. With increasing concentrations
of coating antibody (pG/mL) represented by the x-axis. The error bars represent the mean +
3 sd. The cpm for blank wells at each antibody concentration are also shown. .
The titration graph shows that capture of PrPc by D18 increases as the concentration
of coating antibody increases but that the titration curve does not flatten off
completely in the concentration range tested. Binding has not reached a maximum
and the antibody is not present at saturating concentrations. The level ofbackground
binding increases as the concentration of coating antibody increases. Comparing this
titration with that ofFH11, FH11 gives much higher binding of PrPc than D18 at
lower antibody concentrations and it reaches saturation at lower concentrations.
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These differences illustrate how epitope affinity and avidity differences between
antibodies affect binding in this assay.
The titration results for D18 present certain difficulties in its use as a capture
antibody. Ideally it is advisable to use antibody at concentrations where binding has
reached a maximum, where any further increases in antibody concentration do not
further enhance binding. In the case ofD18, binding is still increasing at a
concentration of 25 pG/mL. Despite this it would not be economical to use D18 at
this or higher concentrations since you would require 525 pG of antibody at this
concentration to coat one microtitre plate. An additional factor to consider is that
background binding is at high levels where coating concentrations are high. The use
ofD18 as a capture antibody requires a compromise between achieving the highest
level of antigen capture without excessive levels ofbackground binding given that it
would require large quantities of antibody to achieve saturation and that the use of
high concentrations of antibody would be associated with high background binding
and would be expensive. A coating concentration of 10 pG/mL would ensure
economical use of antibody resources, comparatively low levels ofbackground
binding less than 2000 cpm, and relatively high degree of antigen capture. It is worth
pointing out that the level of antigen capture using D18 at this concentration is
approximately half that you would expect using FH11 at 5 pG/mL.
5.2.1.2 CDI assay of spiked plasma samples
Conformation dependent immunoassay of the spiked plasma series was carried out
exactly as with the FH11 and europium labelled 3F4 antibody pairing described in
5.2. The results of the mean ratio of cpm for denatured samples divided by those for
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the native sample for both runs of the spiked dilution series assayed twice in separate
assays are shown in Figures 41 and 42 below.
Figure 41
cut-off—■ Mean ratio
Detection of 10% vCJD brain homogenate spiked into platelet poor plasma assayed by CDI.
Error bars represent + 2 sd. The cut-off is the mean ratio + 3 sd calculated from five plasma
samples from healthy adults.
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Figure 42
cut-off ■ Mean ratio
3.2-
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Log dilution
Detection of 10 % vCJD brain homogenate spiked into platelet poor plasma assayed by CDI.
Error bars represent + 2 sd. The cut-off is the mean ratio ±3 sd calculated from five plasma
samples from healthy adults.
Both assays produce similar results with a limit of detection above cut-off for 10 %
vCJD brain homogenate ofbetween 10~2 5-10"3'° logs. In a comparison with capture
antibody FH11, D18 exhibits a superior sensitivity and higher ratios for the more
dilute spiked samples. However D18 also shows ratios of< 1 for the plasma control
and higher log dilutions of spiked samples as was seen with FH11, and indicates a
change in antibody affinity as a consequence of denaturation with GdnHCL.
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5.2.2 1120-64-9 &3F4
Monoclonal antibody 1120-64-9 was kindly supplied by Dr Martin Vey and Dr
Albrecht Groner from Aventis Behring GmbH, Marburg, Germany. The production
of this anti-prion monoclonal antibody and its use in conformation-dependent
immunoassay have been described previously 152. Epitope, reactivity and
immunogen information for this antibody are shown in table 6 (page 82).
5.2.2.1 Titration of coating antibody
We had a limited quantity of this antibody and its use in conformation-dependent
immunoassays had previously described, so rather than use antibody performing our
own titration experiments microtitre plates were coated with 10 pG/mL of antibody
as recommended 152. A personal communication from Dr Albrecht Groner
confirmed that the antibody is present at saturation at this concentration and maximal
binding is reached.
5.2.2.2 CDI assay of spiked plasma samples
Conformation-dependent immunoassay was carried out exactly as described above to
ensure valid comparisons between different antibody pairings. Figures 43 and 44





Detection of 10% vCJD brain homogenate spiked into platelet poorplasma assayed by CDI.
Error bars represent ± 2 sd. The cut-off is the mean ratio + 3 sd calculated from five plasma
samples from healthy adults.
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Figure 44
cut-off ■ Mean ratio
Log dilution
Detection of 10 % vCJD brain homogenate spiked into platelet poor plasma assayed by CDI.
Error bars represent ± 2 sd. The cut-off is the mean ratio + 3 sd calculated from five plasma
samples from healthy adults.
The conformation-dependent immunoassays performed using this antibody do not
show greatly increased sensitivity for the detection of PrPSc compared with using
FH11 or D18 as capture antibodies. The first assay has a limit of detection of two
logs dilution above cut-off, and in the second assay the ratio of counts flattens off
and does not decrease with dilution as the assay reaches two and a half log dilutions.
With a sensitivity ofbetween two and two and a half log dilutions the assay performs
as well as FH11 but not as well as D18 which has a higher sensitivity. What is
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striking about the results using monoclonal antibody 1120-64-9 is that the ratios for
all spiked and control samples are greater than one. This is significant since this is
the only capture antibody which does not exhibit different patterns ofbinding to
native and denatured samples. The mean ratio from 5 control plasma samples
assayed is 1.683. This is higher than 1.0 due to exposure of the 3F4 epitope
associated with denaturation ofprotein to a monomelic form. Although this epitope
is fully exposed in PrPc, denaturation will allow slightly better interaction of the
detection antibody with its epitope thus explaining a ratio between 1.0 and 2.0.
Given the ratio of the control samples it can be stated that the capture antibody is
capturing just as much PrP in denatured samples as is captured in native samples.
The 3F4 epitope is hidden in PrPSc but accessible after denaturation with GdnHCL.
Therefore in the log dilutions where the ratio is higher than the cut-off, PrPSc
contributed by the spike of vCJD brain homogenate can be detected, and the
increased ratio is a direct consequence of increased binding to the 3F4 epitope after
denaturation with GdnHCL. The values of ratios for spiked plasma samples are
much more separated with monoclonal antibody 1120-64-9 between approximately
2.0 and 9.0 for spiked dilutions 10"1 -10"2'5 with good separation between dilutions in
contrast with using capture antibodies FH11 and D18 where ratios for this same
series of dilutions are concentrated within less than a range of two ratios. Good
separation between dilutions is essential to ensure the clear definition ofpositive
samples above cut-off.
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5.3 A study of the interaction of different capture antibodies with PrP°
To study the interaction of these three different capture antibodies with PrPc more
closely we set up an experiment comparing the detection of PrPc in platelet poor
plasma from healthy adult donors and in recombinant human PrPc obtained from
Prionics, Zurich, Switzerland.
Two rows of amicrotitre plate were coated for each of the three monoclonal capture
antibodies FH11, D18, 1120-64-9, using concentrations determined in the previous
experiments. Six aliquots of 100 pL platelet poor plasma and six aliquots of 100 pL
recombinant PrPc at a concentration of 50 pG/mL were assayed following the CDI
protocol described in materials and methods section 2.4. For each of the three
different capture antibodies two samples each of platelet poor plasma and
recombinant human PrPc were assayed under native and denatured conditions in
triplicate. The mean ratios and two times the standard deviation were calculated and
the results illustrated in Figure 45. Europium labelled monoclonal antibody 3F4 was
























Ratio ofplatelet poor plasma (PPP) and recombinant PrPp assayed by CDI using three
different capture antibodies. Error bars show the mean ratio +2 sd.
This assay permits the assessment of the capture ofboth PrPc present in platelet poor
plasma and recombinant PrPc by three different antibodies. Because the epitope of
the detection antibody 3F4 is more fully exposed in PrPc, differences in the CDI ratio
should reflect the relative affinity of each capture antibody under native and
denaturing conditions and the suitability of antibody pairs. The CDI ratios for the
human recombinant PrPc are all very similar despite the use ofdifferent capture
antibodies with ratios in a range between 1.095 - 1.21. However the ratios for the
detection of PrPc in platelet poor plasma are extremely low for MAbs FH11 and D18
at a ratio of approximately 0.2 but much higher with MAb 1120-64-9 at 1.43. These
figures support results found for each different antibody pair with platelet poor
plasma samples assayed to ascertain cut-off values in CDI analysis of spiked samples
184
in section 5.2. The results indicate that monoclonal antibodies FH11 and D18
capture less PrPc after denaturation compared to assaying the native sample hence the
ratio of less than one. An interesting finding is that ratios are similar for all
antibodies when purified recombinant human PrPc is assayed. This would appear to
rule out the possibility of the disruption of discontinuous epitopes after denaturation
as a cause for the reduced ratios with MAbs FH11 and D18. It may be that there are
proteins present in platelet poor plasma which bind non-specifically with MAb FFI11
and MAb D18, and compete with PrPc for binding to the antibody. The antibodies
affinity for denatured treated PrPc may be altered therefore allowing interaction with
other proteins. It may also be that MAbs FH11 and D18 are more specific for the
conformation of native PrPc and that the affinity is reduced in denaturing conditions.
It is significant also to note that the immunogen for 1120-64-9 was human PrPc
whereas MAb FH11 was raised using recombinant ovine PrPc and MAb D18 with
purified PrP27-30 from experimental scrapie in hamsters. The findings here may
simply reflect the fact that MAb 1120-64-9 has a much higher affinity for human
PrPc which is retained even after denaturation. With MAbs FH11 and D18 the
relative affinity for human PrPc is reduced after denaturation and the interaction
between paratopes and epitope maybe subject to interference from other cross-
reactive factors in human plasma.
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5.4 A study of the interaction of different capture antibodies with PrPSc
To assess the suitability of the same three antibody pairs for the detection of PrPSc an
experiment similar to that described above was carried out. One row of a microtitre
plate was coated with each of the three different capture monoclonal antibodies
(FH11, D18, 1120-64-09) using coating conditions as described in 5.3. Six 100 pL
aliquots of 10 % vCJD brain homogenate supplied by NIBSC were treated with 50
jiG/mL PK for one hour at 37 0 C and Pefabloc added to a final concentration of 1
mM. Two samples were assayed by CDI in triplicate for each of the three different
coating antibodies following methods described in section 2.4.
Because the 3F4 epitope is occluded in PrPSc the interaction of 3F4 under native
conditions will be low and therefore you would expect a low level ofbinding for all
of the different antibody pairs. Under denaturing conditions PrPSc will unfold
exposing the 3F4 epitope and permitting the binding of the antibody. The level of
europium counts obtained for each antibody pair under denaturing conditions will
indicate the suitability of each antibody pair for the capture and detection of PrPSc.
Figure 46 below illustrates the europium counts obtained for PrPSc samples assayed
under native and denaturing conditions for each of the three antibody pairs.
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Figure 46
UFH11 MD18 □ 1120-64-09
Capture antibody
Europium cpm for the detection of PrP30 under native and denatured conditions captured
with either monoclonal antibody FH11, D18, or 1120-64-09. Europium labelled 3F4 was
employed as detection antibody, error bars represent ± 2 sd.
As predicted the europium signals for PK treated vCJD brain homogenate under
native conditions are low for all three antibody pairs. This is a consequence of the
epitope for the detection antibody remaining hidden in PrPSc. The residual signal
probably reflects the small amounts of PrPc remaining in the brain homogenate
which were not degraded with PK treatment. The low signal may also represent
minor changes in conformation of PrPSc as a result of its binding to the capture
antibody, which permit a low affinity interaction between 3F4 and its epitope.
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Using MAbs D18 and 1120-64-09 the detection of PrP by MAb 3F4 was increased
following denaturation. The europium signal obtained with FH11 and 3F4 does not
show any increase. Europium counts are lowest with capture antibody FH11 due to
the fact that very little PK treated PrPSc is captured by this antibody. Reference to
Figure 2 shows that FFT11 has two epitopes in the N-terminus of PrP. Also shown on
this diagram are the two major sites ofPK cleavage, and these illustrate that the first
FH11 epitope which spans amino acid (aa) residues 46-58 is N-terminal to both sites
ofPK cleavage. In addition one of the cleavage sites lies within the second FH11
epitope which spans amino acid residues 90-101. Therefore after PK treatment of
vCJD brain homogenate, cleavage ofPrP will seriously disrupt the ability for FH11
to interact with its epitopes. It is likely that MAb FH11 will capture N-terminal
fragments which have been cleaved from the rest ofPrP and do not have the 3F4
epitope. This would explain the lack of increase in europium counts when the
denatured samples are assayed.
The D18-3F4 pairing shows a 2.26 fold increase in signal with denaturation. By far
the best pairing is 1120-64-09 - 3F4 which shows a 15.4 fold increase in signal.
These differences in signal increases may reflect the capture of PrPSc at different
epitopes which may govern the success of the interaction ofMAb 3F4 with its
epitope. Monoclonal antibody 1120-64-09 captures PrP in the C-terminal region
somewhere between amino acid residues 175 -230, and D18 captures PrP between
residues 133-157. The 3F4 epitope is aa 109-112 and it is plausible that a capture
epitope distal to the epitope of the detection antibody such as that of 1120-64-09 may
permit better interaction of the detection antibody than a capture epitope which is
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closer for example that ofD18. It may simply be a case of steric hindrance where
capture of the antigen in a particular manner permits better physical interaction of the
detection antibody.
The experimental studies presented in this chapter investigated the suitability of three
monoclonal antibodies for the capture ofPrP in a CDI immunoassay format.
Affinity differences for the three antibody pairs for binding to PrPc and PrPSc
produce differences in CDI ratios for spiked plasma samples.
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Chapter 6: Studies into the purification and concentration of PrPSc
6.1 Background
In order to improve the sensitivity of the CDI DELFIA assay system for the detection
of PrPSc and to permit the analysis of larger volumes of sample, sodium
phosphotungstate (NaPTA) was used to precipitate PrPSc. This methodology has been
described and used previously in these types of assays by Safar et al21 and others 152
to precipitate PrPSc. Safar et al claim that NaPTA complexes with oligomers and
polymers of PrPSc but not PrPc in the presence ofmagnesium chloride and neutral
pH. These complexes are collected by high-speed centrifugation. Here these
methods have been adapted and are described in the materials and methods section
2.4.1. The use of this precipitation method permits the isolation of PrPSc from larger
volumes of spiked samples and is suited to tissues in which PrPSc may be present in
low concentrations.
6.2 Detection of PrP80 in spiked plasma samples using NaPTA
precipitation.
A dilution series ofplatelet poor plasma samples spiked with 10 % vCJD brain
homogenate provided as a standard by NIBSC was prepared in 0.5 log increments
between 0.5 to 5.0 log dilutions. 900 pL of each spiked sample was treated with
NaPTA and analysed by CDI as described in section 2.4. It is important to note that
in these experiments 900 pL of each spiked dilution is subject to NaPTA
precipitation and the 50 pL resuspended volume is analysed by CDI. You would
therefore expect the sensitivity for the detection of PrPSc to be in the region of 0.9
logs greater than in the previous CDI experiments where 100 pL of spiked sample
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was assayed assuming that the recovery ofPrPSc by this method is unaffected by
increases in sample volume. The first 0.9 log increase may simply be a
consequence of analysing a nine-fold greater sample volume.
Spiked and control plasma samples were assayed in triplicate on a microtitre plate
precoated with 10 pG/mL ofmonoclonal antibody 1120-64-09. Captured PrP was
detected using europium labelled monoclonal antibody 3F4.
The mean ratios of denatured europium counts divided by the native counts were
plotted for each spiked sample and the limit of detection assessed against a cut-off
provided by unspiked human control plasma samples plus three times the standard
deviation. The results for this spiking experiment are plotted in Figure 47.
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Figure 47
-♦ Mean Ratio Cut-off
Dilution
NaPTA concentration and CDI analysis of vCJD brain homogenate spiked into human
plasma. Mean ratios for each spiked plasma dilution are plotted and the error bars
represent +2 sd. The cut-off is the ratio of unspiked control human plasma + 3 sd.
The limit of detection is 1CT3 against a cut-off of control plasma samples.
Comparison with a previous experiment where 100 pL of the same spiked plasma
sample series were assayed with the same antibody pairing (section 5.2.3) the limit of
detection in this previous experiment was 10"2. This finding was expected
considering that PrPSc was concentrated from a sample nine times greater in volume
than that assayed in 5.2.3. These results illustrate that NaPTA can be used as a
means of precipitating PrPSc from larger sample volumes. There are considerable
192
increases in the CDI ratios obtained with spiked samples after NaPTA precipitation
compared with the spiked samples assayed in 5.2.3 see Table 22.
It is claimed that NaPTA binds and precipitates PrPSc but not PrPc. Therefore would
not expect PrPc to be present in large quantities in NaPTA precipitated samples. In
the absence of large quantities of PrPc there will be less competition between PrPc
and PrPSc for binding to the capture antibody. NaPTA precipitated samples should
give higher ratios since it is claimed that NaPTA binds to PrPSc but not PrPc. This is
indeed the case with sample ratios highly elevated in this experiment compared with
smaller volumes of the same spiked plasma sample series assayed in experiments
described in section 5.2.3. Differences in ratios for each spiked sample dilution are
shown in the Table 22.
Table 22
Log dilution Mean Ratio + NaPTA Mean Ratio - NaPTA Fold increase
1050 3.820 1.313 2.909
1CT45 2.821 1.894 1.489
10~4 0 4.873 1.648 2.958
10"35 4.647 2.017 2.304
10"3° 7.138 1.890 3.777
10-25 23.249 1.968 11.814
oCN
O 34.856 3.293 10.584
10~15 96.942 3.629 26.711
10"1° 112.188 8.632 12.996
Ratios of spiked plasma samples assayed by CDI with and without NaPTA pre-treatment.
The data shown in Table 22 illustrates the considerable increases in CDI ratio
obtained with NaPTA precipitation. As mentioned above at least a nine-fold increase
in sensitivity is expected due to a nine-fold difference in the volume of sample
assayed in these two separate experiments. What is unclear though is whether
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NaPTA is in fact specifically binding PrPSc. Reference to the CDI ratio of 4.27
generated by NaPTA precipitation of control unspiked plasma samples from healthy
adults would suggest that NaPTA also precipitates PrPc and possibly other protein
factors present which bind non-specifically to capture and detection antibodies. PrPc
shows a relatively small increase in antibody binding with denaturation so it would
appear that additional factors are interacting with the capture antibody.
It is likely that NaPTA effectively precipitates not only PrPSc but also additional
protein factors from samples including PrPc, and that it is the specificity of the
capture antibody 1120-64-09 which mediates the binding of PrP. IfNaPTA
precipitation was specific for PrPSc alone then the use ofPK should not increase the
assay sensitivity unless N-terminal cleavage of PrPSc improves its interaction with
the capture antibody. The epitope for this antibody is situated in the carboxyl
terminus and you would not expect N-terminal cleavage to improve binding. If
NaPTA precipitated PrPSc alone then it is more likely that you would expect PK to
degrade some of the PrPSc reducing the level present and so in-turn decreasing the
sensitivity of its detection. The use ofPK in these assays is considered in the section
below.
6.3 Use of PK as a pre-treatment to NaPTA precipitation and CDI
analysis.
To consider whether the pre-treatment with PK is sufficient to increase the sensitivity
of the CDI assay for the detection of PrPSc, log dilutions of vCJD 10 % brain
homogenate spiked into platelet poor plasma (as prepared in section 6.2) were pre-
treated with 250 pG/mL PK for one hour at 37 0 C. The proteolysis was stopped
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with the addition of Pefabloc to a final concentration of 1 mM. This experiment was
carried out exactly as that performed in section 6.2 except that each log dilution was
pre-treated with PK. The ratio of the denatured sample divided by the native sample
europium counts are plotted against log dilution in the Figure 48 below.
Figure 48
Mean Ratio cut-off
NaPTA concentration and CDI analysis of vCJD brain homogenate spiked into human
plasma. Spiked plasma samples are pre-treated with 250 pG/mL PK. Mean ratios for each
spiked plasma dilution are plotted and the error bars represent +2 sd. The cut-off is the ratio
of unspiked control human plasma + 3 sd.
In comparison with the experiment carried out with the same vCJD spiked plasma
series in section 6.2 the effect of pre-treatment with PK is to increase the sensitivity
for the detection of PrPSc. This is increased from three logs in the absence ofPK
treatment to four logs dilution of 10 % vCJD brain homogenate spiked into platelet
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poor plasma. PK degrades PrPc and other proteins which may be precipitated by
NaPTA, and it is likely that its removal reduces competition between PrPc and PrPSc
for binding to the capture antibody ensuring that PrPSc is bound and subsequently
detected after denaturation by 3F4. This explains the increase in sensitivity for the
detection of PrPSc. The cut-off value (the ratio for unspiked platelet poor plasma plus
three times the standard deviation) is reduced considerably after PK treatment
compared to the cut-off value obtained in the experiment described in section 6.2
which is also a likely consequence of the degradation of PrPc in plasma samples.
These results suggest that the NaPTA precipitation is not specific for PrPSc.
6.3.1 CD I analysis of PK treated vCJD spiked plasma samples using
neurological control brain homogenate as cut-off.
The previous experiment described in 6.3 was reproduced but incorporated a non-
CJD neurological control using an Alzheimer's disease brain homogenate as control
to provide the cut-off value. The results from this experiment are shown in Figure 49
below. They illustrate that PrPSc can be detected to 5 logs dilution above the cut-off.
This is equivalent to a minimum detectable volume of 9 nL of a 10 % vCJD brain
homogenate. This is an extremely sensitive measure for PrPSc and is very similar in
sensitivity to the findings ofBellon et al 152.
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Figure 49
cut-off ■ Mean Ratio
Log Dilution
NaPTA concentration and CDI analysis of vCJD brain homogenate spiked into human
plasma. Spiked plasma samples are pre-treated with 250 pG/mL PK. Mean ratios for each
spiked plasma dilution are plotted and the error bars represent +2 sd. The cut-off is the ratio
+ 3 sd of unspiked 10 % brain homogenate from an Alzheimer's disease case.
The increases in sensitivity seen in this assay compared with the previous assay are
likely to be a consequence of normal variability in the success ofNaPTA
precipitation. After NaPTA precipitation and centrifugation sample pellets vary in
appearance. Sometimes an insoluble white chalky precipitate ofmagnesium salts
forms making the precipitated material difficult to solubilise and resuspend. This
may affect interaction of antibodies with PrPSc thereby reducing its detection by CDI.
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6.4 An investigation into the use of Sodium Chloride as a pre-step
precipitation method for the detection of PrPSc by CDI.
Results generated by experiments performed in 6.2 and 6.3 illustrate that NaPTA
does not appear to bind PrPSc alone. Were NaPTA to bind and precipitate PrPSc
alone then the use of PK should not increase the limit of detection of PrPSc unless
proteolysis of PrPSc improves interaction with the capture antibody. The treatment of
samples with PK prior to NaPTA precipitation increases the sensitivity for the
detection of PrPSc. These results suggest that increases in sensitivity are due to
degradation of PrPc and perhaps additional proteinaceous factors which compete with
PrPSc for binding to capture antibody 1120-64-09 in the CDI assay. Given these
findings it is possible that the effect ofNaPTA is to precipitate all proteinaceous
material in a sample much like the traditional use of sodium chloride for these
purposes known as 'salting out'. The specificity of the monoclonal antibodies used
in the CDI assay ensure that only PrP is captured and the use of PK as a pre-
treatment ensured the removal ofPrPc and other PK sensitive proteins.
As an alternative to NaPTA precipitation the use of sodium chloride (NaCl) as a
precipitation method was assessed using the same vCJD spiked platelet poor plasma
log dilution series as used in experiments described in sections 6.2 and 6.3. The use
of 10 % NaCl for the precipitation of PrPSc following treatment with PK has been
described previously by Polymenidou et al l60and is thought to precipitate 97 % of
PrPSc along with other proteins present in a given sample Methods were adapted for
the analysis of spiked plasma samples by CDI and are described in section 2.4.2.
The CDI ratios for each spiked platelet poor plasma sample are plotted in Figure 50
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below. An Alzheimer's disease non-CJD control 10 % brain homogenate was
assayed to provide the cut-off.
Figure 50
Mean Ratio cut-off
NaCI precipitation and CDI analysis of vCJD brain homogenate spiked into human plasma.
Spiked plasma samples are pre-treated with 250 pG/mL PK. Mean ratios for each spiked
plasma dilution are plotted and the error bars represent +2 sd. The cut-off is the ratio ±3 sd
of unspiked 10 % brain homogenate from an Alzheimer's disease case.
This assay shows that 10 % NaCI can be used with some success to precipitate
proteins including PrPSc from PK treated spiked plasma samples for analysis by CDI.
This result shows a sensitivity of four log dilutions of 10 % vCJD brain homogenate
spiked into platelet poor plasma which is equal to that obtained with the first NaPTA
precipitation experiment shown in Figure 47. This is particularly interesting since it
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shows that simple protein 'salting out' achieves a similar sensitivity to the use of
NaPTA.
Both NaPTA and NaCl can be used for the precipitation and concentration of PrPSc
from large sample volumes prior to analysis by CDI. It does not appear that NaPTA
is specific for PrPSc alone. Such methods may permit the detection of PrPSc in blood
and tissues where it is present at very low concentrations by allowing the
precipitation of PrPSc from large sample volumes.
In this chapter NaPTA precipitation combined with a CDI detection assay have been
used to measure PrPSc in platelet poor plasma samples spiked with 10 % vCJD brain
homogenate. The screening of 900 pL of each spiked sample dilution had a
maximum detection sensitivity for PrPSc above cut-off equivalent to a 1/1000 000
dilution ofwet brain homogenate. These results are extremely similar to those
published by Bellon et al 152 who used these methods in almost identical spiking
studies of vCJD brain homogenate into human plasma.
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Chapter 7: Detection of PrPSc in lymphoreticular tissues of patients with
vCJD.
7.1 Background
PrPSc is present at very high concentrations in brain tissue and its use as a source of
PrPSc for the development of diagnostic assays to detect PrPSc in blood has been
criticized over concerns that the PrPSc found in brain tissue may not be representative
of the PrPSc which you might expect to find in peripheral blood 161. Its use to assess
the sensitivity of assays designed to detect PrPSc in blood may not be appropriate
because PrPSc if present in blood may differ in its presentation of epitopes, protease
sensitivity and glycosylation pattern, all ofwhich may render it unsuitable for
detection using methods developed using brain and peripheral tissues as a source of
Prpsc -phe bi00(j brain barrier, as its name suggests, does not permit direct
interaction of the blood with the brain tissue, but is selective and active in regulating
which blood constituents enter the brain, but the blood circulatory system is closely
associated with peripheral lymphoreticular tissues such as the spleen, tonsil, and
appendix. Immunohistochemistry and western blotting studies have detected the
presence of PrPSc in peripheral tissues of patients with vCJD but not at equivalent
levels in patients with sCJD 97. It is plausible that the PrPSc present in peripheral
tissues is acquired from or exchanged with the blood, which in turn acquires it from
the gut associated lymphoid tissue following dietary exposure to BSE. PrPSc found
in peripheral tissues may be closer physiologically to the PrPSc you might expect to
find in the blood ofpatients with vCJD when compared with brain PrPSc.
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To investigate whether NaPTA precipitation and CDI analysis was suitable for the
detection of PrPSc in peripheral tissues from patients with vCJD, spleen tissue
homogenates were assayed.
7.2 NaPTA precipitation and CDI analysis ofplasma samples spiked with
vCJD spleen tissue.
10 % spleen homogenate prepared in 0.25 M sucrose from a neuropathologically
confirmed case of vCJD obtained from NIBSC (Potters Bar, UK) was spiked into
platelet poor plasma in a log dilution series prepared in the same manner described
for vCJD brain homogenate in section 6.2. 900 pL of each 0.5 log dilution of sample
was NaPTA precipitated and analysed by CDI. Unspiked platelet poor plasma
samples and 10 % non-CJD spleen homogenate in 0.25 M sucrose (the latter also
obtained from NIBSC) were included as assay controls and all samples were assayed




cut-off • Mean Ratio
Log dilution
10-4 10-3.5 10-25 1fr1S
NaPTA concentration and CDI analysis of NaPTA concentrated vCJD spleen homogenate
spiked into human platelet poor plasma. Mean ratios for each spiked plasma dilution are
plotted and the error bars represent +2 sd. The cut-off is the ratio + 3 sd of unspiked 10 %
spleen homogenate from a non-CJD neurological control.
The presence of PrPSc in spleen homogenate from a patient with vCJD can be
detected using these methods to 1.5 log dilutions of a 10 % homogenate spiked into
human platelet poor plasma above a cut-off of non-CJD neurological control spleen
homogenate. This sensitivity is half that of the 3 logs found for vCJD 10 % brain
homogenate spiked into plasma assayed using these methods. PrPSc is present at
very low levels in spleen homogenate and this is reflected in the low ratios for those
positive dilutions, which are a consequence of trying to measure very small amounts
of PrPSc in the presence of very large quantities of PrPc.
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7.3 Use of PK as a pre-treatment to NaPTA precipitation and CDI
analysis.
Pre-treatment with PK may be sufficient to increase the sensitivity of the CDI assay
for the detection of PrPSc by removing competing PrPc. Log dilutions of vCJD 10%
spleen homogenate spiked into platelet poor plasma (as prepared in section 7.2) were
pre-treated with 250 pG/mL PK for one hour at 37 0 C. The proteolysis was stopped
with the addition of Pefabloc to a final concentration of 1 mM. 900 pL samples were
then NaPTA precipitated and assayed by CDI following methods as described in
section 7.2. The ratio of denatured sample divided by the native sample europium
counts are plotted against log dilution in the Figure 52 below.
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Figure 52
cut-off ♦ Mean Ratio
NaPTA concentration and CDI analysis of vCJD spleen homogenate spiked into human
plasma. Spiked plasma samples are pre-treated with 250 pG/mL PK. Mean ratios for each
spiked plasma dilution are plotted and the error bars represent +2 sd. The cut-off is the ratio
+ 3 sd of unspiked 10 % spleen homogenate from a non-CJD neurological control.
Although including PK treatment appears sufficient to increase assay sensitivity, the
CDI ratio for the first log dilution is less at 3.069 than the 5.045 obtained for the
same spiked dilution in the absence ofPK treatment. This may indicate that PK is
degrading a good proportion of PrPSc as well as PrPc. It is likely that the enzyme to
substrate ratio is less with brain tissue than with spleen tissue due to much higher
levels ofPrP in brain compared with spleen tissue. As discussed in section 4.5 the
problems of using PK to degrade PrPc will always be relatively limited in sensitivity
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but could be improved in this case by titrating the PK. Although values at 1.5 and
2.0 log dilutions lie above the cut-off their standard deviation which crosses the cut-
offline makes these values not significant above the cut-off. Therefore the limit of
detection for with PK treatment is in fact 1 log and is less than the same assay
performed in the absence ofPK.
The PrPSc present in vCJD spleen homogenate is detectable using these methods to at
best 1.5 log dilutions of a 10% homogenate spiked into platelet poor plasma. In an
attempt to provide a more accurate determination of assay sensitivity for spleen
PrPSc, platelet poor plasma samples spiked with vCJD 10 % spleen homogenate were
prepared in doubling dilutions between 1/10 and 1/5120. 900 gL samples of each
dilution were assayed by CDI following NaPTA precipitation in the absence ofPK
treatment. The results of this assay are shown in Figure 53 below.
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Figure 53
Cut-off • Mean Ratio
NaPTA concentration and CD! analysis of vCJD spleen homogenate spiked into human
plasma. Mean ratios for each spiked plasma dilution are plotted and the error bars represent
+2 sd. The cut-off is the ratio ± 3 sd of unspiked 10 % spleen homogenate from a non-CJD
neurological control.
The assay results shown in Figure 53 illustrate that PrPSc in vCJD spleen homogenate
can be detected above cut-off to a limit of 1/640 dilution in platelet poor plasma, this
is equivalent to a log dilution of 10~2'64.
This and the other vCJD spleen spiking assays described in this chapter confirm the
suitability ofNaPTA precipitation and the CDI assay technique for the detection of
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PrPSc in spleen tissue. The levels of PrPSc in spleen tissue are in the order of 2-3 logs
less than levels found in brain tissue. These differences reflect previously found
differences in PrPSc levels between vCJD spleen and brain by western blotting
studies 98'99. These relative levels parallel the reported differences in infectivity
between vCJD spleen and brain tissue as found in mice infectivity studies 10°. The
results are consistent with PrPSc being the infectious agent, given that PrPSc remains
in proportion with infectivity in these tissues, and also that the PrPSc found in spleen
tissue is not physiologically different to that found in brain tissue.
7.4 The detection of PrP80 in tonsil tissues ofpatients with vCJD
To continue studies to detect the presence of PrPSc in the peripheral tissue of patients
with vCJD, tonsil tissue was assayed using the CDI technique. 10 % homogenates of
tonsil tissue in PBS + 1 % sarkosyl pH 7.4 from five patients with vCJD, four
patients with sCJD and two non-CJD neurological controls were prepared. To 900
pL of each tonsil homogenate was added 100 pL of 20 % sarkosyl. Tissue
homogenates samples were then pre-treated with PK at a final concentration of 50
pG/mL following those methods described in section 2.8.3. PK treated samples were
then NaPTA precipitated and assayed by CDI following those methods described in
sections 2.4.1 and 2.4.2. The results of this assay are shown in Table 23 below.
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Table 23
Sample ID Mean Ratio 2sd Cut-off Pos / Neg
vCJD
RU 99/82 2.822 0.980 1.776 +
RU 99/90 36.046 4.086 1.776 +
RU 99/129 3.639 1.901 1.776 +
RU 00/25 4.536 2.006 1.776 +
RU 01/69 9.589 3.841 1.776 +
sCJD
RU 96/153 1.101 0.341 1.776 -
RU 97/8 0.775 0.181 1.776 -
RU 97/15 1.016 0.136 1.776 -
RU 97/292 0.853 0.010 1.776 -
Ctrl
Buffer Ctrl 0.980 0.361 1.776 -
RU 99/20 1.264 0.022 1.776 -
RU 99/54 0.842 0.090 1.776 -
Pos Ctrl 256.641 226.766 1.776 +
Mean ratio of denatured sample / native sample europium cpm obtained by CDI analysis for
tonsil samples obtained from 5 vCJD patients, 4 sCJD patients, 2 non-CJD neurological
controls, a buffer control, and a positive control of 1/10 dilution of vCJD brain homogenate.
The cut-off value was calculated from the mean + 3 sd of non-CJD controls. All tonsil
samples from patients with vCJD test positive for the presence of PrP^c above cut-off, all
other samples except the positive control test negative.
The results from this CDI analysis confirm previous analysis of tonsil tissue from
patients with vCJD and sCJD 99'162. All vCJD tonsil samples test positive for the
presence of PrPSc above a cut-off calculated from non-CJD neurological control
samples, and all sCJD tonsil samples test negative for the presence of PrPSc. These
results demonstrate the suitability ofNaPTA precipitation and CDI analysis for the
detection of low concentrations of PrPSc in tonsil tissue from patients with vCJD.
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7.5 Detection of PrP80 in muscle tissue from vCJD and sCJD patients
Recent studies by Glatzel et al 163 have identified the presence of small quantities of
PrPSc in both spleen and muscle tissue in a subset of Swiss patients who died of
sCJD. This is the first report which details the presence of PrPSc outside the central
nervous and olfactory systems in sCJD cases. Attempts to reproduce these findings
in the National CJD Surveillance Unit have had limited success probably due to the
reasons for variable results cited in the original publication, such as the non-
homogenous distribution of PrPSc in muscle fibres and in distinct samples taken from
the same tissue, and the fact that uncommon variants of sCJD with long duration are
associated with those patients with extraneural PrPSc. Indeed the positive muscle
sample was an atypical case with an unusually long disease duration.
NaPTA precipitation and CDI techniques were employed here to detect PrPSc in
muscle tissue homogenates from patients with vCJD and sCJD. Muscle samples
from 6 vCJD patients, 4 sCJD patients, and 2 non-CJD neurological controls were
homogenised to 10 % in PBS + 1 % sarkosyl pH 7.4. Tissue homogenates were PK
treated, NaPTA precipitated, and assayed by CDI following those methods described
in sections 7.4, 2.4.1 and 2.4.2. The results of this assay are shown in table 24
below.
PrPSc was only detected in muscle tissue samples obtained from a single patient with
sCJD. All remaining muscle tissue homogenates from patients with sCJD and vCJD
tested negative for the presence of PrPSc against a cut-off provided by the CDI ratios
of non-CJD neurological control muscle samples. The positive sCJD muscle sample
had previously tested positive by western blot analysis following methods of Glatzel
et al163 (personal communication Dr A Peden, National CJD Surveillance Unit).
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Table 24
Sample ID Mean Ratio 2sd Cut-off Pos / Neg
vCJD
RU 99/82 1.241 0.156 1.5467 -
RU 99/90 0.994 0.150 1.5467 -
RU 99/129 1.223 0.372 1.5467 -
RU 00/25 0.837 0.099 1.5467 -
RU 00/101 0.962 0.253 1.5467 -
RU 01/69 1.001 0.342 1.5467 _
sCJD
RU 96/153 1.123 0.338 1.5467 -
RU 97/8 0.920 0.178 1.5467 -
RU 97/15 1.114 0.311 1.5467 -
RU 97/292 8.438 24.959 1.5467 +
Ctrl
RU 99/54 1.078 0.392 1.5467 -
RU 98/145 0.829 0.228 1.5467 -
Pos Ctrl 129.411 129.411 1.5467 +
Mean ratio of denatured / native europium cpm obtained by CDI analysis for muscle samples
obtained from 6 vCJD patients, 4 sCJD patients, 2 non-CJD neurological controls, and a
positive control of 1/10 dilution of vCJD brain homogenate. The cut-off value calculated from
the mean + 3sd of non-CJD controls.
To verify the result of the detection of PrPSc in this particular sCJD muscle sample,
the tissue was re-sampled and assayed as above alongside a non-CJD neurological
control muscle sample and a positive vCJD brain control. In this assay (data not
shown) the sample did not test positive for PrPSc above the cut-off. This illustrates
the likely non-homogeneous distribution of PrPSc in muscle tissue, and the
difficulties of verifying positivity with different samplings from the same tissue. The
lack of significant numbers ofmuscle samples which test positive for PrPSc are
possibly a consequence of the small number of samples tested. It may also be
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because in CDI analysis NaPTA precipitated samples are resuspended in larger
volumes and assayed in triplicate, whereas in western blot analysis the PrPSc if
present in a sample is more concentrated and is run on a single lane of a western blot.
In this chapter NaPTA precipitation and CDI assay techniques have been used to
detect PrPSc in spleen, tonsil, and muscle tissue homogenates from patients with
vCJD, sCJD, and non-CJD neurological controls. PrPSc can be readily detected in
spleen and tonsil tissue homogenates from patients with vCJD using these methods.
PrPSc was undetected in tonsil samples from patients with sCJD, but could be
detected in a sample ofmuscle tissue. These studies verify that CDI is suitable for
the detection of PrPSc in peripheral tissues. It does not appear that any physiological
differences that may exist between the type of PrPSc present in brain and peripheral
tissue restrict the ability for its detection using these methods. Indeed it suggests that
the PrPSc present in both brain and peripheral tissue is the same component and that
there do not appear to be any differences in form, presentation, protease sensitivity or
epitope presentation which affect the methods used here for its detection.
Considering that PrPSc present in peripheral tissue most likely originates from
peripheral blood this methodology may with further refinements of sensitivity be
suitable for the detection of PrPSc in the peripheral blood ofpatients with vCJD.
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CONFIDENTIAL
Chapter 8: Atomic Dieletric Resonance (ADR) spectroscopy analysis
of blood samples from patients with vCJD and sCJD.
8.1 Background
An opportunity arose to employ ADR spectroscopy techniques in an analysis of
clinical CJD whole blood samples. This technology is distinct from other assays
presented in this thesis because the distinction ofCJD samples from control samples
is not based upon the detection of PrPSc but of the ADR of undefined markers. ADR
is proprietary and patented technology owned and developed by RadarWorld Ltd,
Edinburgh. ADR has actual or potential use in a wide range of applications
including satellite and subsurface imaging, statistical classification techniques,
geological and biological material identification, and veterinary and medical
applications. It is derived from specialised RADAR used in satellite imaging and
surveillance. ADR has remarkable subsurface imaging properties, used mainly in
geological, engineering and archaeological investigations. ADR can also be applied
to materials recognition. Materials have unique energy absorption and reflection
properties and provide spectra in the broad range of frequencies employed that
provide signatures for recognition and matching. Related materials will match
closely and matches can be ranked. As yet, only some of the spectral peaks can be
attributed to constituents of complex materials such as the presence of certain
elements, dielectric constants however can be measured very accurately. The power
output is very low and the technology has been approved as a medical device and
some trials have been undertaken and are planned in imaging contexts. In materials
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analysis it does not consume sample and is essentially non-destructive, and there are
also no reagents involved.
8.2 ADR scanning apparatus
The apparatus used for the ADR spectral analysis was composed of the following
hardware components: a radar control unit (RCI), a pulse generator, and a sample
chamber incorporating the transmission and receiving antennae. These components
are illustrated in Figure 54 below.
214
Figure 54




Diagram and photographs to show the components of the radar analysis hardware.
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In an early study in collaboration with the Institute ofAnimal Health, Edinburgh,
slides ofbrain sections from experimental scrapie infected mice and uninfected
controls were scanned by ADR. It was possible to discriminate scrapie-infected mice
from the normal controls by simple match ranking of their ADR spectra (see section











• selected comparator scrapie sample
O matched samples - (all scrapie)
O matched sample (first non-scrapie)
Mouse brain samples (histology slides)-best 10 matches using ADR rank matching methods
These results were reported in a poster session at the International Conference on
Transmissible Spongiform Encephalopathies, Edinburgh 2002. This spectroscopic
methodology was given further credence by the report of the use of Fourier-
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transformed Infrared spectroscopy for the discrimination between BSE-infected and
non-BSE cattle sera 141.
To consider whether ADR scanning may be of use in the development of a peripheral
blood screening test for CJD the following two experimental studies were carried
out.
8.3 First experiment study design.
Clinical whole blood samples from patients with vCJD, sCJD, and non-CJD
neurological controls were obtained from the National CJD Surveillance Unit.
Healthy adult whole blood samples were obtained from the Scottish National Blood
Transfusion Service, Edinburgh. In addition a series of aliquots of healthy adult
whole blood were spiked to a 1/10 dilution with 10 % brain homogenates prepared
from brain tissue obtained from vCJD, sCJD, a non CJD neurological control patient
with Alzheimer's disease, 263K scrapie infected hamster brain homogenate or
healthy hamster brain homogenate. Unspiked control whole blood was included as a
control. There were therefore 10 classes ofblood samples coded A to J, consisting of










Blood SPIKED with brain material
Sample Description






Clinical and spiked sample group codes A-J for the first ADR spectral analysis
Of the 5 samples in each group 2/5 were un-blinded as controls for training, leaving
the remaining 3/5 samples as blind test samples which were randomised. 4 scans of
each sample were taken, so that for training there were 20 known samples (4 scans
per sample = 80 scans), and for the blind tests there were 30 samples (4 scans per
sample =120 scans).
For the clinical series A-D each class is composed of 5 different individual patient
samples. Samples were retrieved from frozen archived material stored by the
National CJD Surveillance Unit. Samples E-J represent the spiking study, the same
blood was used throughout E-J and was frozen before use to give it the same
treatment as archived clinical material. All samples (0.5 mL) were dispensed in the
same batch of 2 mL polypropylene tubes with caps and readings were also taken on
empty tubes for subtraction of spectra. As far as we could ensure, no artefacts were
introduced from any differences in handling, storage, or dispensing samples.
All tubes were vortexed for even dispersal of contents immediately before placing in
the ADR chamber for scanning. Sample codes were recorded with each ADR
spectra stored in the linked data acquisition computer. ADR scanning was performed
by Dr Colin Stove and Mr Michael Robinson from Radar World Ltd.
218
8.4 Analysis ofADR spectra.
The ADR spectral data generated for clinical and spiked blood samples was analysed
in several stages using Radamatic ADR and image analysis software developed by
Radar World. Firstly un-blinded training clinical blood samples of vCJD and sCJD
were studied to determine whether there were any predominant spectral features
which could be used to distinguish the two groups.
8.4.1 Primary analysis
Using Radamatic ADR software, spectral reflections for a single vCJD and sCJD
sample were analysed. The data generated by scanning an empty 2mL storage tube
was firstly subtracted from the spectral data generated for the vCJD and sCJD
samples so that the resultant data represented the reflections in blood samples alone
with no contribution from the sample tube. Data was complied into tables which
show ADR parameters (fl, and f2) between 1 - 20 % and between 90 - 99 % energy
bins (E-bin) and the ADR-ratio which is a measure of the rate of change of resonance
with frequency cut-offper energy bin. This data is shown for vCJD and sCJD
samples in Table 26 below.
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Table 26
E(%) fl(MHz) f2(MHz) ADR-Ratio
vCJD sCJD vCJD sCJD vCJD sCJD
1. 0 186 22 42 . 0 1 . 4 4 .412 15.700
2 . 0 212 45 17 . 8 2 . 9 11.939 15.700
3 . 0 230 67 7.4 4 . 3 31.063 15.700
4 . 0 248 90 5 . 0 5 . 7 49.842 15.700
5 . 0 266 112 8 .1 7 . 1 32.733 15.700
6 . 0 284 134 13 .4 8 . 6 21.246 15.700
7 . 0 302 157 19 .1 10 . 0 15.858 15.700
8 . 0 321 179 24 .2 11 . 0 13.264 16.292
9 . 0 339 199 25 . 6 10.2 13.229 19.478
10 . 0 357 214 24 . 0 10 . 9 14.851 19.674
11. 0 375 229 20.4 11 . 0 18.373 18.048
12 . 0 391 245 15 . 6 14 . 7 25.022 16.605
13 . 0 394 260 10 . 9 16 . 9 36.211 15.393
14 . 0 397 275 7 . 4 19 . 1 53.853 14.390
15 . 0 400 290 6 . 0 21.4 66.388 13 . 559
16 . 0 403 305 6 . 1 23 . 7 66.204 12.866
17 . 0 406 320 6 . 1 25 . 9 66.019 12.351
oCO1—1 409 335 6.2 26.7 65.832 12 .516
19 . 0 412 350 6 . 3 27 . 1 65.644 12.887
20.0 415 365 6.3 27.2 65.456 13 .394
O O 717 904 22 . 5 6 . 1 31.810 147.013
91. 0 727 915 21. 8 5 . 6 33 .446 162 . 748
92 . 0 738 927 22 .3 5 . 1 33.075 181.498
93 . 0 748 938 24 .1 4 . 6 31.050 204.118
94 . 0 759 950 28.2 4 . 1 26.890 231.745
95 . 0 769 961 34 . 6 3 . 6 22.233 265 . 856
96 . 0 780 973 42 . 9 5 . 6 18.170 174 . 787
97 . 0 832 1054 51.2 26 . 7 16.253 39.452
98 . 0 889 1173 48 . 0 22 . 1 18 . 539 53 . 040
99 . 0 947 1320 32 . 3 13 . 6 29 . 348 97 . 216
Data shows the ADR parameters f1 and f2 and the ADR-ratio for individual vCJD and sCJD
samples for energy levels E-bin 1 % to E-bin 20 %, and E-bin 90 % to E-bin 99 %.
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There are a number of important observations which can be made from studying the
data presented in Table 26 which summarises the 1st 20 % E-bin results and the last
10 % E-bin results for vCJD and sCJD from the detailed fast Fourier transform (FFT)
tables computed by the Radamatic software. At the 99 % energy level the frequency
resonance is 947 MHz for vCJD compared with 1320 MHz for sCJD. However the
actual resonance value at this level as computed by the standard variance f2 ADR
parameter statistic is much higher (+/-32.3 MHz) for vCJD than that (+/-13.6 MHz)
for sCJD. This is a significant result, which can be summarised in the ADR-Ratio.
This is an inverse index and the lower the ADR-Ratio the higher the ADR parameter.
In this case vCJD yields an ADR-ratio of 29.348 at the 99 % energy-bin compared
with 97.216 for sCJD. There is also a distinct trend of resonance variability with
vCJD compared with sCJD. For the 1st 7 energy-bins the ADR-ratio for sCJD is
constant at 15.7, whereas the ADR-ratios for vCJD vary considerably from 4 (1%),
11 (2%), 31 (3%), 49 (4%), 32 (5%), 21 (6%) and 15 (7%).
To highlight spectral differences between samples, the amplitude (or maximum wave
displacement of absorption spectra) of the same vCJD and sCJD samples was plotted
against energy in decibels (Db). Log amplitude plots are shown for vCJD and sCJD
in Figures 56 and 57 below. Figure 58 shows the FFT difference plot created by
subtracting the vCJD spectral data from the sCJD spectral data. This illustrates the
variability of vCJD over sCJD, particularly from 3000 MHz to 25000 MHz and




Log Amplitude Plot ofAbsorption Spectra for vCJD sample ID01 A1-a minus




Log Amplitude Plot ofAbsorption Spectra for sCJD sample ID03 B1-b minus
ET-04 Chamber and sample container effects
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Figure 58
Illustrates the FFT Difference plot by subtracting the vCJD spectra from the sCJD spectra.
This shows the variability of vCJD over sCJD, particularly from 3000MHz to 25000MHz and
is again a useful diagnostic indicator of differences.
It is not apparent at this stage of the analysis whether these interesting spectral
differences between individual samples are associated with the clinical class of the
samples. They may merely reflect differences such as blood type between individuals
and factors which are not associated with disease status. A detailed analysis ofmuch
larger sample numbers from each clinical class may permit the identification of
particular spectral patterns able to distinguish vCJD from sCJD or from healthy adult
blood samples. Infraraed spectral analysis and pattern recognition analysis
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techniques have been used in a similar way by Schmitt et al140 to distinguish sera
from 263K scrapie infected hamsters from healthy control animals, and by Lasch et
al 141 to distinguish BSE serum samples from non-BSE controls. These methods
detect characteristic signatures originating from the various biomolecules present in
sera which distinguish groups without the need to detect PrPSc. These studies
needed very large sample numbers, and a simple two-way classification before they
could identify discriminatory spectral properties. Here we are using very small
numbers of samples and several sample categories by comparison.
8.4.2 Match ranking analysis.
In an attempt to identify blind samples, unprocessed Fourier transformed ADR
spectra were match ranked. This method employed a single scan of a known training
sample used as a reference spectrum against which the remaining scans of control
and test samples were matched. The closeness of the matching was based upon
determining the correlation coefficient values and setting them in order, therefore the
closer to 1 or in this case 100 % the more exact the match. Three samples, Test 44
(D5 - clinical, healthy control), Test 45 (E - spike control, unspiked control blood),
and Test 31 (J - spiked, normal hamster brain) were rejected from the analysis
because of bad replication, apparent through the spread of replicate scans on match
ranking. It is not know why this occurred, one suggestion is that the vortexing
immediately before scanning introduced features, for example currents and bubbles,
which were still stabilising during the relatively rapid scanning. This should be
investigated, and might be avoided by procedural and design modifications.
225
The inclusion of the spiking study in the analysis of the clinical study made analysis
complicated due to the number of different class variables. To simplify the analysis
blind samples from the spiking study were excluded. The identity ofblind samples



























































(A,B) Sample class identities for control and blind
samples. (C)Sample codes for clinical samples allow





COMPARISON OF SAMPLE A1-s1mET4 TO CONTROL DATA SET 13 (A+B+C*D+E+F*G+H«7*J) & BLIND TEST DATA SET
|A1mET4 1No Name Sample Dist.
1 A1mET4 2 0.032094 99.92%
2 A1mET4 3 0.20358 99.46%
awKKM 1 0.250892 99.34%
4 19-41 3 0.251589 99.33%
4 0.251724 99.33%
6T9-41 2 0.252874 99.33% 99.3338%
7 T11-43 0.304431 99.20%
8T11-43 0.306708 99.19%
9 T8-40 0.309992 99.18%
10 T8-40 0.310788 99.18%
11 T8-40 0.310859 99.18%
12 78-40 0.311027 99.18% 99.1783%
13 T10-42 0.315265 99.17%
14 T10-42 0.316742 99.16%
15 T11-43 0.31727 99.16%
16 T10-42 0.317705 99.16%
17 T10-42 0.317845 99.16% 99.1618%
18 T11-43 0.327323 99.13% 99.1698%
i9imn 0.374821 99.01 %7nMHH 0.374821 99.01 %
2lHH 0.377015 99.00%
22 17-39 0.379169 99.00%
0.38055 98.99% 99 CO03%
24 8lmET4 0.393229 98.96%
25 B1mET4 0.432744 98.86%
26K1mET4 0.435285 98.85%
27 G1mET4 0.441666 98.83%
28 GlmET4 0.445271 98.82%
29w1mET4 0.45304 98.80% 98.8663%




34 H1mET4 0.49103 98.70%
—
35IHHH 0.492239 98.70%
36 TB-38 0.49502 98.69%
37|H1mET4 0.495057 98.69%
38IC1 mET4 0.495087 98.69%
391&38 £ 0.496163 98.69% 98 7708%
40 H1mET4 0.496705 98.69%
4llHHI 0.497029 98.69%
0.499586 98.68% 98.7025% |
43|C1mET4 0.506293 98.66%
44 H1 mET4 0.506928 98.66% 98.6840%





50 T1-21 0.520938 98.62%
51 T2-22 0.52678 98.61 %
52 DlmET4 0.526902 98.61 % 98.6233%
53 72-22 0.527469 98.61 %
54 0.527591 98.60%
55 T2-22 0.527947 98.60% 98.6045%
56 T1-21 0.528874 98.60%
57 J1mET4 0.531987 98.59%
58 6tm£T4 0.532426 98.59% .98,7598%
59 5EHC1 0.533054 98.59%
60 WffaW 0.533095 98.59%
61 cnsm 0.533367 98.59%
62 0.535264 98.58%
63 3EMZ1 0.53763 98.58%
64 T1-21 0.539702 98.57% 98.6073*1 |
65 HmET4 0.540513 98.57%
66 HmET4 0.541323 98.57%
67 E1mET4 0.543002 98.56%
68 HmET4 0.543481 98.56%
69 E1 mET4 0.543646 98.56% 98 5720%
70 A1mET4 0.544193 98.56% 99.3120%
71 T4-24 0.545318 98.56%
72 T3-23 4 0.545754 98.56%
73 T3-23 3 0.545991 98.56% a
74 HmET4 3 0.546125 98.56% 1 !
75 T4-24 3 0.546492 98.55%
76 T4-24 4 0.546683 98.55%
77 T4-24 2 0.547065 98.55% 98.5545%
78 T3-23 2 0.547166 98.55%
79 T3-23 1 0.547238 98.55% 98.5543%
80 T5-37 4 0.549521 98.55%
81 15-37 1 0.549726 98.55%
82 15-37 3 0.549892 98.55%
83 T5-37 2 0.549988 98.55% 98.5455% ] i












































© Radar World Ltd, 2003 and beyond.
Commercial-ln-Confidence
Match ranking table of all sample classes including blind samples from clinical classes A-D.
Samples are ranked using a scan of a vCJD control as reference sample. The colour key for
sample class, and a table showing the top ranks are included on the right of the Figure.
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An example of a matching rank table is shown in Table 28. A vCJD sample scan
was selected as the reference sample for matching. The class letter and colour
identify the known training samples. The second set of training samples A2-J2 were
excluded from this matching table (saved for a later validation), as were the blind
samples from the spiked classes E-J. Therefore in the matching table above are 4
scans of each of the first training samples from classes A-J alongside the unknown
blind samples from classes A-D.
There was discrete clustering of some of the samples according to class, which
indicated some strong clinical features ofmany samples which dominated over the
individuality of the control blood sample donors, since 2/3 vCJD samples (class A)
and 3/4 sCJD samples (class B) were in the top 6 of the matches to Al, while the
normal adult blood samples were mostly located at the bottom end of the matching
ranks as being least like the vCJD sample Al. Identification of unknowns through
match ranking was not just a case of looking at a single match rank table, but
involved looking at the behaviour of the test sample against other known samples as
a base for matching. The spread of rank match identities in the whole sample
population (100 % - 98.5 %) is close showing that samples share a great deal of
similarity compared with the range for the mouse scrapie match ranking of histology
slides where the rank matching values ranged from 100 % to 82 % for the different
histology slides.
In Table 29 a match-ranking table is shown in which a normal donor sample spiking




No Name Sample | DisL I %
1 E1mET4 2 I 0.000087
2 E1mET4 1 I 0.000195





8 HmET4 4 [ 0.004495 I 99.95%!
M T4-24 ■ME
10 J1mET4 2 0.004978 99.95%
11 J1mET4 1 0.005226 99.95%
12 J1mET4 4 0.005876 99.94%
13 C1mET4 4 0.005886 99.94%
14 J1mET4 3 0.005921 99.94%
15 T4-24 3 0.005955
16 F1mET4 3 0.006402
17 F1mET4 1 0.006487 I 99.93%
18 F1mET4 2 0.006572
19 HmET4 1 0.006801
T4-24 4 0.007097) 99.93%r
m l1mET4 2 0.007538 9992%









31 T2-22 1 0.011736 99.88%
32 T2-22 4 0.012758 99.87%
33 T2-22 2 0.012959 99.87%
34 T2-22 3 0.013262 99.86%
35 H1mET4 1 0.019241 99.80%
36 H1mET4 4 0.020459 99.79%
37 H1mET4 2 0.020901 99.79%
38 H1mET4 3 0.021220 99.78%
39 T1-21 4 0.023994 99.75%
40 B1mET4 4 0.024062 99.75%
41 T1-21 3 0.026774 99.73%
42 T1-21 2 0.027626 99.72%
43 T1-21 1 0.029949 99.69%
44 B1mET4 3 0.032997 99.66%
45 T5-37 1
46 T5-37 4
47 T5-37 2 0.034017 99.65%
48 T5-37 3 0.034244 09.65%
49 B1mET4 2 0.035882 99.63%
50 B1mET4 1 0.052606 99.46%
51 A1mET4 4 0.107274 98.90%
52 A1mET4 3 0.178333 98.17%
53 T6-38 2 0.214793 97.79%
54 T6-38 3 0.215055 97.79%
55 T6-38 1 0.221169 97.73%
57 1T7-39 1 0.257028 97.36%
58 G1mET4 2 0.257412 97.35%
59 IT7-39 2 0.258854 97.34%
60 G1mET4 3
61 G1mET4 4
62 T7-39 3 0.268383 97.24%
63 T11-43 1 0.269600 97.23%
64 ! T11 -43 2 0.271049 97.21%
65 T11-43 3 0.272931 97.19%
66 !T11-43 4 0.274540 97.18%
67 T6-38 4 0.281850 97.10%
68 T7-39 4 0.281850 97.10%
69 T8-40 1 0.300316 96.91%
70 T8-40 4 0.300499 96.91%
71 T8-40 3 0.301854 96.90%
72 T8-40 2 0.302718 96.89%
73 T10-42 3 0.304834 96.86%
74 T10-42 1 0.306779 96.84%
75 T10-42 4 0.307093 96.84%
76 T10-42 2 0.307821 96.83%
77 T9-41 3 0.315264 96.76%
78 T9-41 4 0.315754 96.75%
79 T9-41 2 0.316873 96.74%
80 T9-41 1 0.317068 96.74%
81 A1mET4 2 0.386593 96.02%
82 A1mET4 1 0.543002 94.41%
Matching a healthy donor (single













replicate E1mET4) to other known and blind test replicate
clinical study samples and the control samples from the
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Normal donor samples (class D) were most like the reference sample (unspiked
control blood) while vCJD and sCJD samples (classes A and B) were least like it.
These were essentially the same samples which lay at opposite ends of the ranking
shown where a vCJD sample was used as the reference in Table 28. The CJD spiked
sample classes tended to be located at the clinical CJD end of the rank while the
Alzheimer's and control samples tended to lie at the normal end of the rank.
However, only in the extreme end ranks of these series in either table could the blind
test samples be identified with any confidence.
To simplify the matching tables the known control spiked samples were removed so
leaving a rank matching of known and blind samples from classes A-D and the class
E control of unspiked healthy adult whole blood. This rank-matching table
demonstrates the suitability of this method to segregate vCJD, sCJD, neurological
control non-CJD, and healthy adult donor whole blood samples. This match ranking




MATCHING TABLE FOR A1-s1mET4 RANKING TABLE FOR A1-s1mET4 I
No Name Sample Dist. % Mean A% Mean B% Mean C% Mean D% Mean E%
RANK CLASS MEAN % S.D. % p-RATIO
1 A 99.6880% 0.00321 311
1 A1mET4 2 0.032094 99.9150% 99.92% 2 T9-41 99.3338% 2.05E-05 48470
2 A1mET4 3 0.20358 99.4610% 3 TB-40 99.1783% 1.26E-05 78819
3 79-41 1 0.250892 99.3360% T11-43 E-irsro ■•lull*K!
4 79-41 3 0.251589 99.3340% 5 T10-42 99.1618% 0.001126 881
5 79-41 4 □ 251724 99.3340% 6 T7-39 99.0003% 6.6E-05 14996
6 79-41 2 0.252874 99.3310% 99.33% 9B8663% 0001236 800
——RqZ
8 \fmr~ 3 0.305545 98.9460% 98.95% "~Z TB-38C [98 7708% [0001582!9
Ttr
T11-43 2 0.306708 99.1890% 99.19% 98.6725% 0 0003081 mi
T12-44 1 0.307082 98.9410% 98.94% -arpf ■ttTsNelKf KiD!
11 TB-40 1 0.309992 99.1800% 99.18% 1? T1-21 I 98.6073% 0.000272 36291
12 TB-40 3 0.310788 99.1780% 13 T2-22 98.6045% 1.29E-05 76379

















18 3 0.31727 99.1610%
19 T10-42 4 0.317705 99.1600%
20 T10-42 1 0.317845 99.1590% 99.16%
21 T11-43 4 0.327323 99.1340%
22 TB-38 4 0.374821 99.0080% 99.01%| CTRL CLASSES COLOUR
23 T7-39 4 0.374821 99.0080% 99.00% vCJD A
24 T7-39 3 0.377015 99.0030% sCJD B
25 T7-39 1 0.379169 98.9970% 'mom
26 T7-39 2 0.38055 98.9930%
27 B1mET4 1 0.393229 98.9600% GRB norm!
28 4 0 399565 98.6220%
29 B1mET4 2 0.432744 98.8550%
30 B1mET4 3 0.435285 98.8480%
31 B1mET4 4 0.45304 98.8020% 98.80%
32 C1mET4 2 0.489889 98.7040% 98.70%
33 TB-38 1 0.492239 98.6980%
34 TB-38 3 0.49502 98.6900%
35 ClmET4 1 0.495087 98.6900%
36 TB-38 2 0.496163 98.6870%
37 C1mET4 3 0.506293 98.6610%
38 C1mET4 4 0.515813 98.6350% 9867%
39
40
1 0.515917 98 6350% ■■■
T1-21 1 0.516305 98.6340% 98.63%
41_^^H 2 0.51775 98.6300%
3 0.520766 98.6220% 98.62%
43 T1-21 2 0.520938 98.6220% 98.62%
44 T2-22 1 0.52678 98.6060%
45 T2-22 2 0.527469 98.6050%
46 T2-22 4 0.527591 98.6040%
47 T2-22 3 0.527947 98.6030% 98.60%
48 T1-21 3 0.528874 98.6010%
49 E1mET4 1 0.535264 98.5840% 98.58%
50 E1mET4 2 0.53763 98.5780%
51 T1-21 4 0.539702 98.5720% 98.61%
52 E1mET4 3 0.543002 98.5640%
53 E1mET4 4 0.543646 98.5620% 98 57%
54
55
T4-24 1 0.545318 98.5570% 98 56%
T3-23 4 0 545754 98.5560%
56 T3-23 3 0.545991 98.5560%
57 3 0.546492 98.5540%
58 mm 4 0.546683 98.5540%
59
60
mmm 2 0.547065 98.5530% 98.55%
73-23 2 0.547166 98.5530%
61 T3-23 1 0.547238 98.5520% 98.55%
62 T5-37 4 0.549521 98.5460%
63 T5-37 1 0.549726 98.5460%
64 t.-:~ 3 0.549892 98.5450%
65 I 2 0.549988 98.5450% 98.55%
Rank matching table matching a vCJD known control (single
other known and test sample replicate scans from clinical
control from group E.
replicate of 4 replicate scans) to
groups A-D alongside a single
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The match ranking method still does not improve the ability to identify unknown
samples with confidence. Test 22 (B3: sCJD) and Test 21 (A3: vCJD) are still
located away from the other CJD samples towards the normal samples, and the
neurological non-CJD samples are scattered across the mid range of the ranks.
However many normals and CJD clinical samples still segregated at opposite ends of
the range, which infers the presence of a unique combination ofphysiological factors
which make these samples different.
A number of strategies, such as applying filters to the spectral data, image analysis
and other various intuitive methods based on the experience of the Radar World
team, were tried for analysis to identify unknown samples, but it became evident that
the match ranking method was not sufficient to reliably discriminate all clinical
samples. At this stage the identities of the remaining test samples were un-blinded so
that the entire data set could be used as a training set to develop an expert system
analysis for the identification of clinical and control samples.
8.4.3 Analysis of variance classification: Expert Systems Analysis.
An expert system was developed based upon analysis of variance of frequency data
within groups and between groups. Studying firstly the similarities, and then the
differences between different samples groups produces a series of relationships
which can be used to develop logic relationships and an expert system. Radar World
has used this method in various applications ranging from coastal surveys by satellite
imaging to the discrimination between sound and rotten timbers by a customised
ADR apparatus. The identification of robust sets of P-value relationships for each
sample group allows the classification of test samples. The P-ratios of variance
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between and within groups are calculated by rank and cluster analysis ofADR-ratio
data using Radamatic software.
Four scans of the first training samples from each class (Al, Bl, CI, Dl, and El) 20
% as a training set, were used to compute P-value tables producing a series of 13
parameters to define each sample class. Each parameter produced a series of
defining statistics and relationships between sample classes. For example, for the
first test variable the between group statistics difference between samples show that
sample B was 3 times that of sample A, that sample B was 2.7 times that of sample
C, and sample D was 2.1 times that of sample C. Similarly ifwe consider the third
test variable statistics, sample A is 10619, sample B 68392, sample C 11198, and
sample D 24207. The summation of these relationships between sample classes for
all 13 indices led to the development of an expert system of analysis able to
characterise different sample classes.
This left 14 unknown samples from classes A-E to be identified using this expert
system (the second sample in each set was kept aside for later validation). This
clearly identified with certainty test samples 22 and 39 as sCJD, and test samples 21
and 40 as vCJD, which is also fairly evident from the match ranking tables shown in
section 8.4.2. All other unknown blind test samples from classes A-E were not
identified with 100 % reliability but gave high P-values ranging from 93 - 99.9 % in
probability, however this was not good enough for certainty and reliability. To
improve this, values for those correctly identified samples were introduced into the
P-value computation to produce revised parameters. Revision in these parameters
enabled the correct classification of all blind samples with 100 % certainty and
reliability. The second set of control samples from each class which were reserved
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(A2, B2, C2, D2, E2) and were not used in any matching or P-value assessments
were used to validate the knowledge base. They were correctly identified with 100
% confidence.
Due to the variability between patients and different blood types the identity of 20 %
of all samples was necessary for training to ensure correct classification of unknown
samples. Therefore ifwe have 100 unknown samples then 20 need to be revealed to
correctly identify the remaining 80 at the 0.001 % significance level, or 0.05 %
confidence level.
The results described so far shown that the match ranking method cannot distinguish
the clinical classes of unknown samples with high certainty, but it does indicate that
many vCJD and sCJD blood samples are sufficiently different from normal blood to
segregate as a distinct group least like normal blood. The P-value expert system
approach looks much more robust, and may yield a useable system after further
evaluation. This would suggest that there are distinct physiological markers present
in whole blood ofpatients with sCJD and vCJD that can be detected using ADR
spectroscopy.
In the development of the P-ratio expert systems analysis described in section 8.4.3
samples were un-blinded to aid its development. Therefore to evaluate the suitability
of the expert system for the identification of clinical CJD blood samples a second
small blind study was performed.
235
8.5 Study design
10 whole blood samples were obtained from the National CJD Surveillance Unit
frozen archives. Samples included 4 vCJD, 3 sCJD, and 3 samples from non-CJD
neurological controls. The controls were obtained from patients initially referred to
the unit as possible CJD cases but which subsequently proved to be non-CJD. It was
ensured that all samples had not been included in the first ADR spectroscopy study.
0.5 mL whole blood samples in 2mL storage tubes were vortexed and then allowed
to settle for 10 minutes prior to ADR scanning. 4 scans of each sample were taken
and scans of an empty storage tube was taken so that this background data could be
subtracted from sample scans so that spectral data was for the blood sample alone.
8.5.1 Data analysis: variance classification
Analysis of the ADR spectra generated in this second blind study was performed as
described in section 8.4.3. Frequency analysis ofADR spectral scans produced
ADR-ratio data. Rank and cluster analysis using Radamatic software was used to
produce P-ratios of variance which produced a range of indices used as discreet
classifiers for samples groups. This is referred to as a 'proper analysis of variance'.
The P-variance data classification parameters produced for vCJD, sCJD, and
neurological sample groups in 8.4.3 were used to correctly identify the blind samples
in this second study. For example, sample 7 was a whole blood sample from a sCJD
patient and the percentage correlation of oscillation between it and 3 controls from
vCJD, sCJD, and neurological control classes were used for supervised clustering.
Its correlation was 0.981 with the sCJD control compared to 0.939 with the vCJD
control and 0.948 with the neurological control. This sample was correctly classified
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as sCJD. All other blind samples were correctly classified in the same way. To
illustrate indices which were used to correctly classify samples ADR-ratio and time
(t) / amplitude (a) plots for nine of the ADR test parameters were plotted for ratios of
different clinical groups. These graphs are presented in Figures 59 and 60 below, the
separation between sample series ratios illustrate how different ADR test indices can
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Figure 59
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In this chapter we have presented proofof principle of a potential method employing
ADR spectroscopy and an expert systems statistical spectral analysis for the
classification of sCJD and vCJD clinical and neurological control and healthy adult
whole blood samples. The developed classification system was then validated by a
small blind study. The findings suggest that there are distinct physiological markers
detectable in clinical whole blood samples from vCJD and sCJD patients by ADR
spectroscopy. These methods present a rapid, non-destructive test system for the
antemortem diagnosis of patients with CJD that is not dependent on the detection of
PrPSc for their classification. The number of samples analysed in these studies is
very small and a much larger validation study of healthy adult controls, clinical CJD,
non-CJD control samples, along with samples from patients with a wide spectrum of
neurological, infectious and non-infectious conditions is required to assess to what
extent the expert system statistical parameters are specific for each group. Although
the exact nature of the ADR spectral alterations is unknown it may be that they are
due to distinct combinations of blood physiological features for particular disease
classes rather than due to the detection of PrPSc as was the assumption with the
mouse scrapie study. A panel of blood group typing samples was used to train the
system to recognise differences associated with different blood types so to increase
the reliability of the system analysis. This approach presents a unique diagnostic
approach for the detection of CJD blood samples, and it is possible that with further
study these methods may be adapted for the detection of other diseases.
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Discussion
This thesis presents a detailed study of the expression ofPrP in the peripheral blood
ofpatients with vCJD and sCJD using DELFIA and flow cytometry techniques, and
describes the development ofDELFIA based assays for the detection of PrPSc in
blood and other tissues. In addition ADR spectroscopic methods have been
investigated as a potential means of distinguishing vCJD and sCJD blood samples
from healthy adult and neurological control samples.
The DELFIA assay technique described in chapter 3 for the detection of PrPc has
been used previously 9 and is well suited to the screening ofwhole blood and
separated components of blood from clinical and control samples for PrPc. The assay
is quick and has a high sensitivity for the detection of PrPc. DELFIA technology is
compatible with high throughput and has a high signal to background ratio, due to
background deteriorating rapidly while the signal has a long lifetime. Flow
cytometry analysis, which is also used in this chapter for an analysis of PrP, has been
used previously to illustrate the expression of PrP on healthy adult human blood cells
6,10
No previous studies have evaluated the concentration and expression ofPrP in the
whole blood and separated components ofpatients with vCJD. DELFIA analysis of
separated components from controls and clinical patients found the highest levels of
PrPc associated with the platelet and plasma components and much lower levels
associated with red blood cells, which is in agreement with previously described
findings ofMacgregor et al9. Levels of PrPe in the leukocyte-enriched buffy coat
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fractions were very low, often at the detection limit of the assay, and these levels
could not be accurately calculated particularly in clinical groups, hence their
exclusion from further analysis. The separation method used here for the preparation
of separated blood components was a compromise for greatest utility of archived
samples, and was not ideal for isolation of the platelet and buffy coat components;
cells often clumped together and proved difficult to resuspend, this may explain the
large median ranges in the platelet data, and the low levels of detectable PrPc in buffy
coats. These large ranges in platelet PrPc concentrations are not supported by any
large fluctuations in platelet counts as seen in haematological data for patients and
controls used in this study; the data does not show any abnormalities.
In the analysis ofwhole blood there was a statistically significant decrease in the
concentration of PrPc in vCJD (p=0.005) and neurological control patient samples
(p=0.0001) compared to healthy adults but not when compared with the sCJD group.
There was significant elevation (p=0.022) in the plasma PrPc concentration in sCJD
patients when compared with both healthy adult and neurological control groups;
however no significant differences were evident between levels in sCJD and vCJD
patients. The elevation ofplasma PrPc in sCJD patients agrees with a previously
published report; however in this study a distinct finding is that levels of plasma PrPc
in sCJD patients were significantly elevated by comparison with healthy and the
neurological control group, which was not the case in previous published findings
164. These differences may be a consequence of using neurological controls with
conditions other than Alzheimer's disease, as was the case in the previous study.
There was a significant reduction in the concentration of red cell PrPc in neurological
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controls compared with all other groups. Flow cytometry analysis also demonstrated
significantly less PrP expression on red cells ofneurological controls than healthy
controls. These results would appear to indicate that there is less PrPc per red blood
cell in neurological controls compared with other groups. It is difficult to explain the
reduced expression ofPrP on red blood cells. It was considered that the differences
between groups might be a consequence of the age ofpatients affected by vCJD,
sCJD, and neurological disorders, however no relationship between age and PrPc
concentration was found in either control or clinical sample groups. It is possible
that the reduced concentration ofwhole blood PrPc in vCJD patient samples might be
due to the conversion of PrPc to PrPSc as part of the replication process involved in
disease pathogenesis. The absence of a similar reduction ofwhole blood PrPc in
sCJD patients would be expected since PrPSc is largely confined to the CNS and
replication of PrPSc in the periphery prior to neuroinvasion is not a feature of sCJD.
Alternatively the vCJD whole blood reduction could be a summation of reductions in
PrPe in the plasma and platelet components, whereas in sCJD the low platelet PrPc
value is offset by the high plasma value so balancing out in whole blood levels. It is
likely that the reduced levels ofwhole blood PrPc in neurological controls is a
consequence of the reduced PrPc levels found in red cells and platelets in this group.
The possibility was considered that increases in sCJD plasma PrPc levels may be a
consequence of its release from platelets, since platelets are known to express PrPc
on the cell surface and to store PrPc in alpha granules which is released into plasma
in a soluble form on platelet activation 150'165. To support this theory there was a
significant reduction in the platelet PrPc concentration in sCJD patient samples
compared to healthy adults implying that platelets may have shed PrPc into plasma.
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The expression ofPrP on platelets of vCJD and sCJD as determined by flow
cytometry was elevated compared with healthy adult and neurological controls, and
although this elevation did not reach significance perhaps this represents
upregulation of PrP prior to its release into plasma Investigations of cell surface PrP
on platelets did not implicate blood sample storage and transit as a possible cause for
increased cell surface PrP, it found cell surface PrP on platelets decreased with
sample age.
There was no evidence of a reduction in the expression ofPrP on lymphocytes of
patients with sCJD when compared to neurological controls in contrast to a previous
report 166. However, here both 4F2 and 3F4 anti-PrP MAbs were used together for
flow cytometry studies, whereas the previously reported study used 3F4 alone which
does not to bind to human red cells 6. It is possible that MAb 3F4 might show
reduced binding to PrPc on lymphocytes in some clinical conditions if PrPc
expression were altered or PrPc interacted with other membrane components due to
lymphocyte activation 167>168. prp on red cells, platelets and lymphocytes was
reduced to background levels after PK treatment in all clinical and control groups,
indicating the absence of any detectable cellular expression of abnormal disease
associated forms ofPrP.
These findings indicate that a reduction in concentration ofwhole blood PrPc may be
common in vCJD and other neurological diseases but not sCJD. An elevated level of
plasma PrPc may be common in sCJD. These differences between groups appear
genuine, presumably reflecting differences in the disease process in the patients in
these particular groups and not an artefact of age, specimen collection, storage or
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analysis. Despite the significance of differences between groups the variation in
values are large and there is considerable overlap between CJD groups and control
groups, which rules out the exploitation of these differences in whole blood and
plasma in screening strategies. These studies expose the limitations in the use of
blood PrPc levels as a diagnostic tool. However they illustrate important
observations on the distribution ofPrPc in the peripheral blood ofCJD patients and
the potential ofDELFIA-based PrP assays in clinical practice. The analytical
sensitivity of DELFIA-based assays used here represent a significant step towards
the development of DELFIA for the detection of PrPSc, which is a much more
reliable indicator of infection, and the findings emphasize the need to develop assays
911 59
for its detection in blood ' .
Use of PK and GdnHCL in the Development of assays for PrPSc
The development of a sensitive DELFIA based assay for PrPSc was the main focus of
the remainder of this thesis. Part of the initial development process involved an
assessment of the suitability of using existing methods employing PK and GdnHCL
to discriminate between PrPc and PrPSc. The partial resistance of PrPSc to proteolysis
by PK was first described by Prusiner et al and remains a key means of
discriminating between PrPc and PrPSc in existing western blotting,
immunohistochemical and ELISA based assays for post-mortem TSE diagnosis.
Studies into the susceptibility of untreated healthy adult human whole blood PrPc to
proteolysis with increasing concentrations ofPK found that PK could be used
successfully to eradicate almost all PrPc in samples. These studies however
highlighted one of the major problems of using PK as a means of removing PrPc, it
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has a broad specificity and since PrPc levels are likely to fluctuate between samples
its optimisation would require constant readjustment to ensure that conditions of
proteolysis were sufficient to remove PrPc but not PrPSc. IfPK concentrations are
too high they may remove PrPSc as well as PrPc because the resistance of PrPSc to PK
is not absolute, and ifPK concentrations are too low they will not remove all PrPc 2.
The use ofPK will therefore always be technically difficult and limit sensitivity.
Also, PK appeared to degrade the capture monoclonal antibody FH11 affecting
antigen capture and therefore the mechanics ofbinding and accurate detection of
PrPc. This was shown in preincubation studies described in section 4.3.
As an alternative to PK, GdnHCL was assessed as a means of distinguishing PrPc
from PrPs\ The use ofGdnHCL in these assays has been described previously by
several groups 21'152'158. The methods of Barnard et al 158 for the differential
extraction and separation of PrPc from PrPSc in BSE infected bovine brain tissue
were well suited to the isolation ofPrPc from healthy adult whole blood samples.
This methodology was also used successfully to distinguish 263K-scrapie infected
hamster brain homogenate from uninfected healthy hamster controls, and to detect
PrPSc in a vCJD brain homogenate spiked plasma log dilution series. The CDI assay
described by Safar et al 21 was adapted successfully for the detection of human PrPSc
in vCJD spiked human plasma samples. A comparison of candidate monoclonal
capture antibodies found that antibody 1120-64-09 was best suited to this type of
assay because it did not show different binding affinities for native and denatured
PrP as was the case with the capture antibodies FH11 and D18. MAb 1120-64-09
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had a superior signal for the detection of plasma PrPc and PrPSc purified from vCJD
brain material.
Development of the CDI assay for PrPSc detection
The CDI assay employing monoclonal antibody 1120-64-09 as capture antibody and
europium labelled MAb 3F4 as detection antibody was selected for further
development. NaPTA and NaCl precipitation techniques described previously21 160
were adapted and used successfully to precipitate and concentrate PrPSc from larger
volumes of vCJD brain spiked human plasma prior to detection using the CDI assay.
These precipitation methods may permit the detection of PrPSc in blood or tissues
where it is present at very low concentrations because they effectively concentrate
PrPSc from larger quantities of sample. Claims by Safar et al21 that NaPTA binds
specifically to oligomers and polymers of PrPSc but not PrPc were not supported by
experiments presented here. PK treatment before NaPTA precipitation and CDI
analysis increased the sensitivity for the detection of PrPSc. In addition a traditional
salting out protocol using NaCl, adapted from Polymenidou et al 160 had a very
similar sensitivity to that ofNaPTA precipitation for the detection of PrPSc. These
experiments do not support a specificity ofNaPTA for PrPSc alone, unless proteolysis
of PrPSc increases the affinity of the binding interaction between it and the capture
antibody. The increases in sensitivity are most likely caused by the removal of PrPc
which competes for binding to the capture antibody, and, or other proteins which
compete non-specifically. Despite this the CDI assay and NaPTA precipitation
methods were adopted to develop a sensitive assay for the detection of human PrPSc.
The assay has a maximum limit of detection of 10"5 log dilution for 10 % vCJD brain
homogenate spiked into human control platelet poor plasma. This represents the
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most sensitive reported assay in existence for the detection of PrPSc when compared
with other promising assays (see Table 5 pp.62). The developed NaPTA
precipitation and CDI assay techniques were used to detect PrPSc in spleen, tonsil,
and muscle tissues from patients with vCJD, sCJD, and non-CJD neurological
controls. PrPSc was detectable in spleen and tonsil homogenates from patients with
vCJD. PrPSc was not detected in sCJD tonsil samples but was detectable in a single
sCJD muscle sample. These studies verify the suitability of this assay for the
sensitive detection of PrPSc in peripheral tissues. Any physiological differences or
structural abnormalities that may exist between the type of PrPSc in brain and in
peripheral tissues do not restrict its detection using these methods. The sensitivity of
this method shows promise for the detection of PrPSe in the peripheral blood of
patients with vCJD and is certainly a candidate assay for consideration as a means to
ensure the safety of blood and blood products used in the transfusion services.
ADR spectroscopy study
Finally ADR spectroscopy techniques were employed in an analysis of sCJD and
vCJD clinical and neurological control, healthy adult, and spiked whole blood
samples. Spectral analysis, rank matching, and expert systems statistical analysis
methods were explored to evaluate methods able to correctly identify blinded clinical
and control samples. Expert systems statistical analysis approach was found with
training to be best suited to the identification ofblind samples with 100 % certainty
and reliability. A second small validation study of clinical CJD and control whole
blood samples presented proof of principle of employing ADR spectroscopy and
expert systems statistical spectral analysis for accurate classification.
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Recent developments and conclusion
In 1997 the Transfusion Medicine Epidemiology Review (TMER) study funded by
the Department ofHealth was set up to study potential links between vCJD and
blood transfusion. The first case of possible transmission of vCJD by blood
transfusion was identified by this study was reported in early 2004 76, and is
described in section 1.6.5. The report identified a further 17 individuals who had
received blood products from donors who subsequently developed vCJD. During the
writing of this thesis there have been further critical developments concerning blood-
borne iatrogenic vCJD transmission. A report in the Lancet in August 2004
described a preclinical case of vCJD infection identified by autopsy which appeared
to have been transmitted by blood transfusion 169. The case identified was one of the
17 individuals who had received blood products from donors who subsequently
developed vCJD. The patient was elderly and had received a donation of non-
leucodepleted red blood cells in 1999 from a donor who developed vCJD 18 months
after donation. The donor died in 2001 and vCJD was confirmed after autopsy. The
recipient died in 2004, 5 years after receiving the transfusion with no signs of a
neurological disorder. It is interesting to note that in both reported cases of
transfusion-related transmission of vCJD the donor received non-leucodepleted red
blood cells products which are relatively unprocessed compared with fractionated
plasma products which are subject to processing steps which remove 3 to 5 logs of
infectivity 131. A medicolegal instruction for autopsy was issued and allowed
detailed examination of the patient. The patient was heterozygous for Methionine /
Valine at codon 129 of the PRNP gene. PrPSc was detected by western blot in the
spleen and cervical lymph node but not in the brain. This case represents the first
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recorded case of autopsy detected pre-clinical vCJD infection in the UK. The
identification of this case is critical for a number of reasons. This is the first known
case of vCJD, be it sub-clinical, detected in an individual who is heterozygous at
codon 129 of the PRNP gene. To date all clinical reported cases of vCJD have been
homozygous for Methionine at this codon, and considering that the heterozygous
genotype represents the largest genetic subgroup in the population this case has
important implications for future predictions of the number of vCJD cases
considering that there has been uncertainty as to the susceptibility of this genetic sub¬
group. One possibility is that after exposure to the vCJD infectious agent
heterozygous individuals have a longer incubation period than homozygotes with
infection remaining at sub-, or pre-clinical levels for many years. This is particularly
critical since such individuals may represent a significant source of iatrogenic
transmission either via blood transfusion or the contamination of surgical instruments
by lymphoreticular tissues. If sub-clinical vCJD infection in this genotype is
prevalent it at present remains undetected and uncontrolled. In the absence of a
screening test for vCJD these individuals could be a major source of future iatrogenic
transmissions. Indeed there is the potential for iatrogenic vCJD transmission cases to
exceed those caused by BSE. The possibility remains that both apparent transfusion-
related transmission cases may be a consequence of exposure to BSE through
contaminated beef, however statistically the chances of observing vCJD transmission
in two recipients ofblood donated from patients who subsequently died of vCJD will
be considerably less than the 1/15000 to 1/30000 odds reported for the first case 76.
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This most recent case of transmission by transfusion highlights the increasing need
for preclinical blood screening tests for vCJD to enhance the safety of blood
transfusion, to reduce future iatrogenic transmission of vCJD between individuals by
identifying those individuals harbouring sub-clinical infection. The need for such a
test is compounded by recent studies by Gregori et al 170 which in an assessment of
leucodepletion filtering found that it removed only 42 % of total TSE infectivity in
263K-scrapie endogenously infected hamster blood. Universal leucodepletion was
introduced by the UK blood transfusion services in 1998 as a response to advice that
infectivity if present was mainly associated with the buffy coat and plasma. This was
closely followed by the decision in October 1999 to import all plasma for
fractionation used to manufacture plasma derivatives from the United States.
In this thesis a CDI assay incorporating NaPTA precipitation and PK treatment has
been developed with a sensitivity of 10"5 for the detection of 10 % vCJD brain
homogenate, and 10"2'5 for 10 % vCJD spleen homogenate. NIBSC spleen and brain
preparations were used as a source of PrPSc. This represents the sensitive detection
of 10" and 10" ' for unhomogenised brain and spleen tissue respectively. At present
this assay represents one of the most promising PrPSc assays with a sensitivity
approaching levels at which it might be possible to detect PrPSc in blood. At present
the NIBSC working reference preparations of vCJD brain and spleen homogenate are
undergoing assessment for infectivity in the hope that levels of infectivity can be
equated with levels of PrPSc. Accurate infectivity titres were hoped to be obtained
from chimeric mouse-human transgene expressing mice but these were insensitive to
infection with vCJD but readily infected with sCJD 171. Titres in wild type mice
inoculated intracerebrally are approximately 1,000,000 infectious units (IU) per gram
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for vCJD brain and 1000 IU per gram for vCJD spleen. Whether this represents
infectivity titres for humans considering the species barrier and route of infection is
open to question. Studies in rodent models 172 predict that infectivity in human
blood will be in the region of 10 IU per mL. Therefore a PrPSc assay able to detect
levels associated with < 1-10 IU / mL ofblood may be of use for screening. Titres of
PrPSc in vCJD brain and spleen homogenates in this thesis have shown that
differences in the levels of PrPSc reflect the same reported levels of difference in
infectivity between these tissues, and given recent reports by Legname et al 173 that
PrPSc is in fact the infectious agent, it may be at last be possible to refer to PrPSc as
the infectious agent. If PrPSc levels are synonymous with infectivity then the
sensitivity of the CDI assay assessed with NIBSC vCJD brain and spleen
homogenates presented here would equate to a limit of detection of 1 IU which is a
level of sensitivity perhaps capable of detecting infected blood. It may not be quite
so straightforward; the assay may not be suited to the detection of PrPSc in human
peripheral blood. PrPSc here may be less aggregated or in a different form than that
in spleen and brain tissue, and may be more susceptible to proteolysis with PK used
to achieve the sensitivity in brain and spleen assays. Although results presented in
this thesis do not suggest that differences which might exist between vCJD brain and
peripheral tissues in terms ofpatterns of glycosylation, protease sensitivity, and
epitope presentation affect the ability of the CDI assay to detect PrPSc, this may not
be the case with blood. The testing of clinical vCJD blood samples may be useful to
ensure that this assay approach is able to detect PrPSc in blood but such experiments
would not validate the capability of the assay to detect infectivity in the
asymptomatic phase. This represents a significant problem; one of few alternatives
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is to assess assay sensitivity using blood ofknown infectivity from experimentally or
natural TSE infected animals. It is probable that the use of animal TSE blood will
constitute all validation studies. However in the case of the CDI assay described and
assessed in this thesis the specificity ofmonoclonal antibodies would not be
appropriate for the detection of ovine or murine PrP. Substitution with antibodies of
the required specificity may not afford the same sensitivity of detection. In addition
the form of PrPSc in animal blood may not be the same as that associated with human
blood. In the absence ofpreclinical blood samples from individuals known to be
incubating vCJD, the validation ofpromising assays using clinical vCJD blood
samples and blood from experimentally or naturally occurring animal TSEs remains
the only alternative. Therefore if the CDI assay is to be considered as a candidate
assay for blood screening, this would be the next step in its validation. The issue of
specificity is also critical for all screening tests when the ethical considerations of a
positive test and its adverse effects upon blood supply with the removal of false
positive donations and the negative impact upon donor recruitment, is considered. A
specificity of 100 % would naturally be desirable. In a recent publication by
MacGregor at al 174 a false positive rate of greater than 1/200 or specificity of 99.5 %
was deemed unacceptable. Considering that in the UK there are 2.5 million
donations per anum, a screening assay with 99.5 % specificity would yield 12500
false positive donors and this would have a significant impact upon the blood supply
chain. Specificity is therefore ofparamount importance. Sensitivity is less critical
since the identification of some if not all infected blood donors would significantly
contribute to curtailing the risk of iatrogenic transmission of vCJD by blood
transfusion despite not detecting all positive donations. A confirmatory assay would
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be essential, reliant upon a different approach to retest those positive blood samples
identified using the first screening assay, probably an assay based on the detection of
infectivity. It would require a sensitivity similar to the first assay in the region of 1-
10 IU / mL. One possibility would be to use a mouse bioassay although this would
take considerable time to produce results. In-vitro assays such as one producing
results in 2 weeks reported for a scrapie strain by Weissmann et al175, or the knock-
in mouse expressing humanized chimeric PrP spleen bioassay able to produce results
in 30 days described by Kitamoto et al176 would be ideal as confirmatory assays for
human blood screening. Perhaps with further validation the ADR-spectroscopic
analysis technique presented in this thesis may be of use as a screening assay with
the CDI assay used as a confirmatory assay for the detection of PrPSc. Whether
assays used are for infectivity, PrPSc or surrogate markers of vCJD infection they
would need to be quick, cheap, and suitable for the screening of all UK donors.
The ethical considerations of introducing a blood screening test are a major issue for
the UK blood transfusion services 177. The transfusion services are under increasing
pressure to introduce a vCJD-screening test once a viable option becomes available,
and this pressure has been compounded by the two recent reports of transfusion-
related transmission. In the past the policy of the UK transfusion services has been
to inform donors of the types of tests carried out on their donation and to contact and
counsel those who produce a positive test. Screening tests are where ever possible
implemented along with a confirmatory test to assure that test results are correct. In
the case of vCJD there are many ethical difficulties with implementing a test without
being certain of the implications of a positive test result, whether this does in fact
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equate to an increased risk of vCJD, and in the absence of any tried and tested
therapeutic strategies. Indeed these ethical issues are being faced presently as a
consequence of the decision of the CJD clinical incidents panel to inform all
recipients of blood components donated by individuals who later developed vCJD.
These individuals were informed of the risk. They were advised that they could no
longer donate blood and also that surgical precautions would be required. However
there is considerable uncertainty as to whether these individuals will actually develop
vCJD; and more significantly there are at present no available tests to investigate the
risk. Despite these ethical considerations it is essential that any available blood-
donor screening test be implemented to enhance the safety of blood transfusion and
to reduce the spread of vCJD amongst recipients of blood products.
Much like vCJD screening tests, therapeutic strategies are at an early stage of
development. Many show promise and could be useful for prophylaxis in preclinical
vCJD patients. The use ofbis-quinacrine is undergoing evaluation, and pentosan
polysulphate, which showed promise in animal TSE infectivity models has been
administered to vCJD patients on an ad hoc basis. Quinacrine is currently being used
in the Prion-1 trials conducted by the MRC Prion Unit, London, UK. In addition the
use of anti-prion antibodies and peptides, and beta-sheet breakers are alternatives
also under development. Any effective treatment would be ofmost use at the
preclinical disease stage since the neural degeneration associated with clinical
disease is probably irreversible. Prophylactic treatments could be made available to
blood donors and other individuals who produced a positive result with any
implemented vCJD screening test so offsetting some of the ethical difficulties
associated with implementing a screening test.
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In the next 5 years it is likely that the most promising diagnostics for the detection of
vCJD in blood will undergo necessary validation using vCJD clinical blood samples
and preclinical blood samples from both natural and experimental TSEs in animals.
It seems likely that NIBSC along with the UK blood transfusion services and the
Department ofHealth will work closely together to evaluate and implement a
screening assay to enhance the safety of blood transfusion and reduce the iatrogenic
transmission of vCJD via transfusion. Therapeutic strategies will also be developed
to produce prophylactics. Blood collection bag filter technologies are being
developed and evaluated by both Pall Corporation and by MacoPharma in alliance
with Pathogen Removal and Diagnostic Technologies Inc (PRDT). Pall reported in
November 2004 at the annual meeting of the American association of blood banking
that their Leukotrap® affinity prion reduction filter reduced infectious vCJD prions
from red blood cell concentrates below the limit of detection of the western blot
assay. The filtering technology had been shown previously to remove scrapie
infectivity from scrapie infected mouse blood. The filter is a leucodepletion device
which also removes infectious prions. The MacoPharma PRDT alliance has
developed blood bags with ligands that absorb infectious prions from blood and
blood derived products. Both companies are aiming to launch products in Europe in
2005, and it seems likely that these technologies will be implemented before a
screening test. It seems likely that the blood transfusion services will implement
further restrictions on donors and blood product manufacture and use. For example a
recent ban on donors who received a blood transfusion after January 1980 was
implemented in April 2004 and resulted in the loss of 3.2 % ofblood donors, and
options are being considered to reduce the plasma content of red blood cell
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components. In addition a decision was taken in April 2004 to import fresh frozen
plasma from the United States for all patients born after January 1996. The number
of countries deemed to be free of vCJD from which blood and blood products can be
sourced will probably fall, and the number of countries trying to import such
products will rise, as other countries develop significant clusters of vCJD like the
UK. This will mean a worldwide shortage of blood and blood-products. Also, while
some countries are free of vCJD, there are other endemic risks to such blood which
need consideration.
vCJD is clearly having a significant effect upon the blood transfusion services, and a
screening test in place of such precautionary measures remains a priority. The CDI
assay and ADR-spectroscopic techniques presented in this thesis represent two of the
most promising techniques which require further investigation for their potential as
vCJD blood screening tests. Further work is required to assess their ability to
identify PrPSc and, in the case of ADR-spectroscopic methods, physiological markers
for vCJD which would enable the identification of individuals incubating vCJD
It is likely that there will be further cases of vCJD transmission by blood transfusion,
though without a highly specific and sensitive screening test it may not be possible to
make an accurate assessment of the numbers of individuals pre-clinically incubating
vCJD, and so it is difficult at this stage to predict whether or not iatrogenic
transmission will lead to a much wider incidence of vCJD.
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TRANSFUSION COMPLICATIONS
Variation in concentration ofprion protein in the peripheral blood
of patients with variant and sporadic Creutzfeldt-Jakob disease
detected by dissociation enhanced lanthanide
fluoroimmunoassay and flow cytometry
Tim Fagge, G. Robin Barclay, Ian MacGregor, Mark Head, James Ironside, and Marc Turner
BACKGROUND: A highly sensitive dissociation-
enhanced ianthanide fluoroimmunoassay (DELFIA) and
flow cytometry techniques have previously been
developed and employed to characterize soluble cellular
prion protein (PrPc) expression in whole blood and
separated components from healthy adult blood donors.
No previous studies with these techniques have evaluated
the concentration and expression of PrP in the blood of
patients with variant Creutzfeldt-Jakob disease (vCJD).
STUDY DESIGN AND METHODS: For blood from vCJD
patients, sporadic CJD (sCJD) patients, non-CJD
neurological controls, and healthy adults, PrPc was
measured by DELFIA and cell-associated PrP was
measured by flow cytometry.
RESULTS: DELFIA analysis identified a significant
reduction in the concentration of PrPc in the whole blood
of vCJD (p = 0.012) and non-CJD neurological patients
(p = 0.0004) compared with healthy adults. A significant
elevation was found in plasma PrPc in sCJD patients
compared with healthy adult (p = 0.022) and neurological
controls (p = 0.050). Flow cytometry found no significant
differences between groups in expression of PrP on
platelets and lymphocytes, nor in sensitivity of cellular PrP
to proteinase K. Neurological controls show significantly
less PrP on red cells than healthy adults.
CONCLUSION: There are differences in free and cell-
associated PrP found in blood of CJD patients and control
groups, some of which might be useful with other tests in
disease profiling as an aid to diagnoses.
The human prion diseases or transmissiblespongiform encephalopathies (TSE) are a groupof fatal neurodegenerative disorders believed tobe ca sed by a posttranscriptional conforma¬
tional change in cellular prion protein (PrP) from its solu¬
ble form (PrPc) to pathogenic protease resistant isoform
Prpsc i most common of these is sporadic Creutzfeldt-
Jakob disease (sCJD) but recently a variant form of CJD
(vCJD) was identified in the United Kingdom2 and has
been linked to human infection by the bovine spongiform
encephalopathy (BSE) agent. The presence of PrPSc in
the peripheral tissues of patients with vCJD3,4 and recent
experimental transmissions of BSE and natural scrapie
between sheep by blood transfusion raise the possibility
of the potential for iatrogenic transmission in humans by
ABBREVIATIONS: BSE = bovine spongiform encephalopathy;
DELFIA = dissociation-enhanced lanthanide fluoroimmuno¬
assay; pK = proteinase K; PrP = prion protein; PrPc = soluble
cellular prion protein; PrPSc = pathogenic protease resistant prion
protein; sCJD = sporadic Creutzfeldt-Jakob disease; TSE(s) =
transmissible spongiform encephalopathy(-ies); vCJD = variant
Creutzfeldt-Jakob disease.
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blood transfusion.5,6 This risk has been highlighted by two
recent reports of possible transmission of vCJD by blood
transfusion,7,8 which supports the likely presence of infec-
tivity in the blood of preclinical vCJD patients. There is
therefore a pressing need for preclinical screening tests,
which either identify PrPSc or are able to identify infected
individuals via the detection of reliable surrogate markers
to enhance the safety of the blood supply.
The association of infectivity with blood is poorly
understood, although there is growing evidence from
studies in mice and hamsters that the initial TSE infection
is carried by white blood cells (WBCs)9,10 to lymphoretic-
ular tissues before neuroinvasion of the central nervous
system via the sympathetic nervous system.11"16 Recent
reports of the transmission of natural scrapie and experi¬
mental BSE between sheep bywhole-blood and buffy-coat
transfusion support the theory that infectivity is associ¬
ated with, but not restricted to, the WBC component.17
Given that levels of detectable PrPSt and infectivity in
peripheral lymphoreticular tissues such as spleen and ton¬
sil in patients with vCJD are 2 to 3 logs lower than levels
detected in the central nervous system,4,18 it is likely that
PrPSc is present at extremely low concentrations in periph¬
eral blood. Attempts to detect PrPSc in human buffy coat
byWestern blot have thus far proven unsuccessful.4 Intra¬
cerebral inoculation of human buffy coat into susceptible
mouse models has failed to demonstrate infectivity,19
although this may be a reflection of small numbers of
animals used as well as insufficient assay sensitivity.
Tests designed for the detection of PrPSc in blood
would require a high level of sensitivity, probably several
logs greater than those already in place for postmortem
TSE disease confirmation in humans and slaughterhouse
cattle testing. Brown and colleagues,20,21 basing calcula¬
tions on studies in rodent TSE models, hypothesized that
at most PrPSc would be present in blood at a level of 100
infectious units per mL of buffy coat, equivalent to 1 to 10
pg per mL; additional studies predict 10 infectious units
per mL of peripheral blood,22 assuming that the ratio of
infectivity to PrPSc found in rodent TSE models is similar
to that in vCJD infected humans. Considering these diffi¬
culties in detection sensitivity, alternatives to PrPSt as sur¬
rogate markers for TSEs have been explored in the hope
that they will provide a test able to distinguish healthy
donors from those harboring preclinical TSE infectivity.
Dissociation-enhanced lanthanide fluoroimmunoassay
(DELFIA) technology was employed here to study poten¬
tial variation in the expression of the normal prion protein
isoform (PrPc) in vCJD and sCJD in humans. This technol¬
ogy has been previously employed by us in the detection
of prion protein in different blood components of healthy
blood donors23 when we found that two-thirds of all PrPc
was associated with the plasma component, one-fourth in
platelets (PLTs), and the remainder associated with mono¬
nuclear WBCs and red cells (RBCs). We also showed that
PrPc is released from PLTs into plasma.24 A similar
approach has also been used in a report of an increase in
PrPc expression in plasma of patients with sCJD and neu¬
rological controls when compared with healthy blood
donor controls.25 The expression of PrP in the peripheral
blood of patients with vCJD has not been previously stud¬
ied. In this study, we report levels of PrPc in whole blood
and separated blood components of vCJD patients, sCJD
patients, healthy adult controls, and neurological controls
as measured with DELFIA. In addition, flow cytometric
analysis of cell surface PrP expression on different blood
cell types was carried out on fresh whole-blood samples
from the same clinical and control groups.
MATERIALS AND METHODS
Collection of blood samples
Anonymized whole-blood samples from 30 healthy adult
apheresis PLT donors were collected by the Scottish
National Blood Transfusion Service Edinburgh and stored
for 24 hours at 4°C before separation to mimic the condi¬
tions of collection of samples from CJD patients trans¬
ported to the National CID Surveillance Unit from around
the country. Blood from CJD patients and neurological
controls was left over from samples obtained by the
National CJD Surveillance Unit for genetic analysis. Sam¬
ples were not obtained solely for this study owing to the
difficulties of obtaining blood from these patients.Whole-
blood samples from 10 vCJD patients, 10 sCJD patients,
and 8 neurological controls were used for DELFIA studies.
Informed consent was obtained from patients and donors
for experimentation and ethics approval for the study was
obtained from the Scottish Multi-Center Research Ethics
Committee. All vCJD and sCJD cases had a probable or
definitive diagnosis based on internationally established
criteria.26,27 Neurological controls were samples referred to
the CJD Surveillance Unit from patientswho subsequently
did not meet criteria for a diagnosis of definite or probable
CJD. These 8 patients were subsequently diagnosed
with neurological disorders distinct from CJD including
Alzheimer's disease (2), paraneoplastic syndrome (2),
mitochondrial disease (1), Lewy body dementia (1),
nonorganic depression (1), and central pontine myelinol-
ysis (1).
All whole-blood samples were handled, separated,
and stored in the same manner to ensure groups were
directly comparable in scientific investigations. Whole-
blood samples were collected into 9-mL vacuettes
containing 1 mL of 3.2 percent trisodium citrate (Greiner
Bio-One Ltd, Gloucestershire, UK). Blood for flow cytom¬
etry (0.4 mL) was set aside fresh as samples arrived at the
National CJD Surveillance Unit and tested immediately.
Samples were then separated into whole-blood, PLT-poor
plasma, RBC, PLT, and buffy-coat components for
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archiving frozen for these and other studies. The separa¬
tion protocol was designed to produce these components
without the need to use Ficoll. Ficoll, like dextran sulfate,
is a polyanion, and it was thought that it may interfere
with the processing and replication of the infectious agent
as has been reported for dextran sulfate.28 A quantity of
1.5 mL of whole blood was transferred to a sterile 2-mL
tube, and the remaining volume was centrifuged at 450 x g
for 10 minutes in a centrifuge (Model 4-15C, Sigma Aid-
rich, UK).
The PLT-rich plasma was removed and centrifuged at
16,060 x gfor 10 minutes in a centrifuge (Heraeus Biofuge,
Kendro Laboratory Products, Sollentum, Germany); the
resulting PLT-poor plasma supernatant was transferred to
2-mL storage tubes. The buffy coat and the RBCs were
transferred into separate 15-mL tubes, and 10 mL of phos¬
phate-buffered saline (PBS; Sigma Aldrich, P4417) was
added before the tubes were spun at 180 xg for
10 minutes. The supernatant and the top 0.5 mL of the
interface from the RBC tube were discarded, PBS was
added to the 14-mL mark, the tube was centrifuged at
180 xg for 10 minutes, and the supernatant was dis¬
carded. The pellet was resuspended in PBS to double the
volume giving a 50 percent solution of cells, which were
transferred to 2-mL storage tubes. The supernatant from
the buffy-coat tube was centrifuged at 16,060xg for
5 minutes to pellet the PLTs. The supernatants were dis¬
carded and the pellets were washed with PBS, resus¬
pended in 1 mL of PBS, and transferred to a 2-mL storage
tube. The buffy-coat pellet was washed in 14 mL of PBS,
the supernatant was discarded, and 13 mL of distilled
water added to shock-lyse the RBCs. One milliliter of lOx
PBS was added before centrifugation at 180xg for
10 minutes. The supernatant was discarded and the pellet
was washed with PBS and centrifuged at 100xg for
10 minutes. The supernatant was discarded and the pellet
was resuspended in 1 mL of PBS. All separated compo¬
nents were stored at -80°C. Protease inhibitors were not
used in the preparation of these components.
DELFIA
The highly sensitive method of time-resolved DELFIA was
employed for the detection of PrPc by sandwich immu¬
noassay with methods described previously by our
group.23 The assay was calibrated with a dilution series of
an expired PLT concentrate as a source of human PrPc.
This had been calibrated as a standard with recombinant
human soluble PrP (Prionics, Zurich, Switzerland); 1 unit
was found to be equivalent to 26 pg per mL. In addition a
quality control plasma sample was included to confirm
assay reproducibility. Blood component aliquots were
thawed and assayed at five dilutions in duplicate. Suitable
dilutions for each component were established in earlier
experiments (data not shown) to ensure parallelism
between dilutions. The means, median, and standard
deviation were calculated and the U test was used to
determine the significance of differences between groups.
Total protein measurement
Data were expressed in units permilligram of total protein
forwhole blood and all separated components to normal¬
ize data by compensating for the effects of the separation
protocol upon cellular particulate recovery in compo¬
nents and to ensure that range differences in cell number
did not contribute to differences in PrP' levels between
groups. Although studies on full blood counts of clinical
patient samples and controls did not show abnormalities,
full blood count data could not be generated from frozen
stored clinical and control samples used in this study;
therefore, normalization by total protein was essential for
all components with the exception ofwhole blood.
Measurements of total protein levels were carried out
with a protein assay (Bio-Rad, Hemel Hempstead, UK).
The microtiter plate format was performed following the
manufacturers instructions.
Flow cytometry
Blood samples. Samples were processed by flow
cytometry immediately on arrival at the National CJD
Surveillance Unit and subsequendy assigned to clinical
groups when diagnoses were made. An aliquot (0.4 mL) of
whole blood from each sample was made available for
flow cytometry studies. Any samples that did not fall into
the diagnostic categories were not included in the analysis
of results. Blood samples were also obtained from healthy
adults described above and, because clinical samples
were at least 24 hours old before arriving in the laboratory,
these healthy adult control samples were processed by
flow cytometry on the day following sampling.
Treatment with proteinase K. A quantity of 0.2 mL of
the sample was set aside for staining (untreated) and the
remaining 0.2 mL was washed once in 2.5 mL of cold cell
wash (Becton Dickinson, Franklin Lakes, NJ), centrifuged
down, and resuspended in 0.5 mL of proteinase K (pK)
(Sigma Aldrich) at 1 mg per mL in Hanks' balanced salt
solution with calcium and magnesium (Sigma Aldrich)
and left at room temperature for 30 minutes (the pK con¬
centration for complete removal of cellular PrP from
healthy human blood cells under these conditions was
determined by preliminary titration). The pK-treated sam¬
ple was washed four times in 2.5 mL of cold cell wash, and
the resultant cell pellet was divided equally between two
12 x 75-mm Falcon tubes (Becton Dickinson) for flow
cytometry staining.
Flow cytometry staining and analysis. This was car¬
ried out essentially as previously described29,30 except
that a combination of monoclonal antibodies (MoAbs)
506 TRANSFUSION Volume 45, April 2005
VARIATION OF PRION PROTEIN IN BLOOD
3F4 and 4F2 was used on the hypothesis that although
MoAb 4F2 clearly identifies PrP on human RBCs whereas
MoAb 3F4 does not bind to human RBCs,28 the 4F2
epitope on any PrPSc may be more susceptible to pK
cleavage than the 3F4 epitope. These MoAbs (5 pL each
at 0.5mg/mL) were added simultaneously to 100 pL of
whole blood or pK-treated washed blood with 100 pL of
cell wash. Second samples of whole blood and pK-
treated blood received 100 pL of cell wash without anti-
prion MoAbs as unstained (negative) control. After
incubation and washing, anti-mouse immunoglobulin
(human absorbed fluorescein isothiocyanate [FITC] -
conjugated goat anti-mouse immunoglobulin F(ab')2»
Biosource, Camarillo, CA) at 1 in 500 in cell wash (100 pL)
was added to all tubes. After incubation and washing, a
sample (10 pL) was removed from each tube for RBC
studies, and 5 pL of peridinin chlorophyll protein-conju¬
gated anti-CD45 MoAb and 5 pL of phycoerythrin (PE)-
conjugated anti-CD41 MoAb (Becton Dickinson) were
added to each whole-blood tube. To each RBC study
sample, 5 pL of PE-conjugated anti-glycophorin A MoAb
(Serotec, Oxford, UK) was added. Samples were incu¬
bated an additional 30 minutes in the dark at room tem¬
perature. The RBC samples were washed twice with
2.5 mL of cell wash and resuspended in 0.5 mL of cell fix
(Becton Dickinson). The whole-blood samples were
resuspended in 2.5 mL of lysing solution (Becton Dickin¬
son) to remove RBCs followed by two washes in 2.5 mL of
cell wash and resuspended in 0.6 mL of cell fix. Fixed
stained samples were kept overnight at 4°C in the dark
before analyzing by three-color flow cytometry as previ¬
ously described.30 Samples from lysed preparations were
collected on linear forward- and side-scatter axes for
WBC studies, and a second set was collected on logarith¬
mic forward- and side-scatter axes for PLT studies. RBCs
were collected on linear forward- and side-scatter axes. A
total of 20,000 events in appropriate forward- and side-
scatter gates were collected to listmode files for each
analysis. Analysis was conducted with computer software
(FCS Express, DeNovoSoftware, Thornhill, Ontario, Can¬
ada) on a personal computer. Samples were gated by
appropriate forward- and side-scatter patterns and addi¬
tionally by CD45 expression (differentWBC populations),
CD41 expression (PLTs), or glycophorin A expression
(RBCs). Other markers ofWBC populations (e.g., CD14)
were susceptible to pK digestion and were not used. His¬
tograms were made of channel-1 (FITC) expression for
negative controls (no anti-PrP MoAbs) and overlaid with
histograms for channel-1 for anti-PrP (primary anti-PrP
MoAbs) for each cell class: single peaks were observed in
each case and their median fluorescence intensities
determined by setting appropriate markers on the histo¬
grams. Net median fluorescence intensity for anti-PrP
staining was obtained by subtracting the negative control
(no anti-PrP MoAbs) value.30
Statistical analysis
Clinical groups were compared with the U test carried out
with computer software (NCSS 2001 software, NCSS,
Kaysville, UT). Box plots were produced by the NCSS 2001
software according to a common procedure in which
boxes represent the interquartile range (IQR), the top and
bottom of the box are the 25th and 75th percentiles, and
the horizontal line through the box represents the median.
The line and bar (whiskers) above and below the box rep¬
resent the upper and lower adjacent values. The upper
adjacent value is the largest observation that is not greater
than the 75th percentile plus 1.5 times the IQR. The lower
adjacent value is the smallest observation that is at least
the 25th percentile minus 1.5 times the IQR. Outliers,
shown as small circles, are those values that lie outside the
upper and lower adjacent values.31
RESULTS
Detection of whole-blood PrPc by DELFIA
Whole-blood samples from 10 patients with vCJD, 10
patients with sCJD, 8 neurological controls, and 29 healthy
adults (1 excluded owing to lack of parallelism between
dilutions) were analyzed in duplicate at five dilutions by
DELFIA. For each group the median and IQR were calcu¬
lated (Fig. 1A; Table 1). There is a significant decrease in
the concentration of PrPc in vCJD (p = 0.012) and neuro¬
logical control patients (p = 0.0004) compared with
healthy adults, but not between vCJD and sCJD, nor
between neurological controls and sCJD patients. Despite
the significance, there was considerable overlap between
the vCJD and healthy adult control groups, which indi¬
cates that this observation would have little use as a
discriminatory test for diagnosis or screening. These
differences between groups were retained and continued
to be significant when PrPc concentration is not normal¬
ized for total protein but is expressed directly as units per
milliliter; there remains a significant decrease in the con¬
centration of PrPc in vCJD (p = 0.005) and neurological
control patients (p = 0.0001) when compared with healthy
adults.
Detection of PLT-poor plasma PrPc by DELFIA
PLT-poor plasma samples from 10 patients with vCJD, 10
patients with sCJD, 29 healthy adults (1 excluded owing to
lack of parallelism between dilutions), and 6 samples (2
samples unavailable) from neurological controls were
analyzed by DELFIA for PrPc (Fig. IB; Table 1). We found
significant elevation in the plasma PrPc concentration in
sCJD patients when compared with both healthy adult
(p = 0.022) and neurological control groups (p = 0.050),
but not when compared to levels found in vCJD patients.
No significant differences were found in comparisons
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Fig. 1. The concentration of PrPc assayed by DELFIA in separated blood components of clinical and control samples. The concentra¬
tion ofwhole blood (A), PLT-poor plasma (B), 50 percent RBCs (C), and PLT (D) PrPc (units per mg) assayed by DELFIA in vCJD, sCJD,
and donor and neurological control groups.
between controls and vCJD groups. Again, there is consid¬
erable overlap of ranges for all groups. Significant differ¬
ences between groups were not evident when data was
expressed in units per milliliter of PrPc.
Detection of RBC PrPc by DELFIA
RBC samples from 10 vCJD patients, 9 sCJD patients, 26
healthy adults, and 7 neurological controls were analyzed
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by DELFIA to determine PrPc concentration (Fig. 1C;
Table 1). vCJD and sCJD patients and healthy adults all
exhibited similar median values for RBC PrPc concentra¬
tion and therefore did not exhibit significant differences
when compared with each other. The neurological con¬
trol group showed a significant reduction in RBC PrPc
concentration when compared with vCJD patients
(p = 0.029), sCJD patients (p = 0.024), and healthy adults
(p = 0.001).
VARIATION OF PRION PROTEIN IN BLOOD
TABLE 1. Medians and range (95% confidence limits [CL]; U/mg) of
separated components from different clinical and control groups as
measured by DELFIA
Sample Blood component Number Median (U/mg) 95% CL (U/mg)
vCJD Whole blood 10 3.438 1.912-3.593
sCJD Whole blood 10 3.227 2.073-5.754
Donor controls Whole blood 29 4.16 3.376-6.635
Neurological controls Whole blood 8 2.35 0.823-3.375
vCJD Plasma 10 8.375 5.225-14.912
sCJD Plasma 10 13.446 8.078-17.314
Donor controls Plasma 29 9.316 8.038-10.624
Neurological controls Plasma 6 8.405 5.31-10.8
vCJD RBCs 10 0.411 0.19-1.045
sCJD RBCs 9 0.434 0.162-0.648
Donor controls RBCs 26 0.499 0.29-0.579
Neurological controls RBCs 7 0.16 0.16-0.27
vCJD PLTs 9 293.93 174.42-1150.442
sCJD PLTs 9 316.56 213.69-400.75
Donor controls PLTs 24 581.11 389.29-855.15
Neurological controls PLTs 7 83.37 35.48-429.6
Detection of PLT PrPc by DELFIA
PLT samples from 24 healthy adults, 9 patients with vCJD,
9 patients with sCJD, and 7 neurological controls were
analyzed for PrPc concentration (Fig. ID; Table 1). Sam¬
ples excluded from each group constitute those where
PrPc concentration could not be measured reproducibly
across a range of dilutions. The concentration of PLT PrPc
in the sCJD samples was significantly reduced compared
with levels in healthy adults (p = 0.021) but not against
vCJD. The level of PLT PrPc in neurological controls was
the lowest of all groups, and this reduction was significant
compared to levels in healthy adults (p = 0.001), vCJD
patients (p = 0.039), and sCJD patient samples (p = 0.017).
Detection of buffy-coat PrPc by DELFIA
Buffy-coat PrPc expression levels were not detected at
significantly high concentrations, particularly in clinical
groups, to permit accurate measurement. Hence, they
were excluded from the analysis.
Flow cytometry
The cell-associated PrP (net median fluorescence inten¬
sity above background) ranges for lymphocytes, PLTs, and
RBCs are shown as interquartile box plots (Fig. 2) for
healthy adult controls, neurological controls, sCJD cases,
and vCJD cases. The only significant difference found
between groups was for RBC PrP in healthy adults com¬
pared to non-CJD neurological controls (p = 0.008).
Although PLT PrP was increased in both sCJD and vCJD
cases compared to healthy adults or neurological controls,
this did not reach significance. Clinical vCJD and sCJD
cases were found to be as sensitive as healthy adults and
non-CJD neurological patients to removal of cell-
associated PrP by pK (Fig. 3). The distribution of FITC
fluorescence after pK treatment was
homogeneous, showing a single low
peak in the FITC channel without any
discernible higher peak, which might
indicate the retention of protease K-
resistant PrP, putative PrPSc, on any sub-
population of cells.
Results are not reported for neutro¬
phils or monocytes because in these
studies we considered the results
unreliable. There appeared to be con¬
siderable nonspecific binding of fluo¬
rescence by bothWBC classes especially
evident in both healthy adult controls
and all clinical cases, which may have
been a consequence of sample age.
Stability of whole-blood PrPc
Some samples from clinical groups took longer than
24 hours to arrive in the laboratory. To consider any effects
of prolonged transit time at ambient temperature, whole-
blood samples from three healthy adult controls were left
at 22°C for 72 hours, and samples were removed from each
control at 24-hour intervals. Samples were analyzed at
each time by flow cytometry, and 1-mL samples for
DELFIA analysis were stored at -80°C until analysis for the
detection of whole-blood PrPc. The expression of PrP on
PLTs measured by flow cytometry at 24-hour intervals
showed sequentially decreasing levels of PrP with time for
each individual (not shown). This contrasted with identi¬
fication of increased expression of PrP on PLTs found in a
preliminary analysis of data for sCJD patients compared
with healthy adult controls, and implied sample storage
was not responsible for this increase in the patient group.
Levels of PrPc detected by DELFIA remained stable across
72 hour (not shown). Prolonged transit time and ambient
storage temperatures had negligible effects on PrPc con¬
centration and are therefore unlikely to contribute to dif¬
ferences between sample groups.
Relationship between age and PrPc levels
Differences between control and clinical sample groups
may be affected by the age of individuals, considering that
vCJD usually affects young people and sCJD older people.
The concentration ofPrPc (U/mg) in whole-blood samples
detected by DELFIA in CJD and control groups was plotted
against age and showed that PrPc expression is unrelated
to this variable (data not shown).
Hematology of clinical and control samples
To ensure that hematologic abnormalities in blood sam¬
ples from clinical patients and controls did not contribute
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Fig. 2. Box plots showing the ranges ofexpression ofcellular PrP
shown by flow cytometry on different clinical and control
groups. Expressed as median fluorescence intensity net of
background, on lymphocytes, RBCs, and PLTs.
to differences in PrP concentration and expression
between groups, full blood count data for clinical and
neurological patients were reviewed. No gross abnormal¬
ities were detected (data not shown).
DISCUSSION
The DELFIA technique employed here, and described pre¬
viously by us,23 is well suited to the screening of whole
blood and separated components of clinical and control
samples for PrPc. The assay is quick and has a high sensi¬
tivity for the detection of PrPc. DELFIA technology is com¬
patible with high throughput and has a high signal to
background ratio, owing to background deteriorating rap¬
idly whereas the signal has a long lifetime. Flow cytometry
analysis has been used previously by us to illustrate the
expression of PrP on healthy adult human blood cells.29,30
No previous studies have evaluated the concentration
and expression of PrP in the whole blood and separated
components of patients with vCJD. DELFIA analysis of
separated components found that the highest levels of
PrPc associated with the PLT and plasma components and
much lower levels associatedwith RBCs, which is in agree¬
ment with our previously described findings.23 Levels of
PrPc in the WBC buffy-coat fractions were very low, often
at the detection limit of the assay, and these levels could
not be accurately calculated particularly in clinical
groups, hence their exclusion from further analysis. The
separation method used here was a compromise for great¬
est utility of archived samples and was not ideal for isola¬
tion of the PLT and buffy-coat components; cells often
clumped together and proved difficult to resuspend,
which may explain the large median ranges in the PLT
data and the low levels of detectable PrPc in buffy coats.
These large ranges in PLT PrPc concentrations are not sup¬
ported by any large fluctuations in PLT counts as seen in
hematologic data for patients and controls used in this
study; the data does not show any abnormalities.
In our analysis ofwhole blood, we found a significant
decrease in the concentration of PrPc in vCJD and neuro¬
logical control patient samples compared to healthy
adults but not when compared with the sCJD group. We
found significant elevation in the plasma PrPc concentra¬
tion in sCJD patients when compared with both healthy
adult and neurological control groups; however, no signif¬
icant differences were evident between levels in sCJD and
vCJD patients. The elevation of plasma PrPc in sCJD
patients agrees with a previously published report; how¬
ever, in our study a distinct finding is that levels of plasma
PrPc in sCJD patients are significantly elevated not only
against healthy adults but also against the neurological
control group, which was not the case in the previous pub¬
lished findings.25 These differences may be a consequence
of our use of neurological controls with conditions, apart
from Alzheimer's disease, that were distinct from those
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Fig. 3. Demonstration by flow cytometry of the removal of cell-surface PrP after pK treatment.The median fluorescence intensity (net
ofbackground) is plotted for cells before and afterpK treatment and connected by a line for each case. (O) Healthy adult blood donors;
(O) non-CJD neurological patients; (□) sCJD patients; (A) vCJD patient; (O) familial TSE (a single case of familial TSE was included
in the study but not included in statistical analysis).
included in the previous study. We found a significant
reduction in the concentration ofRBC PrPc in neurological
controls compared with all other groups. We considered
that the differences between groups might be a conse¬
quence of the age of patients affected by vCJD, sCJD, and
neurological disorders; however, no relationship between
age and PrPc concentration was found in either control or
clinical sample groups. It is possible that the reduced con¬
centration of whole-blood PrP' in vCJD patient samples
might be due to the conversion of PrPc to PrPSc as part of
the replication process involved in disease pathogenesis.
The absence of a similar reduction ofwhole-blood PrPc in
sCJD patients would be expected because PrPSc is largely
confined to the central nervous system and replication of
PrPSc in the periphery before neuroinvasion is not a fea¬
ture of sCJD. Alternatively, the vCJD whole-blood reduc¬
tion could be a summation of reductions in PrPc in the
plasma and PLT components, whereas in sCJD the low PLT
PrPc value is offset by the high plasma value so balancing
out in whole-blood levels. It is likely that the reduced lev¬
els of whole-blood PrPc in neurological controls is a con¬
sequence of the reduced PrPc levels found in RBCs and
PLTs in this group. To some extent the low levels of PLT
PrPc may reflect neurological disease because PrPc levels
were low in PLT samples from CJD and lowest in neuro¬
logical controls but not in healthy adult controls. We are
unable though to speculate on the reasons for this.
We also considered the possibility that increases in
sCJD plasma PrPc levels may be a consequence of its
release from PLTs, because PLTs are known to express PrPc
on the cell surface and to store PrPc in alpha granules,
which are released into plasma in a soluble form on PLT
activation.24,32 To support this theory, we have found a sig¬
nificant reduction in the PLT PrPc concentration in sCJD
patient samples compared to healthy adults, implying
that PLTs may have shed PrPc into plasma. The expression
of PrP on PLTs of vCJD and sCJD as determined by flow
cytometry was elevated compared with healthy adult and
neurological controls, and although this elevation did not
reach significance, perhaps this represents up regulation
of PrP before its release into plasma. Investigations into
cell-surface PrP on PLTs did not implicate blood sample
storage and transit as a possible cause for increased cell-
surface PrP; they found cell-surface PrP on PLTs decreased
with sample age.
Flow cytometry analysis demonstrated significantly
less PrP expression on RBCs of neurological controls than
healthy controls. This finding supports that of a reduced
concentration of RBC PrPc in this group found by DELF1A.
These results would appear to indicate that there is less
PrPc per RBC compared with other groups. We are unable
to explain the reason behind the finding of this reduced
expression of PrP on RBCs. We did not find any evidence
of a reduction in the expression of PrP on lymphocytes of
patients with sCJD when compared to neurological con¬
trols in contrast to a previous report.33 We used both 4F2
and 3F4 anti-PrP MoAbs together for these flow cytometry
studies, however, whereas the previously reported study
used 3F4 alone, which does not to bind to human RBCs.29
It could be possible that MoAb 3F4 might show reduced
binding to PrPc on lymphocytes in some clinical condi¬
tions ifPrPc expression were altered or PrPc interacted with
other membrane components because of lymphocyte
activation.34,35 PrP on RBCs, PLTs, and lymphocytes was
removed to background levels after pK treatment in all
clinical and control groups, indicating the absence of any
detectable cellular expression of abnormal disease associ¬
ated forms of PrP. Our findings indicate that a reduction
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in concentration of whole-blood PrPc may be common in
vCJD and other neurological diseases but not sCJD. An
elevated level of plasma PrPc may be common in sCJD.
These differences between groups appear genuine, pre¬
sumably reflecting differences in the disease process in
the patients in these particular groups and not an artifact
of age, specimen collection, storage, or analysis. Despite
the significance of differences between groups, the varia¬
tions in values are large and there is considerable overlap
between CJD groups and control groups, which rules out
the exploitation of these differences in whole blood and
plasma in screening strategies. These studies expose the
limitations in the use of blood PrPc levels as a diagnostic
tool. They illustrate, however, important observations on
the distribution of PrPc in the peripheral blood of CJD
patients and the potential of DELFLA-based PrP assays
in clinical practice. The analytical sensitivity of DELFIA-
based assays used here represents a significant step
toward the development of DELFIA for the detection of
PrPSc, which is a much more reliable indicator of infection
and is directly associated with infectivity. The current
study emphasizes the need to develop assays for its detec¬
tion in blood.36,37
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